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Abstract 
Transthyretin (TTR) is a protein that binds and distributes thyroid hormones 
(THs). While TTR has long been known to be synthesised in the liver and in the 
choroid plexus of the brain, recent investigation have revealed that it is also 
synthesised by different neuronal cells, such as neurons, astrocytes, transit amplifying 
cells and Schwann cells. To the best of our knowledge, the roles of TTR synthesised 
by these neuronal cells have not yet been clearly elucidated. The TTR synthesised by 
the choroid plexus has a role in moving THs from the blood to the brain and in 
distributing THs in the cerebrospinal fluid. Previously two reports suggested that TTR 
null mice were hypothyroid in the central nervous system compared with wild-type 
mice. Therefore, we decided to investigate a well-characterised TH-dependent process 
in the brains of wild type and TTR null mice: the maturation of oligodendrocyte 
precursor cells into oligodendrocytes that myelinate axons of neurons in the corpus 
callosum and anterior commissure of the brain. Accordingly, four different age groups 
were chosen (P7, P14, P21 and weeks) to investigate key time points for 
oligodendrocyte maturation in the brains of wild type and TTR null mice. 
Interestingly, in complete contrast to what we expected, we observed 
hypermyelination in the brains of the TTR null mice during development. This 
hypermyelination phenotype was synchronous with a substantial increase in the 
density of oligodendrocytes in the medial area of the corpus callosum and in the 
anterior commissure during development from P7 until 12 weeks of age. Thus, we 
studied the maturation of oligodendrocyte precursor cells (OPCs) isolated from the 
cortices of P7 and E18 mouse brains. Interestingly, we found that the absence of TTR 
enhanced the proliferation and migration of the OPCs, as well as decreased the rate of 
apoptosis and affected the progression of the OPC cycle. Furthermore, the NSCs 
isolated from the subventricular zone of P21 TTR null mice showed that the absence 
of TTR promoted NSC differentiation into glial lineages. We have also shown, for the 
first time, that oligodendrocytes synthesise TTR, and the TTR synthesised by OPCs is 
not secreted. This is in contrast to TTR synthesised by the liver and choroid plexus 
(which is secreted). Taken together, these data indicate that TTR has a role in the 
regulation of myelination; where the absence of TTR accelerates NSC and OPC 
maturation and enhances myelination. Therefore, We hypothesised that endogenous 
  
xix 
TTR, which has been shown to be synthesised by OPCs, holds T4 in the cytosol of the 
cells; this controls the level of T4 available for deiodinated to T3, the functional form 
of THs. Elucidation the mechanism of the regulatory role of TTR in NSC and OPC 
biology could lead to potential therapeutic strategies for treatment of demyelination 
disease such as Multiple Sclerosis. 
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Chapter 1 
Introduction  
  
2 
1 Chapter 1: Introduction 
1.1 Thyroid hormones 
There are two main form of thyroid hormones (THs): 3′,5,3-triiodo-l-thyronine 
(T3) and 3′,5′,3,5-triiodo-l-thyronine (thyroxine; T4). THs play an essential role in the 
development of different tissues by regulating cell physiology and controlling cell 
proliferation, differentiation and apoptosis (Oppenheimer et al., 1987). Although in 
mammals the concentration of T4 in the blood is higher than that of T3, the majority 
of TH functions are performed by T3 (Ingbar and Braverman, 1975). Therefore, T4 is 
considered the “transport” form and T3 is considered the “active” form of the thyroid 
hormone. Approximately 20% of T3 is secreted by the thyroid gland and the other 
80% is produced in peripheral tissues as a result of the deiodination of T4 (Surks et 
al., 1973).  
1.1.1 Thyroid hormone synthesis 
There are two main indispensable factors for TH synthesis, which are iodide 
(I-) and thyroglobulin (Tg), a protein made by thyroid epithelial cells (Dunn and 
Dunn, 2000). The first step in the synthesis of THs is the absorbance and conversion 
of iodide by the thyroid gland. Within the colloid of the thyroid follicle, hydrogen 
peroxide (H2O2) will oxidize the iodide into iodine (Bjorkman and Ekholm, 1992). 
Next, the thyroid peroxidase (TPO) will bind the oxidized iodide to the tyrosine 
amino acid residues in the Tg molecules (Ohtaki et al., 1982). Binding one oxidized 
iodide with tyrosine will result in the formation of monoiodotyrosine (T1 MIT) 
whereas binding two oxidized iodides will result in the formation of diiodotyrosine 
(T2 DIT). After this, two molecules must be combined to create a thyroid hormone in 
a process called a coupling reaction. Two DIT molecules join to form T4, whilst one 
DIT and one MIT join to from T3. THs are stored in the follicular lumen of the thyroid 
gland (Berson and Yalow, 1955). Thus, the concentration of THs is 20-40 folds higher 
than in the plasma. Tg protein helps to store THs. Each Tg molecule contains up to 30 
T4 molecules and a few T3 molecules. Before releasing THs, the Tg will be digested 
in lysosomes of thyroid epithelial cells. The THs will then be released into the 
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circulatory system and distributed around the body to their sites of action (Dunn and 
Dunn, 2000). 
Because of the lipophilicity of THs, and to avoid the accumulation of it in the 
membranes (Dickson et al., 1987), >99% are bound to specific plasma proteins and 
less than 1% of TH in blood circulates freely (Mendel, 1989). These plasma proteins, 
called thyroid hormone distributor proteins (THDPs), are thyroxine-binding globulin 
(TBG), albumin, transthyretin (TTR) and lipoproteins (Schreiber, 2002). These 
proteins form a network to ensure that there is adequate distribution of THs to the 
tissue, and they protect the tissue against any modulation in TH production (Bartalena 
and Robbins, 1993). 
Next, THs may enter cells via TH transporters such as monocarboxylate 
transporter 8 (MCT8) and organic anion transporting polypeptide (OATP) 
(Hennemann et al., 2001) or via diffusion (Dickson et al., 1987). Within the cells, T4 
will be diodinated by various enzymes called deiodinases (Figure 1-1). There are 
three different deiodinase enzymes including: deiodinase type I (D1), deiodinase type 
II (D2) and deiodinase type III (D3). The distribution and activity of these three 
deiodinases varies between tissues. D1 is mainly found in the liver and kidneys, D2 is 
found in brain astrocytes and D3 is in brain neurons. D1 and D2 have the ability 
convert T4 into the active form of TH which is T3, by catalysing removal of one 
iodine atom from the outer ring of T4. However, D3 has the ability convert T4 into 
the inactive form of THs, which is rT3, by catalyzing removal of one of the iodine 
atoms from the inner ring of T4 (Figure 1-1) see (Darras and Van Herck, 2012). 
1.1.2 Mechanisms of TH actions 
The mechanisms of the actions of TH can be classified into genomic 
mechanisms, which are mediated by nuclear receptors (TRs) (Hennemann et al., 
2001), and non-genomic mechanisms, which are not mediated by TRs (Farach-Carson 
and Davis, 2003). The genomic pathway starts with the interaction of T3 with thyroid 
hormones receptor (TR). The binding of T3 to the TR which hetero-dimerises with 
retinoid X receptor (RXR) on the thyroid response elements (TREs) of the gene 
promoter and  results in dissociation of the co-repressor proteins and association of 
the co-activator proteins, which then activates the transcription of the target gene 
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(Bogazzi et al., 1994). In case of genes that are negatively regulated by THs, T3 binds 
to the TR which hetero-dimerises with RXR on the TREs, which will result in 
dissociation of the co-activator proteins and association of the co-repressor proteins 
and transcription will cease. 
In non-genomic pathways, the actions of TH are initiated by binding to non- 
TR receptors, located in the cytoplasm, on the plasma membrane or in the 
intracellular organelles (such as mitochondria). Unlike the genomic pathway affects, 
the non-genomic pathway affects can be mediated by signal-transducing pathways 
and may happen within a short time (seconds to minutes) (Davis et al., 2008). 
Although the molecular mechanisms for non-genomic actions are not fully 
understood, some studies have suggested various pathways; including  regulation of 
the state of the actin cytoskeleton (Farwell et al., 2006); insertion of Na+ / K+-ATPases 
into the plasma membranes (Lei et al., 2003) and modulation of their activity (Lei et 
al., 2008). 
1.1.3 Regulation of thyroid hormone synthesis and secretion 
Thyroid-stimulating hormone (TSH) or thyrotropin is the primary stimulator 
molecule for the secretion of TH. It is synthesized in and secreted from the anterior 
pituitary gland (Szkudlinski et al., 2002). The thyroid epithelial cells contain receptors 
for TSH. Thus, the binding of TSH to its receptors in the thyroid cells enhances TH 
synthesis and secretion by activating the required processes to synthesise THs, which 
involves synthesis of the sodium iodide symporter, thyroid peroxidase, and 
thyroglobulin (Trunnell et al., 1948). 
The secretion of TSH is controlled by a hormone called thyroid-releasing 
hormone (TRH), which is secreted from the hypothalamic neurons into the 
hypothalamic-hypophyseal portal blood (Harris et al., 1978). The anterior pituitary 
glands have receptors for the TRH. Thus, binding TRH to its receptor in the anterior 
pituitary gland will result in enhanced secretion of TSH, and the consequent secretion 
of TH. The secretion of both TSH and TRH is regulated by on the level of free THs in 
the blood via negative feedback. 
  
5 
The TH levels should be maintained within the normal range. The mean serum 
thyroid hormone values for FT3 and FT4 are 0.11-0.53 ng/dl and  0.69-1.69 ng/dl, 
respectively (Cioffi et al., 2001). Overactive thyroid glands will result in 
hyperthyroidism, a case in which the thyroid gland produces excessive amounts of the 
TH. The main symptoms of this disease include an accelerated heart rate or 
palpitations, muscle weakness and trembling, nervousness, agitation, anxiety and 
unexplained weight loss (Garg and Vanderpump, 2013). On the other hand, a shortage 
in TH levels in the body is called hypothyroidism. The main symptoms of 
hypothyroidism include a slow heart rate, high sensitivity to coldness, depression, 
swelling of the thyroid gland and weight gain (Garg and Vanderpump, 2013). Because 
of the importance of the TH in normal development, THDP are required to ensure the 
adequate distribution of THs in the body and the formation of a network that 
compensates for any fluctuations in TH levels. 
TTR is the only THDP synthesised in the CNS. TTR synthesised by the 
choroid plexus has been implicated in the movement of THs from the blood into the 
CNS. Moreover, humans lacking either of the other two THDPs albumin (Doweiko 
and Nompleggi, 1991) or TBG (Nusynowitz et al., 1971) have been described, but no 
humans lacking TTR have been identified. TTR was thought to be crucial for 
survival, due to its role in TH distribution in the CNS and the requirement of adequate 
amounts of THs for normal CNS development. Thus, the next paragraphs will 
comprehensively discuss TTR; its structure, expression, functions and metabolism. 
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Figure 1-1: The deiodination of T4 into T3, rT3 and T2. 
Deiodinase type II (D2) converts T4 into the active form by removing one of the 
iodine atoms from the outer ring of the T4. Deiodinase type III (D3) converts T3 
and T4 into the inactive form by removing one of the iodine atoms from the inner 
ring of T4 (Nakao et al., 2008).  
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1.2 Provenance of nomenclature for transthyretin 
The protein that we now know as “transthyretin” (abbreviated as “TTR”) was 
first described in 1942, in human serum (Seibert and Nelson, 1942) and cerebrospinal 
fluid (CSF) (Kabat et al., 1942). Due to the mobility of TTR during electrophoresis at 
pH 8.6, where it was the only serum protein that migrated ahead of albumin, it was 
named “prealbumin” or PA. In 1958, it was found that after adding 131I-thyroxine to 
serum, 131I-thyroxine migrated in association with prealbumin during electrophoresis 
in Tris-maleate buffer (previously, barbital buffer had been used, which we now know 
prevents binding of thyroxine to prealbumin). Thus, it was revealed that prealbumin 
could bind thyroxine and the name was changed to “Thyroxine-binding prealbumin” 
(TBPA) (Ingbar, 1958). In 1969, the ability of TBPA to bind retinol-binding 
protein/retinol was discovered (Raz and Goodman, 1969). Consequently, in 1981 the 
name was changed to “transthyretin”, to reflect its roles in TRANSport of THYroid 
hormones and RETINol-binding protein (1981). As additional functions of TTR are 
being elucidated, perhaps it will require a further change of name in the future 
1.3 Structure of TTR 
TTR was first crystallised in 1966 by Haupt and Heide from ammonium 
sulphate solutions (Haupt and Heide, 1966) and the first x-ray crystal structure was 
determined by Blake and colleagues, initially in 1974, then in greater detail in 1978 
(Blake et al., 1978, Blake et al., 1974). TTR is a homo-tetrameric protein with a 
molecular mass of ~55 kDa (Blake and Oatley, 1977). Each subunit of human TTR 
consists of 127 amino acids corresponding to approximately 14 kDa (Kanda et al., 
1974). TTR has extensive β structure with each monomer being composed of eight β-
strands designated A-H, arranged in an antiparallel configuration. A single short α-
helical region connects strands E and F. The overall topography is a classic β-sheet 
conformation (Figure 1-2) (Blake et al., 1978, Wojtczak et al., 1996), also known as 
the “immunoglobulin fold”. TTR is very stable under physiological conditions in vivo 
and in vitro, probably due to the high β-sheet content, although the subunits are not 
covalently associated (Figure 1-2). All strand interactions are anti-parallel except 
between strands A and G. The inner and outer β sheets, CBEF and DAGH, which are 
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approximately parallel to each other, are separated by about 10 Å (Blake et al., 1978, 
Blake et al., 1974).  
In each dimer, the association of two monomers (A and B or C and D) occurs 
through hydrogen bonds and hydrophobic interactions. These extensive contacts result 
in a strong dimer. Two dimers interact on a twofold crystallographic axis to form a 
tetramer. The dimer–dimer contacts involve several hydrogen bonds and hydrophobic 
interactions of residues in the AB and GH loops (Lai et al., 1996).  
The tetramer has a central channel that contains the two TH-binding sites. The 
channel is 50 Å long and around 8 Å in diameter and could potentially bind two 
molecules of TH, but under physiological conditions only one site is occupied due to 
negative co-operativity (Neumann et al., 2001). Nearly all residues of TTR are 
involved in the β-strands, the loops connecting them or the short α-helix. Of each 
subunit, only the amino acids N-terminal to Cys10 and C-terminal to Asn123 do not 
appear to be involved in the folding (Blake et al., 1974). The possible functions of the 
N-termini are discussed below.  
The process of TTR oligomerisation requires the signal peptide (first 20 amino 
acids) to be cleaved for translocation of the TTR monomer into the endoplasmic 
reticulum lumen, where dimerization occurs. Formation of the tetramer also occurs in 
the endoplasmic reticulum, but special (as yet unidentified) tissue-specific factors or 
microenvironments are required for tetramerisation (Gaetani et al., 2002). 
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Figure 1-2: The structure of transthyretin (TTR). 
(I-III) Three views of the monomer–monomer interaction forming the dimer. Each 
monomer consists of eight anti-parallel β-strands designated A–H. The inner and 
outer β sheets, CBEF and DAGH, which are approximately parallel to each other, are 
separated by approximately 10 Å (Blake et al., 1974, Blake et al., 1978). (IV) 
Transthyretin tetramer with thyroxine (T4) bound in the central channel (Wojtczak et 
al., 1996). (V) Transthyretin with two molecules of retinol-binding protein bound to 
the external surface (Monaco, 2002). Structural data were obtained from "pdb" files 
from the referenced studies and assembled using PYMOL (Schrodinger, LLC, Palo 
Alto, CA, USA) (Alshehri et al., 2015).  
TTR-T4 complex TTR-RBP complex 
III I II 
IV V 
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1.3.1 Evolution of TTR structure 
The x-ray crystal structure has been determined for TTRs from fish (Eneqvist 
et al., 2004), chicken (Sunde et al., 1996), rat (Muziol et al., 2001) and human (Blake 
et al., 1974). These structures are almost completely superimposable, suggesting that 
the overall topological structure of TTR has not changed during vertebrate evolution. 
The main difference between them is the apparent lack of alpha-helical structure in 
chicken TTR (Sunde et al., 1996).  
Alignment of amino acid sequences of TTRs from many vertebrate species 
revealed that the primary structure of TTR has also remained highly conserved 
throughout vertebrate evolution (Richardson, 2007). The region which changed most 
during evolution was the N-terminal region of each subunit, which is usually defined 
as the “unstructured” region (i.e. not defined by x-ray crystallography), being the 
amino acids from the N-terminus until the amino acid prior to Cys10 (numbering for 
human TTR). The character of the N-terminal regions changed from longer and more 
hydrophobic (e.g. in TTRs from fish and amphibians) via intermediates (e.g. reptiles, 
birds and marsupials) to shorter and more hydrophilic in TTRs from eutherian 
“placental” mammals (Richardson, 2007).  
For the TTR genes where the genomic and cDNA sequences are known, the 
positions of the introns have been identified. The positions of the introns have not 
changed throughout vertebrate evolution i.e. intron 1 is between amino acids 2 and 3, 
intron 2 is between amino acids 41 and 42, and intron 3 is between amino acids 92 
and 93 (numbering for human TTR). Thus, the position of intron 1 is within the 
unstructured N-terminal region. The position of the exon 1 / intron 1 border remained 
unchanged, but the position of the intron 1 / exon 2 border shifted in the 3’ direction 
during evolution of the TTR gene in vertebrates (Figure 1-3) (Aldred et al., 1997). 
The series of step-wise shifts of the intron 1 / exon 2 border in the 3’ direction can be 
explained by a series of point mutations which effectively move the recognition 
sequences for intron / exon border splicing consensus sequences in the 3’ direction. 
The net effect is to “move” bases from exon 2 into intron 1 and thereby shorten the N-
terminal region of each subunit (Figure 1-3). 
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The consequences of shortening of the N-terminal regions of TTR subunits 
was apparently to change the function of TTR from binding 3’,3,5-triiodo-L-thyronine 
(T3; the active form of TH) in fish, amphibians, reptiles and birds to binding 
thyroxine (T4; the precursor form of TH) in mammals (Chang et al., 1999). The 
hypothesis that the character of the N-termini was responsible for the change in 
affinity from T3 to T4 came from several studies. Chicken TTR was known to have 
higher affinity for T3 than for T4, but when its x-ray crystal structure was determined, 
there was no difference in its binding site compared to human TTR, which 
preferentially bound T4 (Sunde et al., 1996). Later, a series of studies by Prapunpoj 
and colleagues used chimeric TTRs for domain-swapping experiments comparing (for 
example) affinities of recombinant TTRs composed of N-terminal regions from 
reptilian TTR (higher affinity for T3) attached to the “body” of human TTR (higher 
affinity for T4) and conversely, TTRs composed of N-terminal regions of human TTR 
attached to the “body” of a reptilian TTR (Prapunpoj et al., 2006). This confirmed that 
the unstructured N-termini had a significant effect on determining the affinities of T3 
and T4 to TTRs. 
T3 is the most biologically active form of TH as it has higher affinity than T4 
for the TH nuclear receptors (Samuels et al., 1979) which regulate transcription of 
specific TH-responsive genes. T4 is known as the transport form of TH, as T4 is the 
precursor form of TH and is the main form found in the blood. T4 can be converted to 
the active form T3, by specific deiodinases which are expressed tissue-specifically 
and are developmentally regulated (Darras and Van Herck, 2012). The advantage of 
TTR binding T4 rather than T3, is that in mammals, TTR is distributing the precursor 
form of TH to tissues which is then activated to T3 by specific deiodinases at the sites 
required at the appropriate stages of development. This can be interpreted as a “safer” 
system than distributing the active form of TH throughout the body and cerebrospinal 
fluid (Richardson, 2007).  
This could be of particular importance in the CNS, as exemplified in the rat 
brain, where the proportion of T3 generated by local deiodination of T4 is region-
specific: 65% in the cortex, 51% in the cerebellum, 35% in the pons, 32% in the 
hypothalamus, 30% in the medulla oblongata and 22% in the spinal cord (van Doorn 
et al., 1985). Such tight regulation might not be possible if T3 were the predominant 
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form of TH in the cerebrospinal fluid. Speculation about the driving force or selection 
pressure for greater control of T3 availability in specific brain areas in mammals is 
tempting, but as yet unsubstantiated. Key thyroid hormone-related features that 
distinguish mammalian brains from those of other vertebrates include (i) the corpus 
callosum which is extensively myelinated and (ii) the highly developed cerebral 
cortex. Furthermore, mammalian foetuses have low levels of circulating T3 and 
maternal T4 (not T3) has a crucial role in brain development (Calvo et al., 1990). 
  
  
13 
 
Figure 1-3: Stepwise changes in the intron1-exon2 splice site result in shortening 
of the N-termini of TTR. 
 (Aldred et al., 1997)  
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1.4 The history of the discovery of the functions of TTR. 
1.4.1 TTR is a TH distributor protein 
The first function ascribed to TTR was that of TH binding (Ingbar, 1958). 
TTR is one of the TH distributor proteins (THDPs) present within the blood and 
cerebrospinal fluid of humans. In addition to TTR, other THDPs include thyroxine-
binding globulin (TBG), albumin, and some lipoproteins (Schreiber, 2002). The name 
“distributor” protein was originally coined as it differentiated the function of these 
proteins from other TH “binding” proteins (deiodinases, cytosolic TH binding 
proteins, TRs). This nomenclature is even more pertinent today, since the discovery of 
the membrane-bound TH transporter proteins that transport THs into and out of cells 
(Hennemann et al., 2001). For a schematic summary of the five classes of TH binding 
proteins, see Figure 1-4. THDPs form a network to ensure that there is an adequate 
pool of circulating TH and an even distribution of THs throughout tissues (Mendel et 
al., 1987). Furthermore, as >99% of THs in blood are bound to THDPs, they form a 
buffering network to protect the tissue against any fluctuation in free TH levels in the 
blood or CSF (Figure 1-5) (Schreiber and Richardson, 1997).  
THs are synthesised by the thyroid gland and secreted into the blood, where 
they are distributed around the body to their sites of action. THs may enter cells via 
TH transporters such as monocarboxylate transporter 8 (MCT8) and organic anion 
transporting polypeptide (OATP) (Hennemann et al., 2001) or via diffusion (Dickson 
et al., 1987). Within the cell, THs can be either activated or inactivated by a family of 
deiodinases. T3 can bind reversibly to specific cytosolic proteins, enter the nucleus 
where it can then bind to TH receptors (TRs) which are ligand activated transcription 
factors that then dimerise and either activate or repress transcription of specific genes 
(see Figure 1-4). 
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Figure 1-4: The five classes of proteins that bind thyroid hormones. 
(1) In mammals, THs are secreted from the thyroid gland into the blood mainly as 
thyroxine (T4). In the blood, > 99% of T4 is bound by one of three TH distributor 
proteins [THDPs: transthyretin (TTR), albumin or thyroxine-binding globulin (TBG)]. 
which distribute T4 where it is needed. (2) THs dissociate from TH distributor 
proteins and enter cells either by passive diffusion or via specific membrane- bound 
TH transporters. (3) THs can be activated or inactivated by a family of deiodinases. 
(4) 3´,3,5-Triiodo-L-thyronine (T3) can bind specific cytosolic proteins. (5) Within 
the nucleus, T3 binds TH receptors, which dimerise and change conformation when 
binding to thyroid response elements (DNA sequences) and protein complexes. The 
entire complex directly regulates transcription of specific genes (Richardson, 2007). 
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1.4.2 TTR, Goldilocks and the three bears 
In the blood >99 % of THs are bound to specific TH distributor proteins 
(albumin, TTR and TBG). It has often been stated in the literature that the function of 
TH distributor proteins is to overcome the limited solubility of THs in the blood and 
CSF. However, the concentration of free T4 in human blood is ~24 pM whereas the 
solubility limit of T4 at pH 7 is 2 µM (Rotzsch et al., 1967) i.e. about 100,000 times 
that of the free concentration of T4 in blood! The function of TH distributor proteins 
was elegantly demonstrated by Mendel and colleagues (Mendel et al., 1987). 
Following perfusion of a rat liver with buffer containing radiolabelled T4, all the T4 
had partitioned into the first cells it came in contact with. However, following 
perfusion of a rat liver with buffer containing radiolabelled T4 and TH distributor 
proteins, the T4 was evenly distributed throughout the liver lobule and some T4 was 
present in the perfusate. This clearly demonstrated that TH distributor proteins were 
required to achieve an even distribution of T4 throughout the liver and to maintain a 
circulating pool of T4 
In humans, the three TH distributor proteins have higher affinity for T4 than 
for T3. Furthermore, TBG has the highest affinity for T4 and T3 (1.0 x 1010 and 4.6 x 
108 M-1, respectively), TTR has intermediate affinity (7.0 x 105 and 1.4 x 107 M-1, 
respectively) and albumin has the lowest affinity (7.0 x 105 and 1.0 x 105 M-1, 
respectively). The concentration of TBG is about 0.015 g/l and it carries about 70 % 
of TH in the blood; TTR is present at 0.25 g/l and carries about 15 % of T4 in the 
blood; albumin is present at about 42 g/l and carries about 10 % of T4 in blood. 
Lipoproteins also carry some TH in the blood (Benvenga et al., 2001). This led many 
to believe that TBG was the “most important” TH distributor protein within the 
peripheral circulation and that the quantitative contribution of TTR to TH distribution 
and delivery to cells to be of low significance. However, this interpretation is too 
simplistic, as the bioavailability is related to the delivery of THs to cells which is 
determined by the dissociation rates of THs from the distributor proteins and the 
capillary transit times in various tissues. The dissociation rates for T4 and T3 from the 
distributor proteins are 0.018 and 0.16 s-1 from TBG; 0.094 and 0.69 s-1 from TTR 
and 1.3 and 2.2 s-1 from albumin (Mendell and Florence, 1990). Given the capillary 
transit times of various tissues (Mendel, 1989), TTR is responsible for the bulk of the 
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delivery of THs to tissues (Robbins, 2002) . This can be likened to Goldilocks and the 
three bears: TBG binds THs too tightly to deliver significant quantities under healthy 
conditions; albumin binds THs too loosely; and TTR has “just right” dissociation 
rates. Thus, the role of TTR in TH distribution and delivery to tissues is significant. In 
particular, TTR is the main THDP in the CSF and the only THDP synthesised in the 
CNS. 
Many studies considering the impact of endocrine disruptors (see section 4) on 
human health are carried out using rodents. However, while humans have albumin, 
TTR and thyroxine-binding globulin as the main TH distributor proteins, healthy adult 
rodents have only albumin and TTR as TH distributor proteins in their blood. Rodents 
only synthesise thyroxine-binding globulin as juveniles and in senescence (Savu et al., 
1991, Vranckx et al., 1990). Thus, comparative data on affinities of TTRs from 
rodents, humans and other animals is of interest from an endocrine disruption 
perspective. An analysis and comparison of dissociation rates of T3 and T4 for TTRs 
from human, rat, rabbit, sheep, wallaby, possum, wombat, chicken, pigeon and emu 
(Chang et al., 1999) and a review including a reptile and amphibian (Richardson, 
2007) revealed that Kd values of TTRs for T3 or T4 within each group of animals, did 
not vary greatly. 
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 Figure 1-5: Binding of T4 to human THDPs. 
The range of THDPs’ affinities to T4 forms a buffering system to maintain a constant 
concentration of free T4 in the plasma. (Schreiber and Richardson, 1997)   
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1.4.3 The importance of redundancy and networks.  
Whereas redundancy in engineering usually comes into play only when the 
main system fails, biological redundancy usually works simultaneously in a network. 
We use both eyes most of the time. If we lose sight in one eye, we are not blind 
because the other eye still functions. We would lose depth perception, which is a 
disadvantage, but far better than being blind. However, it would be too simplistic to 
argue that because one eye still functions when the other eye does not, that sight is not 
important. Similarly, if one component of a network fails (or is “knocked out”) and 
the other components of the network can compensate such that the organism 
continues to live, it should not be concluded that the absent component is 
unimportant. On the contrary, null mutants can raise many questions and identify 
redundancy and compensation in biological mechanisms and reveal “new” functions 
of “well-known” proteins. This is the case for TTR null mice (read below). 
1.4.4 Sites of TTR synthesis – is TTR synthesis by the choroid plexus important? 
While TTR is mainly synthesised in the liver and the choroid plexus of the 
brain (Dickson et al., 1985b), it is also synthesised in other tissues, such as the 
visceral yolk sac of rodents and lagomorphs (Thomas et al., 1990), placenta (Sklan 
and Ross, 1987), retinal and ciliary pigment epithelia (Cavallaro et al., 1990, Ong et 
al., 1994), pancreas (Kato et al., 1985), meninges (Blay et al., 1994), fetal intestine 
(Loughna et al., 1995), Schwann cells of mice carrying the human Val30Met TTR 
gene (Murakami et al., 2010) and neurons (Li et al., 2011). After synthesis in the 
liver, TTR is secreted into the bloodstream where it acts as a TH distributor protein 
(as described above) to deliver TH to tissues throughout the body. TTR synthesised 
by the placenta is believed to have a role in transfer of TH and retinol from the 
maternal to the fetal circulation (Sklan and Ross, 1987, Soprano et al., 1986, Thomas 
et al., 1990). TTR and retinol-binding protein (RBP) synthesised by the eye have been 
suggested to be involved in the delivery of retinol to Müller cells and amacrine cells 
(Ong et al., 1994), where retinol is converted to retinal, required for photoreceptor 
function. To the best of our knowledge, the roles of TTR synthesised by the pancreas, 
intestine, meninges, Schwann cells and neurons have not been clearly elucidated. The 
function of TTR synthesised by the choroid plexus has been the subject of much 
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heated debate. Some believe it to be involved with the movement of T4 from the 
blood into the CSF, whilst others dispute this. The story can be divided 
chronologically into three stages: (i) the descriptions of TTR synthesis by the choroid 
plexus; (ii) the analyses of TTR null mice; and (iii) the identification of TH 
transporters. 
1.4.4.1 Discovery of TTR synthesis by the choroid plexus 
TTR mRNA was first described in the brain in 1985 (Soprano et al., 1985). 
Later that year, Schreiber’s group found TTR mRNA only in the choroid plexus of the 
brain (Dickson et al., 1985a) and then specifically in the choroid plexus epithelial 
cells (Stauder et al., 1986). Following injection of 125I-T4 into blood, 125I-T4 was then 
detected in various brain structures: initially it accumulated in the choroid plexus, 
then in the CSF, after which it began to appear in the cortex and striatum of the brain. 
However, there was no specific accumulation of 125I-T3 in such a defined manner. 
This was interpreted as TTR synthesis by the choroid plexus being involved in the 
movement of T4 (but not T3) from the blood across the choroid plexus into the CSF 
(Dickson et al., 1987). It was then demonstrated that the TTR synthesised by the 
choroid plexus was secreted into the CSF and not into the blood (Schreiber et al., 
1990). The groups of Köhrle (Chanoine et al., 1992) and Schreiber (Southwell et al., 
1993), independently and using different models, demonstrated that if the TTR 
synthesis by the choroid plexus was interrupted or its T4 binding capacity was 
inhibited, then the movement of T4 across the choroid plexus was not detectable.  
The development of the choroid plexus and the onset of TTR synthesis have 
been studied in detail. In embryonic rat brains, TTR mRNA was restricted to the 
epithelial cell layer of the choroid plexus primordia as soon as these cells become 
distinct. TTR mRNA was detected first in the choroid plexus primordia lining the 
fourth ventricle at E12.5, then in the choroid plexus primordialining the lateral 
ventricles at E13.5 and finally in the choroid plexus primordia lining the third 
ventricle at E17.5 (Thomas et al., 1988). Most animals can be described as either 
altricial (immature brains at birth e.g. rats) or precocial (developed brains at birth e.g. 
chickens). For altricial animals, the most rapid period of brain growth is postnatal, 
whereas for precocial animals, the most rapid period of brain growth is before birth. 
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For both altricial and precocial animals, the maximal TTR synthesis in the choroid 
plexus is just prior to the fastest period of brain growth (Fung et al., 1988) (Tu et al., 
1990). Given that the critical period of brain growth is dependent on THs, the choroid 
plexus develops more quickly than other parts of the brain, the choroid plexus plays 
an important role in determining the composition of the CSF, it would appear that 
from a developmental perspective, that the TTR in the choroid plexus could have an 
important regulatory role (for detailed discussion see (Richardson, 2005). To the best 
of our knowledge, it is not known if the development of the choroid plexus is TH-
sensitive. 
TTR is the major protein synthesised and secreted by the choroid plexus of 
eutherians, marsupials, monotremes, birds and reptiles (Harms et al., 1991). However 
the main protein synthesised and secreted by amphibian choroid plexus is a lipocalin 
(Achen et al., 1992), which could be the functional precursor of TTR, as lipocalins are 
known to bind small hydrophobic molecules. In contrast to the TTR synthesis in the 
liver, where TTR is a typical negative acute phase plasma protein (i.e. the rate of 
transcription of its gene in the liver is decreased during conditions of inflammation or 
disease), its expression in the choroid plexus is constitutive (Dickson et al., 1985b).  
Most of the early work on the transcriptional regulation of TTR gene 
expression in the liver, choroid plexus and visceral yolk sac of rats, was discovered by 
Cost and co-workers. They identified that the start site for mRNA synthesis was 
identical for the TTR genes in the liver and in the choroid plexus and that both genes 
had a distal enhancer sequence at -1.86 to -1.96 kb and a promoter-proximal region 
from -70 to -200 bp from the mRNA cap site. Furthermore, they found that choroid 
plexus-specific TTR gene expression required positive element(s) within the region 3 
kb upstream (Yan et al., 1990). Four nuclear transcription factors (HNF-1, HNF-3, 
HNF-4 and C/EBP) were required for TTR gene regulation in the liver, but the same 
four did not regulate the TTR gene in the choroid plexus or in the visceral yolk sac, 
indicating that the differential cellular distribution of positively acting transcription 
factors was responsible (at least in part) for tissue-specific TTR gene expression 
(Costa et al., 1990). They then revealed that the decrease in hepatic TTR gene 
expression during the acute phase response in the liver was due to the down-
regulation of HNF-3α (Qian et al., 1995) and HNF-3β (Samadani et al., 1996)). This 
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explained the observation by Dickson et al., (Dickson et al., 1986) that the TTR gene 
is under negative acute phase regulation in the liver but not in the choroid plexus 
In summary, it was proposed that T4 bound to a TH distributor protein in 
blood is in equilibrium with free T4 in blood. Because T4 is lipophilic, it partitions 
into the choroid plexus. Within the choroid plexus, the TTR newly synthesised by the 
epithelial cells binds to the T4 which entered the choroid plexus from the blood. 
Choroid plexus-derived TTR is secreted into the CSF (not into the blood), so the 
TTR-T4 complex would be secreted into the CSF, followed by its distribution via the 
CSF to the brain tissue. Thus, the TTR synthesised by the choroid plexus is involved 
in moving T4 from the blood into the CSF. 
Humans lacking either of the other two TH distributor proteins (albumin or 
TBG) had been described, but no humans lacking TTR had been identified. The 
hypothesis in the early 1990s was that as TTR is the only TH distributor protein 
synthesised in the brain (choroid plexus) and its important role in movement from 
blood to CSF, it was thought to be crucial for survival, most probably due to the 
requirement of adequate amounts of TH for normal CNS development. (However, 
today we believe that the absence of humans lacking TTR could indicate a more 
fundamental role of TTR than just TH distribution, as (i) only about 1 in 200 TTRs in 
the blood have a TH bound. (ii) To our knowledge the only example of a clinically 
silent (non-amyloidogenic; euthyroid) but common polymorphism of TTR is the Ser6 
variant. This Gly6Ser variant TTR has been reported to be present in 6% of the 
American Caucasian population and 1% of African Americans, but interestingly was 
not detected in Africans or Asians (Jacobson et al., 1995). (iii) Variant TTRs 
generally bind THs with lower affinity than wild type TTR. (iv) Despite TTR amyloid 
formation in FAP, FAC and SSA patients, they are usually euthyroid as only about 
1/200 TTRs in blood have a TH bound. 
1.4.4.2 Analyses of TTR null mice 
The production of TTR null mice (Episkopou et al., 1993) that were viable and 
fertile threw the above hypothesis on the role of choroid plexus-derived TTR into a 
heated debate. The TTR null mice had reduced levels of total T4, total T3, retinol and 
retinol-binding protein, but did not show any overt phenotype. Palha and colleagues 
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concluded that TTR was not important for THs to reach the brain. (Palha et al., 1994, 
Palha et al., 2002, Palha et al., 1997) 
This putative TH distribution role of TTR was questioned, with some studies 
disputing whether TTR was carrying THs to tissues and to the brain. One study 
applied special conditions, such as removing the thyroid gland and exposing the mice 
to cold in a way that increased the metabolic demand for THs (Sousa et al., 2005). 
The investigators concluded that there were no differences in the distribution of the 
THs to tissues of TTR null mice compared with wild type mice, except in the choroid 
plexus. Moreover, they determined that in the TTR null mice, the T3 level was 48% 
and the T4 level was 14% in the choroid plexus, compared to wild type mice. 
However, the levels were normal in all other brain regions (Almeida Palha et al., 
2000). Furthermore, morphological data demonstrated that wild type and TTR null 
mice injected intravenously with high specific activity 125I-T4 or 125I-T3 did not show 
any difference in their distribution throughout brains (Palha et al., 2002). This 
bolstered the interpretation that TTR is not important as a TH distributor. Thus, 
several studies by these researchers concluded that TTR is not important for delivery 
of THs to tissues, especially in the brain, and that TTR null mice should be considered 
euthyroid (Palha et al., 1994, Sousa et al., 2005, Almeida Palha et al., 2000, Palha et 
al., 2002). 
Meanwhile, the regulation of neural stem cell (NSC) cycle in the 
subventricular zone of adult rodent brain was shown to be dependent on TRα / TH, 
with these factors influencing both cell proliferation and apoptosis (Lemkine et al., 
2005). Thus, it was hypothesised that if TTR was involved in the delivery of TH to 
the NSC niche, then this population of cells in TTR null mice would be affected. 
Indeed, TTR null mice were shown to have reduced apoptosis of NSCs in 
subventricular zone (SVZ) compared to wild type mice. Furthermore, the level of 
apoptosis was similar to that of hypothyroid wild type mice, implying a significant 
reduction of TH delivery to NSCs in this niche (Richardson, 2007). It was suggested 
that because the dissociation rate of T4 from albumin differs so significantly to that of 
T4 and TTR, that in the absence of TTR, albumin would be unlikely to distribute 
significant amounts of TH beyond the ependymal of the brain, resulting in the 
reduction of TH reaching the SVZ (Richardson, 2007), as healthy adult mice do not 
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synthesise TBG (Savu et al., 1991). This study highlighted the importance of TTR in 
delivering TH to one of the two populations of NSCs in adult mammalian brain. 
Until then, all studies involving TTR null mice had been focused on adult 
mice. However, it is well known that THs affect growth and development, particularly 
of the CNS (Escobar del Rey et al., 1987). In severe cases, TH deficiency in human 
babies during gestation results in stunted growth and mental retardation. Therefore, 
several aspects of growth known to be influenced by TH were examined during post-
natal development in TTR null mice. The absence of TTR resulted in delays in several 
TH-regulated events including bone growth, CNS maturation, intestine and muscle 
development and in weaning (Monk et al., 2013). This indicated that TTR has a role 
in TH delivery to multiple target tissues, including the CNS, during postnatal 
development (Richardson, 2007). 
 
1.4.4.3 Discovery of TH transporters 
The first publication on TH transport that indicated an energy-dependent 
process for TH uptake into cells was in 1954 (Christensen et al., 1954) but was “lost” 
in the literature for decades. For an edifying history of ideas about TH entry into cells, 
see (Hennemann et al., 2001). Initially, it was believed that THs entered cells purely 
by diffusion, however, TH uptake was subsequently shown to be saturable, energy-
dependent and Na+-dependent. Currently, several families of membrane-bound TH 
transporter proteins have been identified, which belong to the solute carrier family of 
transporters (SLC). These include the organic anion transporting polypeptides 
(OATPs), monocarboxylate transporters (MCTs) and L-type amino acid transporters 
(LATs). These SLCs actively participate in entry and efflux of THs into and out of 
cells (Visser et al., 2011, Alkemade et al., 2011). Several TH transporters have been 
localised to the choroid plexus (Mayerl et al., 2012). Intriguingly, there exists 
dramatic species-specificity in TH transporter deficiency phenotypes. For example, 
human males with MCT8 mutations present with mental retardation (IQ <40), speech 
deficits and severe neurological abnormalities, whereas MCT8 null mice are without 
an overt neurological phenotype (Kersseboom and Visser, 2011). The discovery of the 
suite of TH transporters, particularly in the choroid plexus, was important in 
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understanding how TTR null mice were without an overt phenotype. The difference in 
phenotype between MCT8 variant human males and MCT8 null mice, could point 
towards elucidating why TTR null mice exist, yet no human lacking TTR has been 
reported. 
There is now evidence for two mechanisms for TH entry into the choroid 
plexus and other tissues: (1) diffusion due to lipophilicity of THs and (2) TH 
transporters. The relative quantitative contribution of each is currently unknown and 
should be investigated. 
From the above controversy regarding the importance of TTR synthesis by the 
choroid plexus, several points support the hypothesis that TTR plays a role in the 
movement of THs from the blood to the brain and in distributing THs in the blood and 
CSF. These points include:  
(1) The presence of high levels of TTR mRNA in the choroid plexus: there is more 
TTR mRNA per gram wet weight choroid plexus than in any other tissue including 
the liver (Schreiber et al., 1990);  
(2) TTR mRNA is present in choroid plexus primordia (Thomas et al., 1988) 
(3) For both altricial and precocial animals, the peak of TTR synthesis by the choroid 
plexus is just prior to the time of most rapid brain growth (Richardson, 2005); 
(4) The predominant synthesis of TTR in the choroid plexus: TTR comprises about 
20% of the total protein synthesised by the choroid plexus and about 50% of protein 
secreted by the choroid plexus (Dickson et al., 1986); 
(5) That TTR synthesised by the choroid plexus is entirely secreted into the CSF, 
rather than into the blood (Schreiber et al., 1990); 6) The distribution of intravenously 
injected 125I-T4 in the brain, which first appears in the choroid plexus, then in the 
CSF, and lastly, in various parts of the brain (Dickson et al., 1987, Schreiber et al., 
1990). This was not seen in analogous studies in TTR null mice (Monk et al., 2013); 
(6) TTR is the major protein synthesised by the choroid plexus of all reptiles, birds 
and mammals studied to date, which suggests that synthesis of TTR by the choroid 
plexus and its secretion into the CSF is an evolutionarily important function (Harms et 
al., 1991, Achen et al., 1992);  
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(7) Comparison of the amino acid sequences of TTR from all vertebrate classes 
reveals an extremely high level of conservation of amino acid sequence across more 
than 400 million years (Richardson, 2007); 
(8) Reduced TH bioavailability to neural stem cells in subventricular zone of TTR 
null mice (Richardson, 2007); 
(9) Delayed development of the CNS in TTR null mice (Monk et al., 2013). 
In summary, our current hypothesis is that TTR plays a role in movement of 
T4 from blood into CSF, but the quantitative contribution relative to other 
mechanisms needs to be evaluated. This does not preclude TTR from having other 
functions in the CNS. 
1.4.5 Binding of TTR to retinol-binding protein (RBP) 
Besides its role as a TH distributor protein, TTR can also bind to retinol-
binding protein (RBP), which is a single polypeptide chain of 182 amino acids; ~21 
kDa (Goodman, 1984). Up to two molecules of RBP can bind the external surface of 
TTR at sites independent of the TH-binding sites (Figure 1-2) (Noy et al., 1992, 
Monaco et al., 1995, van Jaarsveld et al., 1973). The affinity of TTR is higher for 
RBP-retinol than for apo-RBP (Noy et al., 1992). It was proposed that binding TTR 
(~68 kDa) to either one or two RBP-retinol (~21 kDa) to form complexes of either 
~90 or ~110 kDa would prevent loss of RBP-retinol through kidney glomerular 
filtration into the urine (Kanai et al., 1968, Peterson, 1971). It was also suggested that 
TTR is responsible for the delivery of the RBP to tissues (Blaner, 1989). Robinson 
and colleagues were interested in investigating the delivery of retinol to various 
tissues, so decided to produce TTR null mice. The overall phenotype of TTR null 
mice was surprisingly similar to that of wild type mice and this raised questions about 
the function of the TRR-RBP complex (Episkopou et al., 1993). However, despite the 
TTR null mice having drastically reduced levels of retinol in plasma (<6% wild type 
value) and similarly low levels of RBP in plasma (3% wild type value), they showed 
no signs of vitamin A deficiency (Episkopou et al., 1993) nor impaired visual function 
(Bui et al., 2001). The high levels of RBP in the liver of TTR null mice (Wei et al., 
1995) supported the hypothesis that TTR is required for RBP secretion from the liver 
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(Melhus et al., 1991). However, a small amount of RBP was detected in the urine of 
TTR null and wild type mice (Wei et al., 1995). Despite the fact that adult fish have 
no TTR in their plasma (Richardson et al., 1994), they still have RBP in their 
bloodstream (Berni et al., 1992). The question remains as to whether RBP-retinol 
binds to a different plasma protein in animals such as fish, amphibians, reptiles, 
monotremes and some marsupials which lack TTR in their blood during their adult 
life. Thus, there is no clear understanding of the main function of the TTR-RBP 
complex and the relationship between the levels of TTR, RBP and retinol.  
1.4.6  Binding of TTR to DNA  
When the 3D structure of TTR was determined by Blake and colleagues in the 
1970s (Blake et al., 1978, Blake et al., 1971) it was known that THs regulate gene 
transcription, but the TH receptors had not yet been identified. Close analysis of the 
structure of TTR revealed that it had complementary structure to the major groove of 
DNA. Thus, it was proposed that TTR may act as a model for the TH nuclear receptor 
(Blake and Oatley, 1977) (Figure 1-6A). However, TTR is an extracellular protein 
and has not been identified in the nucleus. Subsequently, the TTR polypeptide was 
found to have a pre-segment which directed it for secretion (and not a nuclear 
localisation sequence). Finally, the suggestion of TTR being a DNA-binding protein 
mediating the effects of TH on gene transcription was put to rest after identification of 
the TRs (Evans, 1988). Thus, the effects of THs on regulation of gene transcription 
are known to be via the TRs, rather than via a TH-TTR-DNA interaction. 
However, in the late 1990s open reading frames which theoretically could 
code for TTR-Like Proteins (TLPs) were identified (Prapunpoj et al., 2000). These 
theoretical transcripts did not appear to have pre-segments which would direct the 
protein for secretion. Furthermore, the organisms whose genomes had genes for TLPs 
included bacteria, which do not have a nucleus. Thus, if these theoretical TLPs were 
transcribed, translated and formed tetramers with structures similar to TTRs, it would 
be feasible for them to bind to DNA, as they would exist within the same 
compartment (in contrast to the situation for eukaryotes). Molecular modelling of a 
TLP and simulated docking to double strand DNA suggested that this interaction 
could be possible (Richardson et al., 2005a) (Figure 1-6B). The genes coding for 
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TLPs were found to be expressed in several organisms including bacteria, the worm 
C. elegans and the plant Arabidopsis (Hennebry et al., 2006). Of the 80+ TLP genes 
identified, most had no signal sequence so presumably coded for proteins that were 
cytosolic i.e. hypothetically could interact with DNA (Hennebry et al., 2006). 
Recombinant TLPs were synthesised and found not to bind THs (Hennebry et al., 
2006, Eneqvist et al., 2004), despite having x-ray crystal structures almost identical to 
those of TTRs (Hennebry et al., 2006). TLP was found to be an enzyme involved in 
uric acid degradation: 5-hydroxyisourate hydrolase (Hennebry et al., 2006). From an 
evolutionary perspective, the original function of TLP/TTR was intracellular. Recent 
reports of TTR synthesis in Schwann cells, dorsal root ganglia (DRG) and neurons 
suggest intracellular functions for TTR in mammals. We are unaware of any 
published data on trials of TLPs binding to DNA. As increasing novel functions for 
TTRs are being elucidated (see below), binding of TTR to DNA cannot be completely 
ruled out until it has been tested experimentally. 
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Figure 1-6: Models showing the similarity of the potential DNA-binding groove 
of transthyretin (TTR) and TTR-like protein (TLP). 
 (A) Close analysis of the structure of TTR revealed that it had a complementary 
structure to the major groove of double-stranded DNA. (B) Molecular modelling of 
Salmonella dublin TLP and simulated docking to double-stranded DNA suggested 
that this interaction could be possible (Richardson et al., 2005b). Dimers are shown 
for simplicity (Alshehri et al., 2015). 
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1.4.7 TTR and cleavage of apolipoprotein AI 
TTR can act as a novel plasma cryptic protease by cleaving the C-terminal 
region of apolipoprotein AI (apoA-I), specifically, after Phe225. This activity was 
reduced in the presence of serine protease inhibitors, indicating a chymotrypsin-like 
activity. Furthermore, this activity was ablated when TTR was bound to RBP, 
suggesting a possible catalytic site on TTR near the RBP binding site. Only a slight 
decrease in activity was noticed in the presence of T4. This study proposed a new 
function for TTR in lipid metabolism, and speculated that TTR may be involved in 
initiating apoA-I amyloid formation (Liz et al., 2004). A later study confirmed that 
apoA-I which has been cleaved by TTR has reduced ability to promote cholesterol 
efflux and bolstered the hypothesis that apoA-I cleavage by TTR could increase the 
potential for the C-terminal region of apoA-I to form amyloid under in vitro 
conditions (Liz et al., 2009). 
1.4.8 TTR and neuropeptide Y proteolysis 
TTR null mice have increased expression of the peptidylglycine α-amidating 
mono-oxygenase (PAM) gene in the DRG and nerves, compared to wild type mice 
(Nunes et al., 2006). The function of PAM is to amidate the C-terminal of peptides, 
including neuropeptide Y (NPY). NPY is involved with regulating food intake, 
energy stored as fat, memory formation and stress responses, and requires C-terminal 
amidation by PAM for activation. Of particular interest, NPY is a neurotransmitter 
implicated in anxiolytic and anti-depressant-like behaviour. TTR null mice were 
found to have increased levels of amidated NPY (Nunes et al., 2006) and 
subsequently, TTR was shown to cleave amidated NPY after Arg33 and after Arg35 
(Liz et al., 2009). Thus, TTR null mice were proposed as a model for NPY 
overexpression. Accordingly, TTR null mice have a lower level of depression-like 
behaviour compared to wild type mice (Sousa et al., 2004), which will be discussed in 
greater detail in (section 1.6.2.1). 
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1.4.9 TTR and neuroprotection and neuroregeneration 
A study investigating the neuroprotective properties of TTR under conditions 
of cerebral ischemia used mice with a compromised heat-shock response (Santos et 
al., 2010). Mice that were heterozygous for heat-shock transcription factor 1 (HSF1), 
which is an activator of heat-shock proteins, were crossed with TTR-/- mice to create 
HSF1+/-TTR-/- mice which were compared with HSF1+/-TTR+/+ mice for their 
responses to induced brain ischemia by permanent middle cerebral artery occlusion. 
HSF1+/-TTR-/- mice had increased cortical infarction volumes, cerebral oedema 
volumes and microglial-leukocyte response compared with HSF1+/-TTR+/+ mice. 
Furthermore, infarcts contained TTR that was derived from the CSF (not from the 
blood). Interestingly, the combination of compromised heat-shock response and lack 
of TTR was required for the neuroprotective effects of TTR to be revealed: there was 
no significant difference in infarct sizes between wild type mice and TTR-/- mice 
following permanent middle cerebral artery occlusion. 
An epidemiological study of 68,602 members of the Danish population 
revealed that individuals who were heterozygous for the TTR variant Thr119Met (a 
TTR variant that has increased stability of the tetramer) had decreased risk of 
cerebrovascular disease and an increased life expectancy (Hornstrup et al., 2013). 
Whilst the individuals heterozygous for Thr119Met had elevated levels of TTR and 
total thyroxine in their blood, all other aspects of thyroid function were considered 
normal. Moreover, carriers of Thr119Met who died from cerebrovascular disease 
were older at diagnosis than non-carriers and had a greater life expectancy than non-
carriers. Thus, it was suggested that compounds that stabilise TTR, such as Tafamidis 
(see section 5.4) could have beneficial effects for the general population. 
Another study based on TTR null mice revealed that TTR may play a critical 
role in the promotion of neuroregeneration (Fleming et al., 2007). This possibility was 
investigated by crushing the sciatic nerve in wild type and TTR null mice, followed 
by morphometric and electrophysiological analyses of the peripheral nerve. The 
investigators observed a decrease in the capacity of the sciatic nerve to regenerate in 
the TTR null mice compared with the wild type mice. 
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Further support for the role of TTR in neuroregeneration came from a study 
investigating the proteolytic (cleavage of apoA-1) function of TTR. A 
glutathionylated variant of TTR in which the proteolytic function was lost (TTRprot-) 
was prepared. The ablation of proteolytic activity did not affect the binding of T4 or 
RBP but did reduce the neurite length of PC12 cells in culture (Liz et al., 2009). This 
finding supported the hypothesis that TTR may have further natural substrates in the 
nervous system, in addition to THs and RBP-retinol and strengthened evidence for the 
role of TTR in neuroregeneration (Fleming et al., 2007). TTR neuritogenic activity 
was then found to be dependent on its internalisation into dorsal root ganglia cells via 
receptor-mediated endocytosis, specifically, by the megalin receptor (Fleming et al., 
2009). Megalin is also expressed by oligodendrocytes (Wicher et al., 2006b) , thus, 
TTR may enter oligodendrocytes via the same pathway.  
An investigation into the expression of TTR in the nervous system revealed 
that neurons can synthesise TTR. TTR mRNA was detected in cultured primary 
neurons isolated from the cortex of adult mice and the hippocampus of embryonic 
mouse brains (Alkemade et al., 2011). A similar observation was revealed for 
peripheral nerve Schwann cells from mice carrying the human TTR gene containing 
the Val30Met mutation (Murakami et al., 2010). However, the precise roles and 
mechanism(s) of action of TTR in these cells has not yet been revealed. 
Given that TTR-Like Protein (the evolutionary precursor to vertebrate TTR) 
was an intracellular protein, it is tantalising to suggest that TTR could have an 
intracellular function in the CNS, in addition to being an extracellular distributor for 
THs and RBP-retinol in the CSF. Alternatively, TTR synthesised by neurons could be 
involved in delivering THs to other adjoining cell types which do not have TH 
transporters (Figure 1-7). 
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Figure 1-7: Schematic of possible roles of transthyretin in thyroid hormone 
delivery in the central nervous system. 
Thyroid hormones thyroxine (T4) (yellow) and T3 (green) are secreted from the 
thyroid gland into the blood where they are transported bound to TH distributor 
proteins (blue; for more details, see figure 1-4). From the blood vessels, THs can enter 
the choroid plexus (CP) either by passive diffusion (not shown; for more details, see 
figure 1-4) or via membrane-bound TH transporters such as MCT8 (orange) or 
OATP1c1 (grey). THs can leave the choroid plexus and enter the cerebrospinal fluid 
(CSF) via either diffusion, membrane-bound TH transporters or via binding to 
transthyretin (TTR) (blue) synthesised by the choroid plexus epithelial cells. THs can 
be transported to astrocytes via MCT8 and OATP1c1 and subsequently can be 
exported to neurons via MCT8. Neurons most probably synthesise TTR in healthy 
individuals (Alkemade et al., 2011). The mechanism for the transport of THs into 
oligodendrocytes is currently unknown. D3, type 3 deiodinase; T2, 3,5-diiodo-L-
thyronine; T3, 3´,3,5-triiodo-L-thyronine (Alshehri et al., 2015). 
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1.5 Endocrine disruption of TTR-mediated TH functions in the CNS 
As described above, liver-derived TTR is involved with distribution of THs 
throughout the body via the bloodstream and in the delivery of TH to cells, whereas 
choroid plexus-derived TTR is involved with the movement of T4 from the blood via 
the choroid plexus into the CSF and with TH distribution throughout the CSF and the 
CNS. If we hypothesise that TTR synthesised by neurons and the hippocampus (and 
possibly elsewhere) in the CNS is related to its role in TH metabolism, then chemicals 
that are structurally very similar to THs and bind TTR thereby preventing TH binding 
to TTR, pose a significant threat to normal TH-regulated development of the CNS. 
Furthermore, given that choroid plexus-derived TTR is involved in moving THs from 
the blood into the CSF, the same mechanism could be used to bring chemicals and 
pollutants into the CSF. TTR in the CSF could distribute such chemicals throughout 
the CNS. Furthermore, TTR is synthesised by the placenta and thus could be 
implicated in moving chemicals and pollutants from the maternal circulation into the 
foetus. This could be particularly dangerous during critical windows of TH-regulated 
development in the foetal brain. Thus, TTR could be an important player in 
facilitating TH endocrine disruption.  
There is a growing awareness of the exponentially increasing number of 
chemical pollutants in the environment, that are biologically stable and structurally 
very similar to THs (Demeneix, 2014). These chemicals include fire retardants used in 
computers, carpet, office furniture, house hold furniture, bedding (mattresses, 
pillows), children’s clothes labelled as “non-flammable” and soft plastics such as used 
for water bottles. These chemicals can enter our bodies via ingestion (food, water) or 
by aerosols and compete with THs for binding to any of the five classes of TH 
binding proteins (Figure 1-4). In particular, interfering with TH metabolism in the 
CNS (of both adults and foetuses) is of great concern. Given the increasing number of 
sites of TTR synthesis in the CNS being revealed, the impacts of chemicals that 
mimic THs in soft plastics (e.g. soft plastic water bottles), petrol and fire retardants 
should be considered very seriously. 
There are many different endocrine disrupting chemicals (EDCs) which are 
able to bind to TTR (Table 1.1). These EDCs can affect both the stability of the TTR 
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tetramer (McCammon et al., 2002), as well as its ability to bind and distribute TH and 
RBP-retinol (Brucker-Davis, 1998).  
Flavonoids or bioflavonoids are groups of chemicals that have similar 
chemical structures to THs, with significant affinities for TTR and therefore can 
interfere with TH distribution (Schroder-van der Elst et al., 2003). Examples of these 
chemicals are the flavone derivatives 4, 4ʹ, 6-trihydroxyaurone (Auf'mkolk et al., 
1986) and 3ʹ, 5ʹ-dibromo-2ʹ, 4ʹ, 4ʹ, 6-tetrahydroxyaurone (Ciszak et al., 1992). 
Flavonoids are widely distributed in plants; therefore, everyday foods (especially 
vegetarian diets) contain large amounts of these compounds. Consumption of these 
foods can increase the levels of these compounds in the plasma, displacing THs from 
TTR. In vivo experiments using the synthetic flavonoid 3-methyl-4ʹ, 6-dihydroxy-3ʹ, 
5ʹ-dibromoflavone (F21388), have shown that the levels of TH in the plasma of rats 
have been altered as a result of F21388 binding to TTR (Kohrle et al., 1989). Certain 
plants have been used in traditional folk medicine, for treatment of symptoms of 
thyroid disorders, including in regions of Germany and Austria. 
Anthranilic acids, which are involved in the synthesis of non-steroidal anti-
inflammatory drugs (NSAIDs), form another group of chemicals that can strongly 
interfere with TH binding to TTR (Munro et al., 1989). Various compounds derived 
from this class have significant affinities for TTR, such as the flufenamic, 
meclofenamic and mefenamic acids. Flufenamic acid has the highest affinity for TTR, 
even higher than that of T4 (Munro et al., 1989). High doses of aspirin or other 
salicylates (more than 2 g/day) decrease TTR binding to TH, and the levels of the 
total TH in the plasma decreases to between 20 % and 40 % (Larsen, 1972). 
A large number of chemicals have been listed as being responsible for the 
reduction in levels of THs (Howdeshell, 2002, Brucker-Davis, 1998). Some of these 
industrial chemicals interfere with TH binding to TTR. For example, polychlorinated 
biphenyls (PCBs) are a group of such environmental pollutants that directly adversely 
affect human health. PCBs have similar chemical structure to THs which allow them 
to easily interfere with TH metabolism (Porterfield, 1994). Members of the family of 
PCBs have a range of affinities for TTR, and 3, 3´, 5, 5´-tetrachlorobiphenyl (TCB) 
has the highest binding affinity compared to the other forms (Rickenbacher et al., 
1986). For in vivo analyses, inverse relationships were suggested between the levels 
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of TH and PCBs in human plasma (Brouwer et al., 1998). Additionally, a decrease in 
the level of TH was observed in the plasma of common seals that were fed with fish 
contaminated with PCBs (Brouwer et al., 1989). 
Due to the role of TTR as a TH distributor to and within the adult and foetal 
brains, various studies have focused on the consequences of EDCs during critical 
periods of neurodevelopment (Porterfield and Hendry, 1998, Colborn, 2004). It has 
been hypothesised that PCBs may have detrimental effects on the development of the 
foetal brain (Brouwer et al., 1998). It has also been suggested that PCBs are 
transported in the blood of the mother, and then enter the foetus by crossing the 
placenta. Once inside the foetus, PCBs interfere with TH distribution, resulting in 
decreasing levels of TH in the foetal brain (Soechitram et al., 2004). Another study 
suggested that PCBs may cause a delay in nervous system development (Brouwer et 
al., 1995). Furthermore, the children of women who ate fish contaminated with PCBs 
have been shown to suffer memory deficits. At the age of 11 it was shown that they 
suffered from both long term and short term memory deficits (Jacobson et al., 1990). 
Hearing deficits have also been reported in rats that have been exposed to PCBs 
(Goldey et al., 1995). The same deficits were noticed in the hypothyroid group 
(Goldey et al., 1995). Interestingly, treating the rats exposed to PCBs with TH 
resulted in a partial return of hearing (Goldey and Crofton, 1998). 
These studies are not recent, yet there has been little pressure on governments 
to more closely scrutinise the increase in such EDCs being used in manufacturing 
(Demeneix, 2014). A recent study has shown that EDCs also adversely affect early 
neurogenesis (Fini et al., 2012). Given the role of THs in normal growth and 
development of the CNS, this could have implications for pregnant women. If the TH 
disruption in the CNS is even in part mediated by TTR, then more recent discoveries 
of TTR functions in the CNS (dendrite outgrowth, synthesis in neurons, nerve 
regeneration, memory etc.) could be adversely affected by pollutants, fire retardants, 
industrial chemicals, compounds in soft plastics etc whose structures mimic THs, as 
well as by some chemicals such as fluorinated surfactants that have no structural 
homology with TH. The accumulation of such compounds in our environment is 
exponential and we are unlikely to see the full consequences in the short term. In our 
opinion, the potential role of TTR in mediating endocrine disruption in the CNS is 
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currently under-estimated. A recent article in Environmental Health Perspectives 
summarises the concerns among scientists from 13 countries, about the impact of 
endocrine disruptors on the health of humans and wildlife (Bergman et al., 2013) and 
a more recent paper in the same journal identified uterine exposure of specific 
endocrine disruptors with increased autistic behaviour with the child was 4 to 5 years 
old (Braun et al., 2014). 
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Table1-1: Endogenous and exogenous compounds that bind TTR. 
A. Endogenous ligands 
• Thyroid hormone (Ingbar, 1958) 
• Retinol- binding protein (Kanai et al., 1968) 
• Apolipoprotein AI (Liz et al., 2004)  
• Neuropeptide Y (Liz et al., 2009) 
 
B. Exogenous disrupting chemicals and drugs 
 (Van den Berg et al., 1991, Munro et al., 1989, den Besten et al., 1991) 
• Amiodarone • 2,4-Dinitrophenol 
• Anthranilic acid class  • 2,4-Dinitro-6-methylphenol 
• Bromoxynil (3,5-bibromo-4-
hydroxybenzonitril)  
• 2,4-Dichlorophenol 
• Bumetanide • 2,6-Dichlorophenol 
• 4-(Chloro-o-tolyloxy) acetic acid  • Ethacrynic acid 
• 4-(4-Chloro-2-methylphenoxy) 
butyric acid  
• Ethyl-bromophos 
• Chlorophenol  • Ethyl-parathion  
• Chloroxuron  • Fenclofenad 
• Diclofenac • Fenoprofen 
• Diflunisal • Flufenamic acid 
• Diphenylhydantoin • 2-Hydroxybiphenyl 
•  2,4-dichlorophenoxyacetic acid • 4-Hydroxybiphenyl 
• 3ʹ, 5ʹDdibromo-2ʹ, 4ʹ, 4ʹ, 6-
tetrahydroxyaurone 
• Heparin 
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• 2,4-Dichlorophenoxybutric acid  • Hexachlorobenzene  
• Dioxtylphthalate • Hexachlorophene  
• o,p´- 1,1-dichloro-2,2-bis(p-
chlorophenyl) ethane. 
• Iopanoic acid 
• p,p´- 1,1-dichloro-2,2-bis(p-
chlorophenyl) ethane. 
• Ibuprofen 
• 2,3-Dichlorophenol • Indomethacin 
• Ipodate • Salicylates 
• Ketoprofen • Sodium salicylate 
• Lindane • Sulindac 
• Linuron • Tolmetin 
• Meclofenamic acid • 2,4,5-Trichlorophenoxyacetic acid 
• Mefenamic acid • 1,4-Tetrachlorophenol 
• Milrinone • PCB-77  
• 3-methyl-4ʹ, 6-dihydroxy-3ʹ, 5ʹ-
dibromoflavone (F21388) 
• Trichloroacetic acid  
• Naproxen • Trichlorobenzene  
• Oxyphenylbutazone • 2,3,4-Trichlorophenol  
• Phenylbutazone • 2,4,5-Trichlorophenol  
• Pentachlorophenol • 2,4,6-Trichlorophenol 
• Phenol  • 2,4,5-Trichlorophenoxyacetic acid 
methyl ester 
• 2-(2,4,5-Trichlorophenoxy) 
propionic acid [fenoprop] 
• 4, 4ʹ, 6-trihydroxyaurone 
• Pyrogallol  • 1,4-Tetrachlorophenol 
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1.6 Diseases caused by TTR 
1.6.1 TTR and amyloidosis 
Amyloidosis is a disease characterised by changes in the solubility of various 
proteins from being soluble proteins to insoluble extracellular fibril protein deposits 
around the tissue, causing dysfunction for the effected organ. A wide range of 
proteins have been involved in causing amyloidosis, and TTR is one such protein. 
TTR amyloidosis is the most common type of heritable amyloidosis (Benson, 2009). 
TTR can cause two main types of amyloidosis: one type is derived from normal-
sequence TTR and the other is derived from variant-sequence TTR. The amyloidosis 
caused by deposition of the normal-sequence TTR is called Senile Systemic 
Amyloidosis (SSA), whereas that caused by variant-sequence TTR is celled either 
Familial Amyloidotic Polyneuropathy (FAP) if amyloid deposition occurs initially in 
peripheral nerves , or Familial Amyloidotic Cardiomyopoathy (FAC) if the amyloid 
deposition initially occurs in the heart (Jacobson et al., 1997). 
SSA is an acquired type of amyloidosis. It is not inherited and can affect 
individuals from any ethnic background. SSA is associated with aging and symptoms 
typically begin after the age of 65, with the incidence being at least ten times more 
prevalent in men than in women (Westermark et al., 1990). The deposition of TTR in 
SSA amyloidosis can be localised to a specific organ or can be systemic (Pitkanen et 
al., 1984), however, it is often found in the heart of elderly patients (Ng et al., 2005), 
and the causes of SSA are still unclear. The observation that nearly all SSA patients 
are male, is also intriguing, compared with TTR FAP where the sex ratio is about 
60:40 male to female (Benson, 2009). 
The variant-sequence TTR amyloidosis (ATTR) is one of the FAP subclasses, 
thus it is called TTR FAP, and most frequent form of hereditary systemic 
amyloidosis. In 1952, FAP was described for the first time in north Portugal 
(Andrade, 1952). Thereafter, TTR was identified as a precursor protein that causes 
FAP Amyloidosis (Costa et al., 1978). TTR FAP occurs as a result of mutations in the 
TTR gene. There are at least 113 point mutations in the TTR gene that result in FAP 
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(Benson and Kincaid, 2007). The most common pathogenic mutant found in TTR 
FAP patients is Val30Met, where the valine is replaced by methionine at position 30 
(Saraiva et al., 1984). This mutation results in the aggregation of variant TTR 
(Val30Met TTR) which then forms stable, insoluble fibrils which are then deposited 
in the tissue. The Val30Met mutation affects about 1 in 500 individuals in northern 
Portugal and is quite common in some regions of Sweden, Japan, Brazil, Majorca and 
Ireland. However, FAP is uncommon in the rest of the world. FAP is found in just 1 
in 100,000 individuals throughout the USA and Europe. It has been estimated that 
worldwide around 10,000 individuals have FAP (Ando et al., 2013). 
1.6.1.1 Symptoms of TTR FAP 
The symptoms of TTR FAP disease differ between countries, even for the 
same mutation. For example, the Val30Met mutation manifests differently in Sweden, 
Japan and Portugal. The age of onset varies between countries also, with some 
starting before the age of 40 (Japanese and Portuguese) while for others, after the age 
of 55 (Swedish) (Benson, 2009). Within 10–20 years, the symptoms start to be severe 
and cause fatal sensory, motor and autonomic polyneuropathy deficits (Coutinho, 
1980). The symptoms start with sensory neuropathy leading to severe affects in 
temperature sensations and weakness in all sensory modalities (Dyck and Lambert, 
1968). The loss of temperature perception followed by loss of touch and pain occurs 
starting at the distal extremities of limbs and progressing in a proximal direction 
(Benson and Kincaid, 2007). The motor neuropathy begins at a later stage and is 
characterised by weakness and wasting. Subsequently, a lower limb manifestation 
occurs followed by loss of reflexes with upper limb involvement (Guimarães et al., 
1980). Bowel dysfunction and early satiety result in weight loss and malnutrition. 
1.6.1.2 Neuropathogenesis of TTR FAP  
TTR amyloid is initially deposited in the peripheral nervous system (PNS) in 
the epineurium, perineurium and universally in the endoneurium of the nerve fiber 
(Da Silva Horta and Trincao, 1963, Andrade, 1952). Conversely, the amyloid can 
accumulate prominently in the stroma of the dorsal root ganglia (DRG) in the area 
which is in close contact with Schwann cells, satellite cells and with progressive loss 
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of neurons (Sobue et al., 1990). The main pathological feature of TTR FAP is axonal 
degeneration in the sensory and autonomic nervous system, and the cause of this 
degeneration is still unknown (Sousa and Saraiva, 2003). Also, a severe loss of neuron 
populations has been revealed, especially small diameter neurons of the DRG (Sobue 
et al., 1990). Nerve biopsy specimens from patients with advanced-stage FAP 
revealed significantly fewer myelinated and unmyelinated nerve fibres. The extent of 
degenerative changes in axons, myelin sheath and Schwann cells reflected the severity 
of the patients’ symptoms (Takahashi et al., 1991).  
1.6.1.3 Treatment of TTR FAP disease 
Until recently, the most common form of treatment for TTR FAP patients was 
a liver transplant, being performed to remove the main production site of the mutant 
protein and thereby helping reduce/remove the mutant TTR from plasma (Suhr et al., 
2000, Ando, 2005, Furihata, 1994). The outcome of the procedure is varied, with 
many cases showing improvement with the progress of amyloid deposition and 
neurological symptoms seeming to halt or slow down after transplantation (Herlenius 
et al., 2004). Unfortunately, for many patients the symptoms worsen and a progressive 
cardiomyopathy seen in some patients is especially problematic, presumably caused 
by continued incorporation of wild type TTR to the pre-existing TTR fibril deposits 
(Herlenius et al., 2004, Yamamoto et al., 2007, Yazaki et al., 2007, Ihse et al., 2011). 
This phenomenon is known as “seeding” where the normal wild type protein can 
continue to be integrated to growing fibrillary aggregates. Other draw-backs include 
the expenses of medical care, constant use of immunosuppressants post- surgery and 
adverse side-effects. However, the greatest problem is the global shortage of liver 
donors (Ando, 2005). Therefore, there is a strong drive for medical research to find 
alternative treatments in the long term (Benson et al., 2010, Liepnieks and Benson, 
2007, Llado et al., 2010, Miller et al., 2004, Palaninathan et al., 2009, Suhr et al., 
2000, Takei et al., 2007, Yamamoto et al., 2007).  
Domino liver transplantation (DLT), where a patient receiving a liver in turn 
donates part of their own liver to another recipient, has been performed since the mid-
1990s (Bispo et al., 2011, Ericzon et al., 2008). Although livers from a handful of 
metabolic disorders cured by liver transplantation have been used for DLT, FAP 
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livers are by far the most common. FAP does not manifest clinically before the age of 
about 20, so FAP livers are given to recipients over the age of 60, so these recipients 
do not develop FAP. Because only a proportion of patients with FAP develop 
symptoms, these livers can be justified being given to other patients on waiting lists 
for liver transplantation. DLT for patients with severe liver damage receiving a FAP 
liver has been very successful, with only 2 out of >500 recipients showing clinical 
symptoms of amyloidosis after 7 or 8 years post transplantation (Bispo et al., 2011, 
Ericzon et al., 2008). However, some reports have revealed that despite receiving a 
healthy liver, some domino liver recipients developed symptoms earlier and amyloid 
deposits have been found in domino liver recipients as early as 4 years after 
transplantation (Stangou et al., 2005). Biopsy samples from various sites such as 
gastric mucosa (Takei et al., 2007), duodenum and nerves (Goto et al., 2006) (Llado 
et al., 2010) have shown amyloid deposits (Liepnieks et al., 2010). 
Despite receiving a healthy liver, some FAP patients progress in the TTR FAP 
disease neuropathy (Liepnieks et al., 2010). This may because the choroid plexus, 
neurons and Schwann cells continue to synthesise the variant TTR.  
Much research has been conducted during the last decade on the development 
of pharmacologic agents capable of targeting TTR-FAP. These drugs have been 
classified to three categories based on their mechanism of action: (i) blockers of TTR 
synthesis, (ii) stabilizers of the TTR tetramer and (iii) clearance of TTR amyloid 
fibrils (Hanna, 2014). Small interfering RNAs (siRNA) (Lachmann, 2013, Malik and 
Roy, 2011) and antisense oligonucleotides have been used to target the first stage of 
the TTR-FAP by blocking synthesis of TTR by hepatocytes and are currently in phase 
III trials. Tafamidis (Bulawa et al., 2012) and diflunisal (Adamski-Werner et al., 
2004) act by stabilizing the tetrameric form of TTR, greatly reducing dissociation and 
consequently decreasing the rate of variant TTR-forming amyloid fibrils. Tafamidis 
has recently been approved for treatment of TTR FAP amyloidosis by the European 
Medicines Agency and is currently under consideration by the Food and Drug 
Administration (USA) (Bulawa et al., 2012) (Johnson et al., 2012); and diflusinal is 
on the market as a non-steroidal anti-inflammatory drug. Doxycycline (Cardoso and 
Saraiva, 2006) and epigallocatechin-3-gallate (Ferreira et al., 2009) act by disrupting 
then clearing TTR amyloid fibrils. Doxycycline is now in phase II trials and while 
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epigallocatechin-3-gallate has not been introduced as a drug, it is naturally present in 
green tea. 
1.6.2 Neurobiological diseases involving altered TTR levels in the CSF 
1.6.2.1 A role for TTR in depression? 
In humans, alterations in the level of TTR in the CSF have been linked with 
behavioural disorders such as depression. In 1988, an increase in the level of TTR in 
the CSF of depressed people was suggested (Jorgensen, 1988). Subsequently, that 
hypothesis was contradicted by studies from the same lab, which found decreased 
TTR levels in the CSF of untreated severely depressed patients compared to bipolar 
disorder patients. In 2006, the researchers used an improved TTR radioimmunoassay 
and found significantly decreased TTR levels in the CSF of depressed people, 
compared to the levels in healthy people. Furthermore, the concentration of TTR in 
the CSF was inversely correlated with the Scale for Suicide Ideation among the 
depressed patients and positively correlated with levels of the serotonin metabolite 5-
hydroxyindoleacetic acid which is the main metabolite of serotonin (low levels of 
serotonin in the CSF are positively correlated with depression) (Sullivan et al., 2006). 
These correlations suggested that the level of TTR in the CSF may play a critical role 
in preventing specific forms of depression, and may be associated with suicidal 
tendencies (Sullivan et al., 2006). It is known that a reduction in cerebral TH levels 
can result in depression (Haggerty and Prange, 1995). Thus, a decrease in the CSF 
TTR may lead to a reduced bioavailability of THs in the brain, precipitating 
depression (reviewed in (Hage and Azar, 2011). 
However, the forced swim test, which is usually used as a screening model for 
depression (Porsolt et al., 1977), was applied to TTR null and wild type mice (Sousa 
et al., 2004). The TTR null mice displayed a lower level of depression-like behaviour, 
compared to wild type mice. However, the levels of serotonin and 5-HIAA were not 
altered in TTR null mouse brains, which was in contrast to the report for humans 
(Sousa et al., 2004). As mentioned previously, the level of NPY in TTR null mice are 
increased, compared with wild type mice (Nunes et al., 2006). NPY administered to 
rodents had both anxiolytic-like effects (Heilig et al., 1989, Sorensen et al., 2004) and 
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anti-depressant effects (Redrobe et al., 2002, Ishida et al., 2007). Similarly, rats 
overexpressing NPY showed anxiolytic-like behaviour (Thorsell et al., 2000), 
whereas NPY knockout mice display anxiogenic-like behaviour (Palmiter et al., 1998, 
Karl et al., 2008), which may explain the anxiolytic behaviour in TTR null mice 
compared to wild type mice. Furthermore, reduced TTR in the CSF of humans could 
result in reduced delivery of THs to the CNS, which is one known cause of depression 
in humans. 
1.6.2.2 A role for TTR in memory and learning 
An alteration of TTR in the CSF, and its involvement in memory and learning, 
was investigated (Brouillette and Quirion, 2008, Sousa et al., 2007). TTR null mice 
showed aging-related memory deficits, compared to wild type mice (Brouillette and 
Quirion, 2008). In addition, a decrease in the level of TTR mRNA in the hippocampus 
was observed in aged memory-impaired rats, compared to aged memory-unimpaired 
rats (Brouillette and Quirion, 2008). The memory deficits in TTR null mice and aged 
rats were cured by introducing the active form of retinol (retinoic acid) to the affected 
animals. It was concluded that retinoic acid has a direct role in the modulation of 
certain neurophysiological process, such as long-term potentiation and synaptic 
plasticity. We hypothesise that, as TTR binds the RBP-retinol complex and RBP 
secretion from the liver of TTR null mice is impaired, perhaps RBP secretion from the 
choroid plexus is also impaired in TTR null mice, resulting in reduced availability of 
retinol in the CSF. 
The Morris water maze test was applied to five-month-old wild type and TTR-
null mice and revealed that the TTR-null mice had a limited capacity to acquire learnt 
behaviours at a young age, compared to the aged wild type mice (Sousa et al., 2007). 
During aging, the performances of 18-month-old wild type mice on the Morris water 
maze test began to decrease, showing a substantial reduction of about 30% in their 
TTR CSF levels (Sousa et al., 2007). However, there were no differences between the 
performances of 18-month-old TTR-null mice and younger ones; nor was there a 
difference between the 18 month old wild type and TTR-null mice (Sousa et al., 
2007). It appears that TTR may have a functional role in memory, and a lack of TTR 
may accelerate the poorer cognition that is normally associated with elderly people 
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(Sousa et al., 2007). A recent study suggested that TTR regulates expression of 14-3-3 
proteins in the hippocampus (Vieira and Saraiva, 2013). A significant reduction in the 
amount of 14-3-3 proteins in the hippocampus (not in other brain areas) was observed 
in 3 and 6 month old TTR null mice compared to age-matched wild type mice. 
However, there were no differences between wild type and TTR null mice at ages > 
12 months. Several studies have revealed that absence of 14-3-3 induces a deficit in 
memory and learning (Philip et al., 2001, Cheah et al., 2012). These findings are 
consistent with the memory and learning tests done with the Morris water maze 
(Sousa et al., 2007). 
Very recently, in a thorough series of behavioural tests, Buxbaum and 
colleagues investigated the differences between TTR null, RBP null and wild type 
mice describing phenotypic differences in locomotor activity and selective memory 
when compared with wild type mice (Buxbaum et al., 2014). Although sexual 
dimorphism did not seem a be a contributing factor to the majority of phenotypic 
differences, both the TTR and RBP null mice showed disparate responses with regard 
to ambulation, rearing and centre activity indicating that rbp is fundamentally 
executing motor tasks. Furthermore, TTR null mice did not differ significantly from 
wild type mice anxiety-like behaviour, working memory, cued and contextual fear-
conditioning. However, TTR null mice displayed behavioural impairments in spatial 
learning and memory when compared with RBP null and wild type mice. 
Neuroanatomically, it was revealed that TTR null mice exhibited reduced calbindin-
positive neurons and/or dendrites in the molecular layer of the CA3 region of the 
hippocampus (involved in memory and learning) suggestive of developmental 
pathology and commensurate with an astrogliotic response. Of seeming importance 
was the observation that a reduction in neuroblasts and their proliferation was 
demonstrated in the SVZs for both ttr and rbp mutant mice. Thus, the reduction in 
neuroblasts in the SVZ could account for the reduction in neurons observed in the 
neocortex, and if this is at all mirrored in the SGZ then it may help explain the 
impairment in spatial learning and memory demonstrated in these studies. 
The precise mechanism(s) of TTR involvement in memory and learning are 
being elucidated but require further clarification. 
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1.6.2.3 A role for TTR in protection against Alzheimer’s disease? 
To understand the role of TTR in AD, we first have to illustrate the 
mechanism of AD pathogenesis. The two main pathological features of AD are (i) 
increase in Aβ accumulation and (ii) abnormal processing of the amyloid precursor 
protein (APP) (reviewed in (Hardy and Selkoe, 2002). APP can be cleaved by several 
secretases to give a variety of fragments, each with an unique function (Tanzi and 
Bertram, 2005) . The first is α-secretase, which cleaves AβPP to produce alpha-
secretase cleaved APP (sAPPα) which can be cleaved further to give a carboxy-
terminal fragment: CTF83. sAPPα appears to have a neuroprotective function and to 
be involved in the development of the nervous system, promoting neurite outgrowth 
(Jin et al., 1994), synaptogenesis (Mucke et al., 1994), enhancing memory formation 
(Meziane et al., 1998) and providing neuroprotection against excitotoxic stimuli 
(Mattson et al., 1993). Moreover, A number of studies have suggested that sAPPα 
protects against AD by inducing the expression of TTR mRNA (Stein et al., 2004, 
Stein and Johnson, 2003). The second secretase is β-secretase, which cleaves APP to 
produce sAPPβ (Tanzi and Bertram, 2005). sAPPβ does not have the same 
neuroprotective properties as sAPPα. Upon further cleavage, sAPPβ releases a 35 kDa 
amino terminal fragment (N-APP) and carboxy-terminal fragment 99 (CTF99) (Liu et 
al., 2006, Wolfe et al., 1999). The N-APP behaves as a ligand for neuronal death 
receptor 6 (DR6) (Liu et al., 2006, Wolfe et al., 1999). It has been hypothesised that 
this molecule is involved in pruning of synapses during the development of both 
central and peripheral neurons. However, the CTF99 is cleaved by γ-secretase, 
ultimately releasing APP intracellular domain (AICD) and a small peptide called Aβ, 
which contribute to the toxicity of AD (Wolfe and Haass, 2001).  
A correlation between the reduction of the TTR concentration in the CSF and 
Alzheimer’s disease (AD) was first described in 1986 (Elovaara et al., 1986). In their 
study, CSF samples from 149 patients were analysed. A lower CSF TTR 
concentration was reported in patients with AD. In 1988, a negative correlation was 
discovered between TTR concentration and the degree of dementia in patients with 
AD (Riisøen, 1988). 
Different opinions have arisen concerning the TTR mechanism related to the 
prevention of AD: (i) It has been proposed that TTR has a direct role in AD by 
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sequestering β-amyloid protein (Aβ) and consequently preventing amyloid formation 
(Schwarzman et al., 1994), which in turn suppresses AD (Buxbaum et al., 2008). 
Backcrossing of the TTR null mice with an AD mouse model resulted in an increase 
in the deposition of Aβ in the brains of these transgenic mice with the hemizygous 
deletion of TTR (Choi et al., 2007). Thus, it has been proposed that in late onset AD 
patients, insufficient TTR in the CSF results in an increase in the Aβ fibre formation. 
(ii) an indirect role for TTR in AD was suggested where TTR prevents Aβ formation 
in the amyloidogenic pathway by inhibiting the cleavage of the CTF99 by γ-secretase, 
thereby reducing the amount of Aβ (Alkemade et al., 2011). (iii) TTR facilitates the 
non-amyloidogenic pathway by increasing α-secretase to cleave AβPP, which results 
in the production of sAPPα (Li and Buxbaum, 2011).  
In summary, the role of TTR in AD is still unclear. Further studies with TTR 
null mice would help to reveal the role of TTR in AD neuropathology. 
1.6.2.4 A role for TTR in protection against Schizophrenia? 
Schizophrenia is a spectrum of psychotic disorders linked with aging that 
affects at least 1% of the worldwide population. The same incidence has been 
reported for males and females (Susser and Wanderling, 1994). Nearly all brain 
functions are affected by schizophrenia. Hence, intensive and continual research is 
currently underway to find any genetic mutations or biomarkers that could help in 
treating and controlling the disease. No genetic mutations or risk genes have been 
found in screenings for the majority of schizophrenia patients (Sullivan, 2005). 
However, a reduction in the CSF TTR was proposed to be a constant biomarker in 
schizophrenia patients, compared to control samples (Huang et al., 2006). A reduction 
of approximately 10% in the CSF TTR was recorded (Reiber, 2001), along with a 
15% reduction in blood TTR, as compared to volunteer samples (Huang et al., 2006). 
Thus, it has been proposed that there is no association between CSF and blood TTR, 
and they are independently regulated (Huang et al., 2006). Differential regulation of 
the TTR gene in the liver compared to that in the choroid plexus was established 
previously (Dickson et al., 1985b). Analyses of the post-mortem prefrontal cortices of 
schizophrenia patients have revealed a nearly 40% reduction in TTR levels, compared 
to control samples (Huang et al., 2006). Therefore, a connection between reduced 
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TTR levels and the level of brain THs appears to be linked to schizophrenia (Huang et 
al., 2006). It has been suggested that a decrease in CSF TTR may lead to the reduced 
bioavailability of THs in the brains of schizophrenia patients (Huang et al., 2006). 
Unbalance in the level of the THs has an impact on the level of the main 
neurochemicals and neurotransmitters that are associated with schizophrenia, such as 
dopamine, serotonin, glutamatergic, and GABAergic. Although it is clear that the 
onset of schizophrenia occurs as a result of the interaction between genetics and 
physiological and environmental factors, the link between TH and schizophrenia can 
be substantial (Santos et al., 2012). 
The levels of TTR in the plasma of schizophrenia patients treated with 
validated antipsychotic drugs have been measured by many investigators. The level of 
TTR was up-regulated in comparison to pre-treatment levels in responding patients, 
whereas the levels of TTR were unchanged in the plasma of non-respondent patients 
(Wan et al., 2006). These findings may support the hypothesis that the presence of 
TTR plays a direct role in the pathophysiology of schizophrenia. As to animal models, 
rats treated with a long-term antipsychotic drug (clozapine) have shown increased 
levels of TTR in the hippocampus and in the cerebral cortices of rats treated with 
clozapine (Chen and Chen, 2007). Based on the above findings, TTR may have a role 
in schizophrenia pathophysiology. More studies need to be conducted to understand 
the role of TTR in the aetiology of schizophrenia.  
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1.7 Stem cells 
Stem cells are known as immature cells that are capable of self-renewal but 
have the potential to undergo differentiation into specialised somatic cell lineages. 
This attribute of stem cells classifies them into different categories based on their 
potency to differentiate into specialised cells (Mitalipov and Wolf, 2009, Till and Mc, 
1961). Thus, totipotent stem cells are those cells that have the ability to divide and 
produce all differentiated somatic cells that make up an organism, such as the zygotes 
(Mitalipov and Wolf, 2009). However, pluripotent stem cells have the potential 
to differentiate into any of the three germ layers: endoderm, mesoderm or ectoderm, 
except the trophoblasts of the placenta (Yu and Thomson, 2008). An example of a 
pluripotent stem cells includes the embryonic stem cells (ES) (Yu and Thomson, 
2008). The third category of stem cells, multipotent stem cells, have the potential 
to differentiate into multiple but limited cell types, and examples of these include 
hematopoietic stem cell (HSCs) and neural stem cells (NSCs) (Alvarez-Buylla and 
Lois, 1995, Rietze et al., 2001). The last category includes the unipotent stem cells 
that exhibit the potential to differentiate into just one cell type, such as neural 
precursor cells (NPCs) (Alvarez-Buylla and Lois, 1995, Rietze et al., 2001). 
1.7.1 Adult neural stem cells 
Neurogenesis is the developmental generation of neural cells that occurs not 
only in the embryonic brain, but also in the adult mammalian central nervous system 
(CNS) (Altman, 1962, Altman and Das, 1965). The idea of self-renewing NSCs in the 
adult brain remains under debate amongst researchers (Taupin, 2006, Rakic, 2002). 
The idea began when two independent studies showed that the adult brain contains 
self-renewing NSCs. In 1992, Reynolds and Weiss became the first investigators to 
report the in vitro characterization of NSCs isolated in the adult brain (Reynolds and 
Weiss, 1992). The researchers used NSCs isolated from the SVZ of adult mouse 
brains to establish a neurosphere colony in a medium supplemented with EGF. They 
reported that the undifferentiated NSCs expressed “nestin”, which is a marker for 
CNS stem cells. Moreover, the isolated NSCs directed themselves to differentiate 
between the main neural lineages of neurons, astrocytes and oligodendrocytes. In 
1995, Gage et al. and colleagues published the same finding, but focused on NSCs 
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isolated from adult rat brains, which they cultured in a monolayer culture system in a 
medium supplemented with fibroblast growth factor (FGF) (Aubert et al., 1995). 
These two independent studies suggested that that the adult brain contains self-
renewing NSCs.  
The debate started when Seaberg and van der Kooy cultured isolated NSCs 
from adult mouse brains as a neurosphere culture in a medium supplemented with 
both fibroblast growth factor (FGF) and epidermal growth factor (EGF) (Seaberg and 
van der Kooy, 2002). They reported that the isolated NSCs did not have self-renewal 
and/or multipotent properties. In agreement with the Seaberg finding, Bull and 
Bartlett showed that the NSCs isolated from the hippocampus of adult mice brains 
have a limited proliferative capacity, without self-renewal or multipotent properties 
(Bull and Bartlett, 2005). Differences in tissue culture protocols, culture conditions 
and the source of the isolated cells may underlie the inconsistencies between these 
studies. Importantly, despite the debate between these studies about the existence of 
self-renewal properties in adult NSCs, researchers agree regarding the presence of 
NPCs, which have the ability to give rise to specific lineages, such as neurons, 
astrocytes and oligodendrocytes (Marvin and McKay, 1992) (Figure 1-8). In the adult 
mammalian brain, the neurogenesis process involving NSCs occurs in two specific 
areas. The first area is the SVZ (Lois and Alvarez buylla, 1993, Temple and Alvarez-
Buylla, 1999, Doetsch et al., 1999), which is the area lining the lateral ventricles of 
the brain. The niche of NSCs in the SVZ contains cells with different characteristics 
such as B cells, C cells and A cells (Doetsch et al., 1999). The role played by the B 
cells, which have self-renewal property, is to turn into a transit amplifying population 
of C cells. Next, The C cells will give rise to a transit amplifying population and 
migratory neuroblasts, the A cells. Finally, the A cells migrates along the rostral 
migratory stream into their target, the olfactory bulb. There, the neuroblasts start to 
differentiate into granule neurons (Lois and Alvarez buylla, 1993). 
 The second area where neurogenesis commonly occurs in the adult brain is in 
the subgranular zone (SGZ) (Doetsch et al., 1999, Johansson et al., 1999, Kornack 
and Rakic, 1999), an anatomical region of the dentate gyrus of the hippocampus. The 
SGZ niche contains three different types of cells defined as type 1, type 2 and type3 
(Gage, 2000). Type 1 NSCs of the SGZ express the immature neural stem cell marker 
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nestin and give rise to type 2 and type 3 cells. The SGZ NSCs have the ability to 
migrate for a short distance into the dentate granule cell layer (GCL) and start to 
differentiate into granule cell neurons (Eriksson et al., 1998, Johansson et al., 1999, 
Kornack and Rakic, 1999), important in memory and learning (Deng et al., 2010). 
1.7.2 Factors that control the behaviour of NSCs/ Neural precursor cells 
Various intracellular mediators and extracellular signals control the 
behaviour of NSCs/Neural precursor cells (NPCs). The intracellular mechanisms 
mainly refer to cell signalling pathways. The Wnt/β-catenin pathway is the first of 
these signals (Isse et al., 2003). Studies show that activation of the Wnt/β-catenin 
pathway within the SVZ proves that β-catenin has a key role in neural development 
(Isse et al., 2003). The β-catenin protein is a central and essential component of the 
canonical Wnt signalling pathway, which functions by activating the T-cell/lymphoid 
enhancer factors (TCF/LEF) (Tsai et al., 2002). Hence, researchers saw decreases in 
the overall size of the nervous system and in the number of neuronal precursor cells in 
mice with the β-catenin conditional knockout mutation (Zechner et al., 2003). 
Notch signalling is the second signal pathway that controls NSCs. It has a 
major function in regulating the balance between differentiation and proliferation of 
the NSCs (Kageyama et al., 2005). The basic-helix-loop-helix (bHLH) transcription 
factors form the main effectors for notch signalling to encode transcriptional 
repressors. The bHLH transcription factors repress neuronal differentiation and 
enhance cell proliferation (Ohtsuka et al., 2001). Consequently, knockdown of the 
canonical notch effector C-promoter binding factor 1 resulted in accelerated 
differentiation of NSCs to NPCs (Kavok et al., 2001). 
The third signal pathway that controls NSCs is Shh-Gli signalling (Wallace, 
1999). The importance of Shh-Gli signalling comes from its ability to modulate the 
proliferation of the NSCs in different anatomical regions of the brain such as the 
neocortex and cerebellum (Dahmane and Ruiz i Altaba, 1999). Over-expression of the 
Gli1 gene in the NSCs results in enhancing the proliferation of these cells in vivo and 
in vitro (Stecca and Ruiz i Altaba, 2009). Conversely, knocking down of the Gli2 
gene in the NSCs by shRNA resulted in a substantial reduction in the number of 
proliferative NSCs in vivo and in vitro (Wilkens et al., 2000). 
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On the other hand, a plethora of extracellular factors have also been shown to 
play a role in NSC/PC proliferation and/or differentiation. The growth factors are of 
significant importance as fate determining extracellular factors. The main examples of 
these growth factors are platelet-driven growth factor (PDGF), acidic fibroblast 
growth factor (aFGF), basic fibroblast growth factor (bFGF) and epidermal growth 
factor (EGF) (Richardson et al., 1988, McKinnon et al., 1990). In addition to growth 
factors, THs are also neuropoietic hormones able to regulate NSC/PC proliferation 
and/or differentiation (Forrest et al., 2002). Because TTR is the main T4 transporter in 
humans (Hagen and Solberg, 1974), and it is an important factor for carrying T4 into 
the CSF and into the brains of rodents (Dickson et al., 1987), any alteration in the 
level of the TTR may alter the availability of TH for NSCs. Thus, the next paragraphs 
will discuss the role of THs in proliferation, differentiation, migration and apoptosis 
of NSCs/PCs. 
THs play an essential role in the development of different tissues by regulating 
cell physiology and controlling cell proliferation, differentiation and apoptosis 
(Oppenheimer et al., 1987). Two genes generate the isoforms of TH receptors (TRs): 
TRα and TRβ. The TRs perform a critical role in mediating the genomic actions of 
TH. In the CNS, fundamental studies of rat and chicken brains have revealed 
interesting observations related to the function and distribution of these receptors 
(Mellström et al., 1991). The studies concluded that while the TRα isoform is 
expressed in all fields of the hippocampus area, the TRβ isoform is expressed only in 
the CA1 field of the hippocampus, and only during the postnatal period. The studies 
also found that the expression of TRα began earlier in the development of the 
animals’ brains than TRβ, and that it was present in the brain in higher concentrations. 
Another study showed that TRα is the only TH receptor that is expressed in the 
nestin-positive NPCs of the subventricular zone (SVZ) (Lemkine et al., 2005). It was 
also found that only the TRα gene expression was detected in oligodendrocyte 
precursor cells (OPCs) (Forrest et al., 1991), and no expression could be detected at 
all from the TRβ genes in the cell culture isolates of the rat brain that contained OPCs 
(Forrest et al., 1991, Baas et al., 1994). Interestingly, TRα is the only TR expressed in 
the SVZ of rats (Fernandez et al., 2004b). Thus, the presence of the TRs in the SVZ 
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indicates that the THs play a critical role in maintaining and controlling the 
proliferation, migration and eventual differentiation of the SVZ cells. 
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Figure 1-8: Differentiation of NSC into the three neural lineages. 
The NSCs will first give rise transiently to dividing progenitors’ transit-
amplifying cells (type-C cells), which subsequently differentiate toward 
neuronal, astrocytic and oligodendrocyte lineages (Casarosa et al., 2013). 
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1.7.3 THs and proliferation of PCs  
THs control the development, maturation, and proliferation of NPCs 
(Fernandez et al., 2004b). The effect of hypothyroidism on cell proliferation was 
investigated in the cerebellar cortex of rat brains (Nicholson and Altman, 1972), with 
the finding that hypothyroidism caused a delay in the rate of NPCs proliferation. 
Immunohistochemistry data from other studies showed upregulation of the expression 
of A2B5 (marker for OPC), NG2 (marker for OL) and MBP (marker for mature OL) 
in the brain of hyperthyroid rats. (Fernandez et al., 2004b). Moreover, Lemkine et al. 
reported that reduced of TH in hypothyroid adult mouse brains severely hampered the 
proliferation potential of the SVZ NSCs. They also stated that rapid introduction of 
TH enhanced the proliferation of these cells, concluding that this accelerated effect of 
TH within hours in the SVZ supports the idea that TH acts directly on the stem cell 
population with specific receptors (Lemkine et al., 2005). These finding supported the 
role of TH in NPCs proliferation. 
1.7.4 THs and the migration of NPCs 
During neurogenesis, NPCs should migrate from their germinal region to the 
target anatomical region, where the cells complete their differentiation. Several 
different factors control the migration of NPCs along this developmental path (de 
Castro and Bribián, 2005). TH is regarded as a central regulatory factor for PCs and 
has been examined extensively.  
In particular one study illustrated the effect of hypothyroidism on the 
migration of NPCs from the SVZ of mouse brain, using a gene transfer technique 
(Lemkine et al., 2005). In that technique, the SVZ NSCs were labeled by expression 
of an exogenous reporter gene (β-galactosidase). The researchers noticed that, in 
hypothyroid mice, only half the numbers of NPCs labelled by the expression of β-
galactosidase were present in the RMS, demonstrating a significant decrease in the 
number of NPCs that migrated successfully from the SVZ. Furthermore, a recent 
study showed that T3 and its receptor, TRα, are directly involved in maintaining the 
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migratory capacity of the NSC in the SVZ (López-Juárez et al., 2012). Regardless of 
the well known function for TH in NSC migration, the molecular mechanism, via 
which T3 regulates NSCs migration, remains poorly investigated. 
1.7.5 THs and differentiation of PCs  
As discussed above, NSCs of the CNS are able to differentiate into three major 
lineages of cells: neurons, astrocytes and oligodendrocytes. Several growth factors 
and hormones have key roles directing the differentiation of NSCs toward variable 
neuronal lineages. For instance, both neurotrophin-3 (NT3) and retinoic acid form the 
major promoters of neuronal differentiation (Guigon and Cheng, 2009). The cytokines 
leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF) (Ishihara et al., 
2008, Ye et al., 2008), FGF2, serum (Leonard, 2008) and bone morphogenetic 
proteins (BMPs) (Stoler et al., 2007) are essential for the production of astrocytes. In 
case of oligodendrocyte differentiation, CNTF and T3 are two of the main 
extracellular signals that direct and restrict the differentiation and maturation of the 
oligodendrocytes (Ye et al., 2008). Thus, T3 is essential for normal differentiation and 
maturation of oligodendrocytes, which are the myelin-forming cells in the CNS 
(Figure 1-9). Cases of hypothyroidism involve deficits in the myelination process in 
the brains of rodents (Rigual et al., 2005, Rocha et al., 2004, Walters and Morell, 
1981) and humans (Mizuno et al., 2004, Wiseman et al., 2003). Likewise, acceleration 
in the myelination process emerges in cases of hyperthyroidism (Wiseman et al., 
2003, Brunaud et al., 2003, Ying et al., 2003). Morover, It has been described that 
introducing of TH (T4) to Lewis rats during the acute phase of experimental allergic 
encephalomyelitis (EAE) is able to direct OPCs progenitors into oligodendroglial 
lineage and enhance remylenation (Calza et al., 2002). The same result was obtained 
by introducing the same treatment but to experimental model of chronic 
demyelination (Fernandez et al., 2004a). It has been conclude that an exposure to TH 
could increase the endogenous production of growth factors and result in influence 
proliferation, differentiation, survival, and regeneration of mature oligodendrocytes 
and OPCs in favor of a myelin repair (Fernandez et al., 2004a). 
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Despite the importance of T3 for oligodendrocyte maturation, the molecular 
mechanism via which T3 regulates oligodendrocyte differentiation remains poorly 
defined. 
However, a few studies tried to expose the role of T3 in oligodendrocyte 
differentiation. A study has suggested that two factors control proliferation and 
differentiation of oligodendrocytes; a counting mechanism and an effector mechanism 
(Barres et al., 1994). The counting mechanism is the internal clock that counts the 
time of cell division. It is based on a mitogen factor that activates the receptors of the 
cell surfaces. In the other hand, the effector mechanism is a hydrophobic signal, 
which activates the intracellular receptors. Examples of these effectors are T3, 
glucocorticoids, and retinoic acid. Culturing OPCs in medium in the absence of T3 
resulted in cessation differentiation of OPCs into oligodendrocytes, but they still 
divided. However, when the same cells were cultured in a medium supplemented with 
T3, the cells stopped dividing and started to differentiate into oligodendrocyte cells, 
leading to the conclusion that hydrophobic signals are critical for OPC differentiation 
(Barres et al., 1994).  
A number of previous studies examined the mechanism of THs in control PCs’ 
differentiation. A 2003 study by Nygard and colleagues suggested that TH has a 
negative regulatory role for the transcription of the E2F-1 gene, a gene that plays an 
important role in controlling the G1-S phase transition. They proposed adding TH to a 
culture of OPC to reduce the synthesis of E2F-1, which would subsequently suspend 
the OPC cycle of the cells requiring differentiation. The authors suggested that this 
cascade is the first step in showing how THs induce OPC differentiation (Nygård et 
al., 2003).  
Another study suggested a different mechanism for TH to control PC 
differentiation via Kruppel-like factor 9 (KLF9) (Dugas et al., 2012). The hypothesis 
was that T3 induces the expression of the KLF9 gene by OPC in vitro and in vivo. 
They noticed that over-expressed KLF9 gene promote oligodendrocyte differentiation 
in vitro. Likewise, loss of KLF9 in vivo causes a delay remyelination in in cuprizone-
induced demyelinated phenotype. The study concluded that KLF9 is essential and 
necessary to stimulate oligodendrocyte differentiation, and it is likely a novel integral 
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component of the T3-driven signalling cascade, which promotes oligodendrocyte 
maturation. 
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Figure 1-9: Schematic of markers for maturation stages of oligodendrocytes. 
Specific markers expressed during each maturation stage. The orange marker indicated a 
nuclear marker expressed by OPCs. The red markers indicate a marker expressed by pre-
oligodendrocytes. The markers indicated in blue represent cytoplasmic markers expressed by 
mature oligodendrocyte cells (Silbereis et al., 2010). 
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1.7.6 THs and apoptosis of PCs  
The programmed death of a cell, or apoptosis, is a normal process that occurs 
in a multicellular organism; it is the opposite of the proliferation process. The balance 
between these two processes is very important for achieving normal growth and 
development. Su et al. (1997) investigated the role of THs in modulating the rate of 
apoptosis for CNS PCs. That study suggested that T3 can activate different pathways 
that lead to inducing apoptosis (Su et al., 1997). Other scientists measured the rate of 
apoptosis in the SVZ of three different groups: TTR null mice, hypothyroid wild type 
mice, and euthyroid wild type mice (Richardson et al., 2007). There were 50% fewer 
apoptotic cells in the TTR null mice compared to the euthyroid wild type mice, and 
the same low number in hypothyroid wild type mice. They concluded that the THs 
played a critical role in controlling apoptosis of PCs in the SVZ of the adult mice. The 
absence of the transthyretin in TTR null mice reduced the availability of THs in the 
mouse brains, which explained the similarity in the number of apoptotic cells in the 
TTR null mice and the hypothyroid wild type mice.  
In conclusion, THs play a critical role in controlling cell physiology. 
Migration, proliferation, differentiation and apoptosis of the NSCs are controlled by 
THs. TTR is a TH distributor that transports the THs from the blood to the CSF and 
brain cells. Therefore, any defect in that distributor will be reflected in the TH level in 
the brain. Further studies should focus on investigating the exact role of TTR in the 
brain as TH distributor, as well as the effects of the absence of that distributor on the 
physiological processes of the NCSs. 
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1.8 Scope of this thesis 
In 1992, TTR null mice were created by disrupting of the TTR gene 
(Episkopou et al., 1993). Initial studies recorded no overt phenotype of TTR null mice 
(Palha et al., 1994). However, a recent study has showed that these mice demonstrated 
delays in intestinal development, growth of long bones and certain aspects of brain 
development compared with normal mice (Monk et al., 2013). Furthermore, the 
behaviour of stem cells in the SVZ of TTR null mice was similar to that of stem cells 
in the SVZ of hypothyroid wild type mice (Richardson et al., 2007). We hypothesize 
that THs play a critical role in maintaining NSCs in general and oligodendrocyte 
precursor cells in specific and that the lack of TTR in TTR null mice reduces the 
availability of THs in the brain. Lower TH levels will alter NCS and OPC biology. 
This project addressed three main questions: 
Chapter 3: Is there a myelination phenotype in TTR null mouse brains? 
Chapter 4: Is the myelination phenotype regulated by altered oligodendrocyte 
maturation? 
Chapter 5: A role for TTR other than an extracellular TH distributor protein? 
The thesis will then conclude with 
Chapter 6: General discussion and future directions  
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Materials and methods 
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2 Materials and methods 
2.1 Materials 
2.1.1 Cells  
Human oligodendrocyte progenitor cells (OPCs) derived from NIH approved 
H9 human embryonic stem cells (hESCs) were purchased from Merck Millipore (Cat. 
No. CS204496). 
2.1.2 Media and reagents 
The following reagents: Human OPC Basal Medium (Part No. CS204464), 
Neural Supplement 1 (50X) (Part No. CS210992), Recombinant Human basic 
fibroblast growth factor (bFGF) (Part No. GF003-10UG), OPC Expansion 
Supplement A (PDGF-AA) 2500X (Part No. CS204471), OPC Expansion 
Supplement B (NT3), 2500X (Part No. CS204470), Reconstitution Buffer 1 for 
Supplement A (Part No. CS204469) and Reconstitution Buffer 2 for Supplement B 
and bFGF (Part No. CS204468) were included in OPC kits from Merck Millipore 
(Cat. No. CS204496). 
The Laminin mouse protein (Cat. No. 23017-015), Antibiotic-Antimycotic 
(100X) (Cat. No. 15240-062), StemPro AccutaseTM (Cat. No. A11105-01), 
KnockOut™ D-MEM/F-12 (Cat. No. 12660), StemPro® NSC SFM (Cat. No. 
A10509-01), N-2 Supplement (Cat. No. 17502), B-27® Serum-Free Supplement (Cat. 
No. 17504), Neurobasal® Medium (Cat. No. 21103), Fetal Bovine Serum, ES Cell-
Qualified FBS (Cat. No. 16141), GlutaMAX™-I (Cat. No. 35050), Recombinant 
Human basic fibroblast growth factor (bFGF) (Cat. No. PHG0024), Recombinant 
Human epidermal growth factor (EGF) (Cat. No. PHG0314), Geltrex™ Reduced 
Growth Factor Basement Membrane Matrix (Cat. No. 12760) and Phosphate buffered 
saline (PBS) (Cat. No. 10010-049) were purchased from Invitrogen. Finally, Poly-L-
ornithine solution (Cat. No. P4957) was purchased from Sigma and recombinant 
mouse CXC chemokine ligand 12 (CXCL12/SDF-1) (Cat. No.460-SD-050) was 
purchased from R&D system company. 
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2.1.3 General cell culture ware and equipment 
The following lab ware: 75 cm2 canted-neck tissue culture flasks and 25 cm2 
canted-neck tissue culture flasks and 6 well, flat bottom cell culture plates were 
obtained from Corning. In addition, 8-well clear tissue culture Millicell EZ SLIDES® 
obtained from Merck Millipore were used to culture, fix, stain and analyze the OPCs. 
2.1.4 Animals 
2.1.4.1 Ethics 
All experimental protocols used in this study were performed in accordance 
with the Prevention of Cruelty to Animals Act 1986 (Australia) and to the guidelines 
set out by the National Health and Medical Research Council of Australia (Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes, 2013). The 
protocols were approved by the RMIT University Animal Ethics Committee (AEC# 
1209) and conform to the International guiding Principles for Biomedical research 
Involving Animals 2012 
2.1.4.2 Sources 
Two strains of mice were used: (i) C57BL/6 mice were purchased from 
Monash Animal Services (Melbourne, Australia) to start a breeding colony at RMIT 
Animal Facility; (ii) CBA/TTR null mice were re-derived at Monash Animal Services 
(Melbourne, Australia) to start a breeding colony at the RMIT Animal Facility. 
2.1.4.3 Housing 
All mice were housed in individually ventilated cages in the breeding facility 
of RMIT Animal Facility (RMIT University, Victoria, Australia) with ad libitum 
access to rat chow (iodine 0.5mg/kg; Specialty Feeds Co. Western Australia) and tap 
water at a room temperature of 22 ± 1°C with a 12:12-h light-dark regimen. 
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2.1.4.4 Backcrossing 
The CBA/TTR Null mice were backcrossed eight generations onto the 
C57BL/6 background. Briefly, for the first generation, female C57BL/6 mice were 
mated with male CBA/ TTR null mice. Then from generations 2 to 8, heterozygous 
males from the previous generation were mated with C57BL/6 wild type females. 
However, the wild-type controls were derived from the knockouts littermates. Genetic 
integrity for each litter was always checked by PCR (section 3.2.6.1). 
2.2 Methods 
2.2.1 Culturing and expansion of human oligodendrocyte precursor cells 
A T25 cm2 tissue culture flask coated with Geltrex solution was used to 
culture OPCs in Human OPC Expansion Complete Medium supplemented with 
recombinant human basic fibroblast growth factor (bFGF) (50 µg/ml), OPC 
Expansion Supplement A (PDGF-AA) 2500X, OPC Expansion Supplement B (NT3) 
2500X and 1 % (v/v) Streptomycin-Antimycotic. The cells were incubated at 37 °C in 
a 5 % CO2 humidified incubator. After 24 h, the medium was changed with 
prewarmed (37 °C) Human OPC Expansion Complete Medium, then the medium was 
changed regularly every 2 to 3 days until cells became 70 to 80 % confluent.  
2.2.2 Subculturing oligodendrocyte precursor cells 
After 1 week, the proliferated OPCs were about 70 to 80 % confluent. The 
cells were dissociated with 3 ml AccutaseTM and incubated at 37 °C for 3 minutes. 
AccutaseTM was inhibited by adding 5 ml prewarmed (37 °C) Human OPC Expansion 
Complete Medium. The disassociated cells were centrifuged at 2800 g for 3 minutes 
at room temperature (RT) to pellet the cells. The supernatant was discarded and the 
cell pellets were resuspended by adding 5 ml prewarmed (37 °C) Human OPC 
Expansion Complete Medium. The number of cells was quantified using trypan blue 
stain. Briefly, an aliquot of 10 µl was removed from the harvested cell suspension and 
mixed with 10 µl of 0.4 % trypan blue. The mixture was incubated at room 
temperature for 1 min. The haemocytometer slide was used to count the cells under 
the inverted microscope by the following steps: first a cover slip was placed over the 
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slide, after which the suspension of stained cells was loaded into the counting 
chamber. The number of cells in a total of eight squares, each of which was 0.1 mm3 
in size, were counted. To determine the dilution factor, the average number of cells 
found in the eight counted squares was multiplied by two. An appropriate number of 
cells were plated in T75 cm2 tissue culture flasks coated with poly-L-ornithine, with 
average seeding density at 1 to 2 x 104 cells/cm2. The OPCs were passaged for a 
maximum of 3 passages. 
2.2.3 Differentiation of human oligodendrocyte precursor cells 
After 3 passages, the expanded OPCs were harvested using the same 
harvesting steps that were used for subculturing (Section 2.2.2). Then the cells were 
resuspended in prewarmed (37 °C) Human OPC Expansion Complete Medium and 
plated in appropriate tissue culture flasks coated with 100 µg/ml poly-L-ornithine and 
10 µg/ml laminin. The average seeding density was 2 x 104 cells/cm2. After 24 h, the 
cells were 20 % confluent. Then 80 % of the medium fresh Human OPC Spontaneous 
Differentiation Complete Medium was supplemented with Neural Supplement 1 
(50x), (without Platelet derived growth factor (PDGF-AA) or basic FGF growth 
factors). The medium was changed every 3 to 4 days with fresh Human OPC 
Spontaneous Differentiation Complete Medium. The cells differentiated for 14 days 
and then the analytical study was performed.  
2.2.4 Isolation and culture of primary mouse oligodendrocyte precursor cells 
(OPCs) and neural stem cells (NSCs). 
Preparation for culturing primary mouse OPCs and NSCs prior to starting the 
isolation protocol, the tissue culture plates were coated with Geltrex® coating 
material (Invitrogen) overnight at 4° C. The entire surface of the culture plate was 
coated with recommended volumes that are commonly used in cultureware, which are 
shown in Table 2.1. The mouse proliferation medium was prepared by adding 20 
ng/ml recombinant human basic fibroblast growth factor (bFGF) (Invitrogen), 20 
ng/ml epidermal growth factor (EGF) (Invitrogen), 2 mM GlutaMAX™-I Supplement 
(Invitrogen), 2 % StemPro® Neural Supplement and 1 % antibiotic-antimycotic 
solution to Knockout™ D-MEM/F-12 medium (Invitrogen) (Table 2-2).  
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Table 2-1: Coating and culture medium volumes based on the flask size 
 	   	  
Plate type Coating volume 
(ml) 
Culturing 
volume (ml) 
T75 flask 8 ml 15 ml 
T25 flask 3 ml 5 ml 
6 well plate 2 ml/well 3 ml 
24 well plate 0.5 ml/well 1 ml/well 
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Before starting dissection, the dissection tools were disinfected with 70% 
alcohol, autoclaved for 30 minutes and sterilized under UV light for 2 hours. 
Furthermore, 70% alcohol was occasionally used to disinfect the external surfaces of 
the fume hood and the dissection microscope. 
2.2.4.1 Dissection of P7 mouse cerebral cortex to isolate OPCs 
To isolate OPCs, Seven-day-old TTR null and wild type mice were deeply 
anesthetised by intraperitoneal injection with sodium pentobarbital (Lethabarb, 0.1-
0.2 ml/mouse). The mice were rendered immobile within a few minutes. Before 
beginning the surgery, the pain response was checked with toe pinching until there 
was no response from the mouse. The brain harvesting protocol that has been 
published by Azari was followed (Azari et al., 2010). Briefly, the mouse was 
decapitated above the cervical spinal cord region using large scissors. The skull was 
then exposed using small pointed scissors to make a median caudal-rostral cut. The 
head was held by the edges, the skin was removed and then a coronal cut was made 
between the orbits. Next, a longitudinal cut was made through the skull, starting from 
the foramen magnum and continuing along the sagittal suture. Additionally, two 
lateral cuts were made at the junction of the lateral walls and at the base of the skull. 
Using curved forceps, the skull flap was pulled away from the back of the brain, and 
the brain was carefully lifted out of the skull (Azari et al., 2010). Brains were quickly 
removed and placed into a 50 ml conical tube with 10 ml of ice-cold Hanks balanced 
salt solution without Ca2+ and Mg2+ (HBSS, Gibco) until all the brains were 
harvested. The brains were then removed one by one, placed in HBSS (without Ca2+ 
or Mg2+) in a glass Petri dish, and the meninges were removed with forceps under a 
dissection microscope as quickly as possible to avoid cell death. Next, the olfactory 
bulbs, the cerebellum and the diencephalon were removed. Finally, by using two fine 
forceps, the cortex was exposed and quickly placed in another glass Petri dish without 
Ca2+ or Mg2+. The tissue was then dissociated mechanically using a surgical blade 
into small pieces of tissue (approximately 1 mm3). Two ml of HBSS (without Ca2+ or 
Mg2+) were added to the Petri dish and the dissected tissue was transferred into a 15 
ml tube by using a 1 ml pipette tip. The cortex tissues of three mouse brains were 
pooled together in one 15 ml tube (up to 400 mg). The tubes were centrifuged at 300 g 
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for three minutes at RT and the supernatant was discarded. By using the “neural tissue 
dissociation kit” (Miltenyi Biotec), the pellets were mixed with 1900 µl Enzyme Mix1 
and 50 µl of Buffer X and incubated at 37 °C with slow continuous rotation. After 15 
minutes, 10 µl Enzyme A and 20 µl Buffer Y were added to each tube then inverted 
gently. Then, by using a fire-polished Pasteur pipette, the tissue was disassociated 
mechanically 10 times up and down. The tissue was incubated again at 37 °C for 10 
minutes. After that, the tissue was disassociated again mechanically 10 times up and 
down by using another fire-polished Pasteur pipette. The tissue was incubated again at 
37 °C for 10 minutes with slow and continuous rotation at 37 °C. The suspension of 
the disassociated tissue was applied to a 70 µm filter (MACS Smart strainer) and 
placed in a 50 ml tube. The 70 µm filter was washed with 10 ml of HBSS (with Ca2+ 
and Mg2+). The filtered cells were centrifuged for 10 minutes at 300 g at room 
temperature. The supernatant was completely discarded and the cell pellets were 
resuspended in 10 ml of Complete OPC Proliferation Medium, and then centrifuged 
for 10 minutes at 300 g at room temperature. Finally, the cells were seeded in a T75 
tissue culture flask (cells from 3 animals/flask). The flasks were incubated at 37 °C 
and 5 % CO2 for a week and the OPC culture medium was changed every two days. 
2.2.4.2 Dissection of E18 mouse cerebral cortex to isolate OPCs 
Mice that were pregnant with E18 embryos (TTR null and wild type mice) 
were deeply anesthetised by intraperitoneal injection with sodium pentobarbital 
(Lethabarb, 0.1-0.2 ml/mouse). The mice were rendered immobile within a few 
minutes. Before beginning the surgery, the pain response was checked with toe 
pinching until there was no response from the mouse. An incision made in the lower 
abdomen of the mouse, then forceps used to pull out embryos (3–8 embryos was 
usual). The connecting tissue was cut away and the embryos were placed in empty 
and sterilise petri dish. The harvested embryonic sac was opened by using fine forceps 
then the embryo holed by the forceps at the neck. At the same time, other small 
forceps were used to peel back the skin and expose the skull. Next, the brain was 
carefully removed and placed in HBSS (without Ca2+ or Mg2+) in a glass Petri dish. 
Finally, the same tissue dissecting and dissociation steps that were followed to 
dissociate the of P7 mouse cortex (section 2.2.4.1) have followed here. 
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2.2.4.3 Purification of OPCs by the shaking technique 
Oligodendrocyte precursor cells (OPCs) were isolated from the mouse brains 
by using the common shaking cultures method for primary OPCs (McCarthy & de 
Vellis, 1980; Armstrong, 1998). A week after culturing the P7 (section 2.2.4.1) and 
E18 embryonic cortices (section 2.2.4.2), the mixture of glial cells became confluent. 
Next, the tissue-culturing flask’s cap was screwed on tightly and the flasks were 
shaken overnight (18-20 hours) in a horizontal orbital shaker at 200 rpm and 37 °C. 
Next, the flasks were removed from the shaker and the outer surfaces of flasks were 
sterilised by spraying them with 70% ethanol. Subsequently, the medium containing 
the detached OPCs was collected rapidly with a pipette and passed through a 40 µm 
nylon mesh strainer (Millipore) placed over a 50 ml conical tube. The filtered cells 
were transferred to an untreated Petri dish and incubated for 30 to 60 minutes at 37 
°C. This step was important for the differential adhesion of contaminating microglia 
and astrocytes, where the microglia and astrocytes attach themselves to the Petri dish 
more efficiently than OPCs. Next, the unattached cells were collected and centrifuged 
for 3 minutes at 200 g at RT. The supernatant was discarded and the purified OPCs 
were resuspended in OPC Proliferation Medium and counted using the trypan blue 
counting assay (see section 2.2.2). Finally, the purified OPCs were seeded in a 6-well 
tissue culture plate with a seeding density of 0.3 x 106. The cells were incubated at 37 
°C and 5 % CO2 and the OPC culture medium was changed every two days until 
ready for performing experiments. 
 
2.2.4.4 Dissection of mouse subventricular zone to isolate NSCs 
Twenty one day-old Wild type and TTR null mice were used to isolate NSCs. 
The same steps that have been followed to harvest the brain in OPCs isolation was 
followed (section 2.2.4.1). The harvested brains were quickly removed and placed 
into a 50 ml conical tube with 10 ml of ice-cold Hanks balanced salt solution without 
Ca2+ or Mg2+ (HBSS, Gibco) until all the brains were harvested. The brains were then 
removed one by one, placed in HBSS (without Ca2+ or Mg2+) in a glass Petri dish, and 
the meninges were removed with forceps under a dissection microscope as quickly as 
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possible to avoid cell death. Next, the olfactory bulbs, the cerebellum and the 
diencephalon were eliminated. Subsequently, the ventral aspects are exposed by 
rotating the brain. At the level of the optic chiasm, a 90° coronal section was made by 
using a surgical blade and the caudal aspects of the brain were discarded. Next, the 
rostral aspects of the brain were rotated to ensure the surface cut was facing upward. 
By using fine-curved, pointed forceps, the brain septum was dissected and discarded; 
then, the thin layer of tissue that bordered the lateral ventricle wall was carefully cut 
and collected, excluding the striatal parenchyma and the CC areas. Next, same tissue 
dissociation steps that were followed to dissociate the cortex tissue were followed 
here (section 2.2.4.1). Finally, the isolated NSCs cells were seeded in a coated T25 
flask for monolayer neural stem cell cultures and in an uncoated 6-well plate for 
neurosphere culture systems. The flasks were incubated at 37 °C and 5 % CO2 for a 
week, and the culture medium was changed every two days. 
2.2.5 Neural-colony forming cell assays (NCFC) 
In order to study the role of TTR in the proliferative potential of NSCs, NSCs 
isolated from the SVZ of P21 wild type and TTR null mice were used to perform 
neural-colony forming assay (NCFC). NSCs were plated in uncoated six-well plates 
to proliferate and make small colonies of cells within one week after culturing in 
proliferation complete medium (Table 2-2). After two weeks, colonies of different 
sizes were able to be distinguished. Thus, after 14 days colonies were classified into 
two categories: (1) less than 2 mm in diameter, (2) ≥2 mm in diameter. Practically, 
colonies smaller than 2 mm diameter were referred to as progenitor derived and 
colonies ≥2 mm in diameter are referred to as NSC derived. The proportion of 
colonies ≥2 mm in diameter to the total number of colonies in each well was 
calculated. 
2.2.6 In vitro differentiation assay for isolated NSCs  
In order to assess the multipotency of the NSCs, a monolayer of cells was 
established for isolated NSCs. The neural stem cell differentiation protocol which has 
been developed by Invitrogen was followed in this assay (Invitrogen, 2015). The 
NSCs were seeded in a 6-well clear-tissue culture plates coated with 10 µg/ml poly-L-
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ornithine and 10 µg/ml laminin, and with a cell density of 0.5 x 106 per well. NSC 
proliferation complete medium (Table 2-2) was added to the cells and incubated for 
14 hours to allow the cells to attach. The next day, 80 % of the proliferation medium 
was removed and replaced with a fresh differentiation medium. A total of three 
different differentiation media were used to direct the NSCs to specific cell types 
(Table 2.2). The differentiation media were changed every two to three days over a 
period of three weeks. At the end of that period, the cells were harvested, fixed and a 
flow cytometry protocol (Section 2.2.12) was performed to quantify the number of 
differentiated cells. A marker for each cell type was used, these being anti β-tubulin 
for neuronal cells, anti GFAP for astrocyte cells, and anti Olig2 and MBP for 
oligodendrocytes (Table 2.3). 
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Table 2-2: Media used for NSC differentiation assays  
(Invitrogen, 2015). 
Medium	  type	   Component	   Final	  concentration	  
NSC/OPC	  proliferation	  
complete	  medium	   KnockOut™	  D-­‐MEM/F-­‐12	   1	  X	  	   StemPro®	  Neural	  Supplement	   2	  %	  	   GlutaMAX™-­‐I	  Supplement	   2	  mM	  	   bFGF	  (100	  μg/ml	  stock)	   20	  ng/ml	  	   EGF	  (100	  μg/ml	  stock)	   20	  ng/ml	  	   Antibiotic-­‐Antimycotic	   1	  X	  
Neural	  differentiation	  medium	   Neurobasal®	  Medium	   1	  X	  	   GlutaMAX™-­‐I	  Supplement	   2	  mM	  	   B-­‐27®	  Serum-­‐Free	  Supplement	   2	  %	  	   Antibiotic-­‐Antimycotic	   1	  X	  
Astrocyte	  differentiation	  
medium	  
D-­‐MEM	   1	  X	  
	   N-­‐2	  Supplement	   1	  %	  	   GlutaMAX™-­‐I	  Supplement	   2	  mM	  	   FBS	   1X	  	   Antibiotic-­‐Antimycotic	   1	  X	  
Oligodendrocyte	  differentiation	  
medium	  
Neurobasal®	  Medium	   1	  X	  
	   GlutaMAX™-­‐I	  Supplement	   2	  mM	  	   B-­‐27®	  Serum-­‐Free	  Supplement	   2	  %	  	   T3	   30	  ng/ml	  	   Antibiotic-­‐Antimycotic	   1	  X	  
  
75 
 
2.2.7 Cell proliferation assay (Ki67) for OPCs 
To quantify the proliferating cells in vitro, the purified OPCs (section 2.2.4.3) 
were seeded in 8-well clear tissue culture Millicell EZ SLIDES with a cell density of 
5 x 104 per well and coated with Geltrex® coating material. After 72 hours, 
immunohistochemistry protocol (section 2.2.11) was performed using double 
markers: proliferation marker “Ki67” detected using the anti-mouse Alexa-Fluor488 
conjugated antibody and oligodendrocyte marker (Olig2) detected using the anti-
mouse Alexa-Fluor555 conjugated antibody. Next, the samples were analysed under a 
confocal microscope with an appropriate filter set (FITC for the Alexa488 and TRITC 
for Alexa555). At least ten representative high-power fields (HPF x40 microscope 
objective) of each well were photographed. The proportion of the cells positive for 
both markers (Ki67 and Olig2) and the cells positive to Olig2 alone were quantified 
for each field. The mean of these ten HPF was calculated and expressed as the 
percentage of cell undergoing proliferation. 
2.2.8 Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
assay for OPCs 
To quantify apoptosis cells in vitro, the purified OPCs were seeded in 8-well 
clear tissue culture Millicell EZ SLIDES with a cell density of 5 x 104 per well and 
coated with Geltrex® coating material. After 72 hours, the medium was removed and 
the cells were fixed with 4 % Paraformaldehyde (PFA) for 10 minutes and washed 
three times with phosphate-buffered saline (PBS). Next, the cells were permeabilised 
by adding 0.2 % Triton X-100 to PBS for 5 minutes. Cell death was detected with a 
fluorescent cell death detection kit (DeadEnd™ Fluorometric TUNEL System, 
Promega Cat. G3250) according to the manufacturer’s instructions. After performing 
the TUNEL protocol, the cells were stained with the Olig2 antibody by using 
immunohistochemistry protocol (section 2.2.11). The samples were analysed under a 
confocal microscope. At least ten representative high-power fields (HPF x40 
microscope objective) of each well were photographed. The proportion of cells 
positive to both TUNEL-positive nuclei and Olig2 and the proportion of cells positive 
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to Olig2 alone were quantified for each field. The mean of these ten HPF was 
calculated and expressed as the percentage of apoptotic cells. 
2.2.9 Cell cycle analysis for OPCs 
The bromodeoxyridine (BrdU) assay was performed to investigate cell 
proliferation and to quantify the proportion of cells in each phase of the cell cycle. 
The purified OPCs (section 2.2.4.3) were seeded in 6-well clear tissue culture plates 
with a cell density of 1 x 105 per well and coated with Geltrex coating material. Next, 
the cells were pulsed with 1 mM BrdU in PBS for one hour. The medium was 
removed and the cells were dissociated with 3 ml AccutaseTM and incubated at 37 °C 
for three minutes. AccutaseTM was inhibited by adding 5 ml prewarmed (37 °C) OPC 
proliferation medium. The disassociated cells were centrifuged at 200 g for three 
minutes at RT to pellet the cells. Next, a BrdU Flow Kit from BD Pharmingen™ (Cat. 
557891) was used to analyse the cell cycle according to the manufacturer’s 
instructions. Briefly, the cells were washed in 1X BD Perm/Wash Buffer. The cells 
were fixed for 30 minutes in BD Cytofix/Cytoperm Buffer, and washed with 1X BD 
Permeabilisation /Wash Buffer. The cells were permeabilised by adding BD 
Cytoperm Permeabilisation Buffer Plus for 10 minutes and were then washed with 1X 
BD Perm/Wash Buffer. The cells were refixed for 30 minutes in BD 
Cytofix/Cytoperm Buffer and washed again with 1X BD Perm/Wash Buffer. The 
incorporated BrdU was exposed by treating the cells with 300 µg/ml DNase in 
Dulbecco's phosphate-buffered saline (DPBS) for one hour at 37 °C. Next, the BrdU 
was stained with anti-BrdU-FITC-labeled antibody (1.3 ul per 106 cells) for 20 
minutes. The stained cells were washed with 1X BD Perm/Wash Buffer. Total DNA 
was stained with 7-amino actinomycin D (7AAD) and resuspended in 500 µl of 
staining buffer (provided with kit). Finally, the stained cells were acquired on a FACS 
Canto II flow cytometer (BD Biosciences) and analysed with FlowJo software. 
2.2.10 Chemotaxis (migration) assay 
The chemotaxis migration assay for OPCs was performed using the Boyden 
chambers method. First, the migration chambers (polyethylene terephthalate 8.0 µm 
membrane; Millipore, Cat. PIEP12R48) were coated with poly-L-ornithine solution 
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for 1 hour at 37 °C. Next, the coating material was removed and the chambers were 
rinsed twice with cell culture sterile water. About 55 X 104 purified OPCs were 
seeded in each chamber with 200 µl of medium, and then the migration chambers 
were placed in 24-well dishes. Medium (750 µl) was added to the bottom well with a 
chemo attraction agent (CXCL12, 200 nM). After 16 hours of incubation at 37 °C in a 
5 % CO2-humidified incubator, the medium was removed and the migration chambers 
were then fixed with 4 % PFA for 10 minutes at room temperature. Next, the 
chambers were washed twice with PBS and stained with 0.1 % cresyl violet for 30 
minutes at RT in darkness. Later, the cresyl violet stain was removed and the 
chambers were washed twice with PBS. Finally, the non-migrated cells were scraped 
from the upper compartment using a cotton swab. The membrane was photographed 
at 10 microscopic fields per each well at ×400 magnification and TIFF images were 
acquired with a CDD video camera (Camera, Canon) mounted on an inverted 
photomicroscope (Lecia, Wetzlar, Germany). Steps in section 2.2.18.5 were followed 
to analyse the images. 
2.2.11 Immunocytochemistry for OPCs 
Purified OPCs that were cultured and grown to 80 % confluence in 8-well 
clear tissue culture Millicell EZ SLIDES (section 2.2.4.3 ) were used for 
immunostaining. The medium was removed from each well and the cells were fixed 
in 2 % PFA in 1x PBS for 10 minutes at RT. To block the nonspecific binding sites, 
the cells were incubated for 2 hours in blocking buffer (5 % BSA, 5 % normal donkey 
serum and 0.1 % triton X -100 in PBS). Then, the cells were washed with PBS and 
then were diluted by adding primary antibody and incubated overnight at 2 to 8 °C 
(Table 2.3). Next, primary antibody was removed, cells were washed three times with 
1X PBS and appropriately diluted secondary antibody was added for 1 hour at RT 
(Table 2.3). Then, the secondary antibody was removed, cells were washed three 
times with PBS and 4'6-Diamidino-2-Phenylindole (DAPI) staining was performed 
for 10 minutes (Table 2.3). Finally, DAPI was removed, cells were washed twice with 
PBS and an antifade reagent ProLong Gold antifade reagent (Invitrogen. Cat#. 
P36930) was used to mount the coverslips. Samples were examined using a laser 
confocal microscope (E800, PCM2000; Nikon, Champigny-sur-Marne, France). 
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Table 2-3: Antibodies used for immunocytochemistry 
 Antibody Dilution Isotype Company Cat. No 
Pr
im
ar
y 
A
nt
ib
od
ie
s	  
anti-­‐Olig2	   I	  in	  150	   Monoclonal	   Merck	  Millipore	   MABN50	  
anti-­‐NG2	   1	  in	  200	   Monoclonal	   Merck	  Millipore	   AB5320	  
anti-­‐PDGFR	   1	  in	  300	   Monoclonal	   Merck	  Millipore	   05-­‐1135	  
anti-­‐SOX2	   1	  in	  100	   Monoclonal	   Merck	  Millipore	   MAB4423A4	  
anti-­‐Nestin	   1	  in	  200	   Monoclonal	   Merck	  Millipore	   MAB353	  
anti-­‐β	  -­‐Tubulin	   1	  in	  100	   Monoclonal	   Merck	  Millipore	   MAB1637	  
anti-­‐GFAP	   1:200	   Monoclonal	   Merck	  Millipore	   MAB360	  
anti-­‐MBP	   1	  in	  300	   Polyclonal	   Merck	  Millipore	   AB980	  
anti-­‐	  TTR	   1	  in	  200	   Polyclonal	   ABBIOTC	   250892	  
	   	   	   	   	   	  
Se
co
nd
ar
y 
A
nt
ib
od
ie
s	   HRP-­‐	  anti-­‐rabbit	  IgG	   1:100	   N/A	   GE	  Healthcare	   NA934	  
Alexa	  Fluor	  488	  Goat	  anti-­‐Rabbit	   1:1000	   N/A	   Invitrogen	   A-­‐21427	  
Alexa	  Fluor	  555	  Rabbit	  anti-­‐Mouse	   1:1000	   N/A	   Invitrogen	   A-­‐11008	  
	  
DAPI	   300	  nM	   N/A	   Invitrogen	  	   D1306	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2.2.12 Flow cytometry 
Flow cytometry is a technique that was used to identify the ability of OPCs 
and PCs to synthesise TTR. Different antibodies were used against specific markers 
(Table 2.3). From a T75 cm2 flask, the cells were harvested using the same harvesting 
protocol that was used for subculturing (section 2.2.2). The cells were transferred into 
a 50 ml conical centrifuge tube for cell counting and viability analysis. The same 
counting protocol that was used in subculturing (section 2.2.2) was followed. An 
appropriate number of cells were transferred into a (12x75 mm FalconTM test tube) 
and washed twice with FACS buffer (1.0 % BSA, 0.05 % azide in PBS) for 5 min 
(400 g at 4.0 °C). The cells were fixed at room temperature with 2.0 % 
paraformaldehyde in PBS for 20 min, after which 0.1 % TritonX-100 in PBS was 
added for 15 minutes at room temperature (as a permeabilisation buffer to allow the 
antibody to pass through the cell membrane to detect the intracellular antigens). The 
tubes were centrifuged (400 g at 4.0 °C), the supernatant discarded and the cells were 
washed twice with FACS buffer for 5 min. The primary antibody, diluted in FACS 
buffer at the appropriate concentration, was added and incubated for 1.0 hr at 4.0 °C. 
The cells were again washed twice with FACS buffer and the supernatant was 
discarded. The secondary antibody, diluted in FACS buffer at the appropriate 
concentration, was added and incubated in the dark for 30 min at 4.0 °C. The cells 
were again washed twice with FACS buffer and the supernatant was discarded. 
Finally, the cells were resuspended in the FACS buffer and analysed by using BD 
FACS Canto II flow cytometry machine.	  
2.2.13 Molecular biology techniques 
2.2.13.1 Polymerase chain reaction 
A polymerase chain reaction (PCR) is an in vitro molecular technique used to 
amplify a small amount of DNA into a large amount using specific primers (Mullis et 
al., 1986, Saiki et al., 1988). PCR was used to check the genotype of mice for 
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backcrossing, and to identify the expression of specific genes, such as TTR and Olig2, 
within the OPCs. 
2.2.13.1.1 Primer design 
Unless otherwise stated, primers were designed using Primer3 at 
http://www.primer3.ut.ee/ (Table 2.5). The mRNA sequence corresponding to the 
gene of interest was obtained from the National Centre for Biotechnology Information 
(NCBI) homepage at http://www.ncbi.nlm.nih.gov. The sequence was pasted into 
Primer3 and the manufacturer’s instructions were followed. The following criteria 
were adhered to during the design of the primers: (i) the length of the PCR primers 
was between 18 and 22 bp, (ii) the guanine-cytosine (GC) content of the primer was 
close to 50%, (iii) the melting temperature (TM) was calculated using the equation 
TM = 4 × (G + C) + 2 × (A + T) and was between ~60 and 65 °C, and (iv) no more 
than 3 Gs or Cs were in the last five bases at the 3' end of the primer. The primers 
were designed to avoid self-complementation. To check the specificity of the 
designed primers and to avoid self-complementation formation and hairpin loops, the 
primers were checked using the oligonucleotide calculator at 
http://www.basic.northwestern.edu/biotools/oligocalc.html and the NCBI BLAST 
tools at http://www.ncbi.nlm.nih.gov/tools/primer-blast. After designing the primers, 
the sequences were sent to GeneWorks to synthesise the primers.  
2.2.13.1.2  Isolation of genomic DNA and total RNA 
2.2.13.1.2.1 DNA isolation from mouse tail 
A 0.5 to 1 cm tip of each mouse tail was used to isolate genomic DNA for 
genotype analysis. Each tail was incubated overnight at 55 °C with 500 µl of DNA 
lysis buffer (Table 2.4) and 25 µl of proteinase K (10 mg/ml). The next day, the 
sample was shaken by vortex for 45 seconds. Then 180 µl of >6 M NaCl was added to 
each vial. The samples were shaken by vortex for 30 seconds, then centrifuged for 10 
minutes at 12,000 g. Then 600 µl of the supernatant was transferred into a new vial 
and 400 µl of cold isopropanol was added. The samples were shaken gently for 2 
minutes. The DNA strands clumped together and were visible by this stage. Next, the 
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DNA was precipitated by centrifuging the samples for 2 minutes at 12,000 g. The 
DNA pellet was washed by adding 400 µl of 70 % alcohol and centrifuged for 2 
minutes at 12,000 g. Finally, the supernatant was discarded and the pellets dried at 
room temperature for 45 minutes, dissolved in sterilized water and stored at - 20 °C 
until used.  
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Table 2-4: Composition of DNA lysis buffer 
Component	  
Final	  
concentration	  
Company	   Cat.	  No	  
Tris/HCl pH8 50 mM Amresco-INC CA531185531 
EDTA 100 mM Amresco-INC 0105-5kg 
NaCl 100 mM Amresco-INC 7647-14-5 
SDS 1 % 
ICN-
biomedicals 
811032 
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2.2.13.1.2.2 Total RNA isolation 
Total RNA was extracted from cultured OPCs using the RNeasy Mini Kit 
from Qiagen (Cat No. 74104), according to the manufacturer’s specifications.  
2.2.13.1.3  Measuring the concentration and purity of extracted total RNA and 
genomic DNA  
A NanoDrop 1000 spectrophotometer was used to measure the concentration 
and purity of extracted total RNA and DNA. Elution buffer (1.5 µl) used during the 
DNA or RNA isolation process was loaded into the NanoDrop pedestal as the 
reference blank. Next, 1.5 µl of each sample was loaded onto the NanoDrop pedestal. 
For each sample, absorbance at 230 nm, 260nm, and 280 nm was measured. The 
machine software (ND 1000 3.2.1) calculated the nucleic acid concentration in ng/µl 
from the absorbance at 260 nm. The absorbance ratios for 260 nm/280 nm were used 
to determine the purity of nucleic acids and the 230 nm was used to determine the 
level of protein contamination. 
2.2.13.1.4  cDNA synthesis 
The AffinityScriptc cDNA Synthesis Kit (Cart No. 600559) from Agilent 
Technologies was used to synthesise complementary DNA (cDNA). The synthesis 
was performed in a sterilized 200 µl microcentrifuge tube. The following components 
were added in order: (i) 10 µl of first strand master mix (2×), (ii) 3 µl of oligo(dT) 
primer, (iii) 1 µl of AffinityScript RT/ RNase Block enzyme mixture, (iv) between 0.3 
pg and 3 µg total RNA, (v) RNase-free H2O added to a total volume of 20 µl. The 
following conditions were used with a 2720 thermocycle machine (Applied 
Biosystems); 25 °C for 5 minutes to allow primer annealing, 42 °C for 15 minutes to 
allow cDNA synthesis and 95 oC for 5 minutes to terminate the cDNA synthesis 
reaction. The completed first-strand cDNA synthesis was stored at -20 oC until the 
time of use. 
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2.2.13.1.5  Standard reverse transcription-polymerase chain reactions (RT-PCR)  
PCR reactions were performed using two types of nucleic acids templates: (i) 
genomic DNA extracted from mouse tails for genotyping (section 2.2.13.1.2.1), and 
(ii) cDNA synthesized from extracted total RNA from cells (section 2.2.13.1.4). For 
both sample types, the reaction was performed in a 200 µl sterile Eppendorf Oxygen 
tube. Different primers were designed and used (Table 2.5). The total volume of the 
PCR reaction was 25.0 µL in each tube, which contained 12.5 µL Qiagen HotStartTaq 
Mastermix, 2.0 µL 4.0 µmol primers, the appropriate volume of DNA or cDNA, and 
ultra-pure water to bring the final volume to 25.0 µL. The samples were loaded into a 
2720 Thermal Cycler (Applied Biosystems) and specific PCR conditions were used 
based on the composition of the primers.  
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Table 2-5: PCR primers 
 
 
Primers sequence Gene Product 
size (bp) 
Designed 
by 
Company 
Forward 
primer 
5’TGGGAGCCATTTGCCTCTG3’ Homo sapiens 
transthyretin 
(TTR) 
240 GeneBank GeneWorks 
Reverse 
primer 
5’AGCCGTGGTGGAATAGGAGTA3’ 
Forward 
primer 
5’CCAGAGCCCGATGACCTTTTT3’ Homo sapiens 
Olig2 
178 Primer3 GeneWorks 
Reverse 
primer 
5’CACTGCCTCCTAGCTTGTCC3’ 
Forward 
primer 
5’TGTTGCCATCAATGACCCCTT3’ Homo sapiens 
GAPDH 
202 Primer3 GeneWorks 
Reverse 
primer 
5’CTCCACGACGTACTCAGCG3’ 
TTR 
primer1 
5’GGTCAAAGTCCTGGATGCTGTCCA3’ Mus musculus 
TTR 
P1+p2= 
286 
P1+P3= 
398 
Dr T. Cole 
(Monash 
University) 
GeneWorks 
TTR 
primer2 
5’TATGAGCTGCCATTCTGGTGCTAGG3’ 
TTR 
primer3 
5’GAACCTGCGTGCAATCCATCTTG3’ 
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2.2.13.1.6  Agarose gel electrophoresis of PCR products 
Gel electrophoresis was performed to determine the length of linearized DNA 
fragments and separate the fragments based on size. Agarose (1.0 %) gels in 100 ml 
1X Tris-EDTA (TE) buffer were used. The PCR product was then mixed with 2.0 µL 
6x loading buffer (Bioline, Cat No. Bio-37068) and 0.5 µL Gel Red (Biotium, Cat No. 
41003), then loaded into the well for electrophoresis at 95 V for 1.0 hr. The gel was 
photographed under UV light using the FluorChem SP Digital Imaging System 
(Alpha Innotech Corporation, San Leandro, California, USA).  
2.2.13.1.7  Densitometry of RT-PCR bands 
By using ImageJ software, the scanned gel images were converted into type 8-
bit format. Next, the Area and Percent values of each band that were calculated and 
returned by ImageJ were expressed as Optimal Density (OD). The band with the 
largest OD value was used as a standard, and the OD value of each band was divided 
by the standard value. Thus, the final result of the bands was from the relative density 
(RD) of each peak, compared with the standard, which had an OD of 1. Two different 
equations were used to calculate the RD value. This equation [OD = Log10 (Io / I)] 
was used by ImageJ software to calculate OD value. Then, the outcome of the OD 
equation was used to calculate the RD value by using this equation [RD= 
ODsample/ODstandard]. 
2.2.13.1.8  DNA Sequencing  
Under UV light, the PCR product bands of interest were excised from agarose 
gels using a scalpel blade. An Ultrafree-DA Centrifugal Filter Unit Kit (Merck 
Millipore, Cat No.42600) was used to extract and purify the DNA fragment from the 
gel following the manufacturer’s instructions. The extracted DNA was sent to 
Melbourne Translational Genomics Platform (University of Melbourne, Australia) for 
sequencing. Finally, the sequencing result was received by email from the Genomic 
Platform. 
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2.2.13.1.9  Translation of DNA sequencing data 
Once the DNA sequence data were obtained, sequence scanner softwareV.1 
was used to open translate ABI format of the sequencing data into FASTA format. 
Then, the FASTA sequence data were copied and pasted into NCBI BLAST at 
http://www.ncbi.nlm.nih.gov/tools/primer-blast to find and identify the gene that has a 
similar corresponding mRNA sequence.  
2.2.14 Protein extraction 
The cell medium was aspirated and the cells were washed with ice-cold PBS. 
The PBS was drained and ice-cold lysis buffer (150 mM sodium chloride, 1.0 % 
Triton X-100 and 50 mM Tris pH 8.0) was added. A cold plastic cell scraper was used 
to scrape the cells, and the suspension was transferred into a microfuge tube. The 
samples were incubated for 30 min at 4.0 °C and then centrifuged for 20 min (350 g at 
4.0 °C). The supernatant was collected and the pellet was discarded. The supernatant 
was stored at -20 °C until required. 
2.2.15 Concentration of media protein. 
Most secreted proteins are usually secreted at low concentrations in the culture 
media. Thus, a concentration step was required to concentrate the media. The 
concentration step was performed by using a 10K Centriprep® centrifugal filter from 
Millipore. From the media, 10 ml was centrifuged at 4000 g for 15 minutes at 4 ˚C. 
The final volume was 0.5 ml with a concentration factor of 20X. The concentrated 
media was used in western blot technique to check the presence of secreted TTR 
(section 2.2.17). 
2.2.16 Measurement of protein concentration 
The protein concentration was measured using a Bradford assay (Iordanidou et 
al., 2010). A BCA assay References from BioRad was used and the BSA was used to 
make the protein standard according to the manufacturer’s specifications. 
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2.2.17 Western blot 
The samples were denatured by mixing an equivalent volume of the sample 
with 6x loading buffer (were 4.0 % SDS, 10 % 2-mercaptoethanol, 20 % glycerol, 
0.004 % bromophenol blue, 0.125 M Tris HCl, pH 6.8) and boiled for 10 min at 100 
°C (Laemmli, 1970). The mixture was then loaded to SDS-PAGE (12% 
polyacrylamide pH 8.8). Precision Plus Protein™ Dual Xtra Standards (Bio-Rad) 
were used as molecular weight markers (Cat No. 161-0377) and loaded into the first 
well. Following electrophoretic separation, proteins were transferred by semi-dry 
transfer via iBLOT into PVDF using regular Transfer Stack (Invitrogen, Cat 
No.lB4010-01). Next, the membranes were incubated in blocking buffer (5% non-fat 
dried milk in Tris-buffered saline-Tween 20 (TBST), pH 7.4) for 1 hour at room 
temperature. After the blocking, membranes were washed three times in TBST, pH 
7.4 and then incubated overnight with the primary antibody diluted in the blocking 
buffer. After three washes with TBST (20 min each), membranes were incubated with 
horseradish peroxidase-conjugated goat anti-rabbit IgG (GE	   Healthcare	   Cat#	   NA	  934) at 1:1000 dilution, The membranes were then washed three times with TBST 
then TBS (without Tween 20) and developed using the ECL™ western blotting 
system (GE Healthcare Cat# 5995578). Then the membrane was exposed to light film 
for 10 mins and developed in dark room. 
2.2.18 Histological techniques. 
2.2.18.1 Harvesting mouse brains for histological staining  
The following procedure was performed on mice in the following age groups: 
P7, P14, P21, and 12 weeks old. The mice were deeply anesthetized by intraperitoneal 
injection with sodium pentobarbital (Lethabarb, 0.1–0.2 ml/mouse). The mice were 
immobile within a few minutes. Before beginning the surgery, the pain response was 
checked by toe pinch until no response occured. The mouse was weighed and fixed on 
a dissection board. An incision was made in the thoracic cavity and the heart was 
exposed. An 18-gauge needle was inserted through the left ventricle and toward the 
ascending aorta. Using a blade, a small cut was made in the right atrium. Through the 
left ventricle, the mouse was slowly perfused with about 10 ml cold-PBS using a 10 
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ml syringe until the fluid that flowed from the right atrium was clear. Next, 10 ml 4.0 
% paraformaldehyde (PFA) diluted in PBS were perfused. The perfusion with fixative 
was continued until the mouse’s forelimbs were fully extended. After perfusion was 
complete, the mouse brain was harvested by following the same steps were mentioned 
in (section 2.2.4.1). The harvested brains were weighed and fixed in 25 ml 4 % PFA 
for 48 hr at 4.0 °C.  
2.2.18.2 Preparing brain tissue for staining 
The entire brain was put in a tissue block and processed in the Leica PSA200S 
according to the following process (Table 2.6). The processed tissues were embedded 
in a paraffin block using the Shandon Histocentre3 (Thermo Electron Corporation). 
The embedded brain blocks were cut at room temperature using a rotary microtome 
with a disposable blade (FEATHER Safety Razor Company). Serial coronal sections 
of 10 µm were cut in the area between 0.6 and 1.3 bregma. Each cut section was 
floated in a warm water bath at 50 °C (10 °C lower than the melting point of the 
paraffin wax). The sections were then mounted with a SuperFrost™ slide (Thermo 
Scientific) and incubated overnight at 37 °C. The next day, the slides were transferred 
to plastic boxes and stored in the dark for the further steps. 
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Table 2-6: Schedule of tissue processing in the Leica PSA200S 
  
Reagent Step duration (Hour) Temp (°C) Drain duration (Sec) 
Alcohol 50% 02.00 RT 80 
Alcohol 70% 02.00 RT 80 
Alcohol 90% 01.00 RT 80 
Alcohol Absolute 01.00 RT 80 
Alcohol Absolute 02.00 RT 80 
Alcohol Absolute 02.00 RT 140 
Xylene 01.00 37 80 
Xylene 02.00 37 80 
Xylene 02.00 37 140 
Paraffin wax 01.00 62 140 
Paraffin wax 02.00 62 140 
Paraffin wax 02.00 62 140 
Total 18.00  
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2.2.18.3 Luxol fast blue (LFB) staining 
The brain tissue sections (section 2.2.18.2) were dewaxed and rehydrated by 
incubating the slides at 60°C for 1.0 hr, and then immersing them in xylene twice for 
3 min each. The tissue sections were then immersed in descending grades of alcohol 
solution for 3 min each (twice 100 %, 95 %, and 70 %), after which they were washed 
in tap water for 3 min. The tissue sections were incubated overnight at 60 °C in 1.0 % 
luxol fast blue solution diluted in 95 % alcohol and then rinsed in distilled water. The 
sections differentiated for 5.0 sec in 0.05 % lithium carbonate solution diluted with 
distilled water. The excess amount of stain was washed in two batches of 70 % 
alcohol for 10 sec. The sections were then washed with distilled water. Finally, the 
sections were counterstained with eosin for 1.0 min, washed, dehydrated in ascending 
grades of alcohol solution (70%, 95%, and 100% x 2) for 2 min each. The slides were 
then cleared twice in xylene for 3 min each and mounted on a coverslip using DPX as 
a mounting medium.  
2.2.18.4 Immunohistochemistry of brain sections 
The brain tissue sections (section 2.2.18.2) were dewaxed and rehydrated 
using the same methods as described in section 2.2.18.3. The sections were then 
treated with 10 mM sodium citrate buffer pH 6 for 10 min in a microwave to retrieve 
the antigens that were masked by formation of formalin molecular cross links. Then, 
the sections were washed twice with PBS for 5 min each. To block the nonspecific 
binding sites, the cells were incubated for 2 hr in blocking buffer (5.0 % Bovine 
serum albumin (BSA), 5.0 % normal donkey serum, 0.1 % Triton X-100 in PBS). The 
cells were then washed with PBS, diluted primary antibody was added and incubated 
overnight at 2.0 to 8.0 °C (Table 2-3). Next, the primary antibody was removed, the 
cells were washed three times with 1 PBS, and the appropriate diluted secondary 
antibody was added (Table 2-3). After 1 hour, the secondary antibody was removed, 
the cells were washed three times with PBS and the cells were stained with DAPI for 
10 min (Table 2-3). Finally, DAPI was removed; the cells were washed twice with 
PBS and ProLong® gold antifade mountant reagent (Invitrogen, Cat. No. P36930) 
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was used to mount the coverslip. Samples were examined using a laser confocal 
microscope (E800, PCM2000; Nikon, Champigny-sur-Marne, France). 
2.2.18.5 Image analysis and cell counting 
The LFB stained slides (Section 2.2.18.3) were scanned using Microtek 
PS4000 scanning system. The bluish area of the mouse brain’s corpus callosum was 
measured using ImageJ. First, the scanned images were opened with ImageJ. Then, 
the images were converted into 16-bit. Next, the thresholds were adjusted, so the 
bluish area of the corpus callosum was made black and the background was made 
white. Then, the area of interest was measured.). Coronal brain sections with 10 µm-
thicknesses corresponding and the area between 0.6 and 1.3 bregma were selected. 
(n=3 sections/mouse). n= 5 mice for each genotype of each age group. 
The density of Olig2-positive cells was calculated in the central part of the 
corpus callosum and the entire area of the anterior commissure of TTR null and wild 
type mice in the P7, P14, P21, and 12 week-old age groups (section 2.2.18.4). Coronal 
brain sections with 10 µm-thicknesses corresponding to the area between 0.6 and 1.3 
bregma were selected. (n=3 sections/mouse) and (n= 6 mice for each genotype of 
each age group) (Figure 2-1). The images were captured by using confocal 
microscope. By using ImageJ software, the images were converted into 16-bit and the 
thresholds were adjusted so the positive florescence cells were made into small black 
dots and the background appeared white. Then, the black dots in an area of known 
size in the anterior commissure and the central part of the corpus callosum were 
counted. 
To count the number of migrated cells in the chemotaxis migration assay 
(section 2.2.10), 7 selected fields of the chamber were chosen and the numbers of 
migrating cells was counted. Next, TIFF images were captured with a CDD video 
camera (Camera, Canon) mounted on an inverted photomicroscope (Lecia, Wetzlar, 
Germany). Then, the photographed images were opened with ImageJ software. The 
images were converted into 16-bit and the thresholds were adjusted so the stained 
cells were made into small black dots and the background was made white. Then, the 
black dots in an area of known field size were counted. 
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Figure 2-1: The coronal brain section illustrates the areas selected to quantify the 
number of oligodendrocytes. 
The section corresponds to the area between 0.6 and 1.3 bregma. The cells in the middle 
part of the corpus callosum (CC) bordered by the bilateral cingula were counted. 
However, for the anterior commissure (AC), the entire area was selected 
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2.2.18.6 Electron Microscopy (EM)  
2.2.18.6.1  Harvesting mouse brains for EM analysis 
The harvesting steps in Section 2.2.18.1 were followed, with the exception of 
the fixative used to perfuse the mice, which was 2 % paraformaldehyde with 2 % 
glutaraldehyde diluted in PBS. The harvested brains were weighed and fixed for 24 
hours at 4.0 °C in 25 ml of the same fixative used for perfusion. 
2.2.18.6.2  Processing and preparing mouse brains for scanning 
The fixed brain tissue was sent to the Monash Histology Platform, where the 
tissue was processed (Monash University, Melbourne, Australia). Briefly, after 
fixation the tissue was washed with 0.1M cacodylate buffer pH 7.4. Next, the samples 
were immersed in a 1:1 solution of 2 % aqueous OsO4 and 0.2 M cacodylate buffer 
pH 7.4. The tissues were dehydrated in ascending grades of ethanol alcohol solution 
(50%, 70%, 95% and 100% x 2) for 15 minutes each. The slides were then decanted 
into propylene oxide twice for 15 minutes each. Then, the samples were immersed in 
resin overnight. The next day, the samples were immersed in fresh resin (Epoxy, LR 
White and Lowicryl) for 2 hours. A rubber mold designed to embed the tissues was 
used in the fume hood. Numbered strips of paper with each mouse’s identifications 
were inserted into each well of the rubber mold. Then, a drop of resin was added to 
each well, and the specimens were transferred to the wells. The ‘blocks’ were 
incubated for 48 hours in an oven at 60 oC. 
2.2.18.6.3  Sectioning of brain tissue 
A semi-thin section (1 µm) of tissue block from (section 2.2.18.6.2) was cut 
using the Ultramicrotome Leica. The semi-thin sections were transferred onto glass 
slides, which were then heated on slide warmer plates at 40 oC until the tissues were 
dried. A mixture of 1% toluidine blue and 2% borate in distilled water was added by a 
plastic dropper to the semi-thin section for two minutes while the slide was still on the 
hot plate. Next, the excess stain was rinsed off with distilled water, and the slides 
were dried at room temperature (Mercer, 1963). The stained slides were scanned 
using a Nikon Optishot (Nikon Corporation, Tokyo, Japan) light microscope, and the 
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areas of the corpus callosum were selected. The tissue blocks were trimmed again, 
and ultra-thin sections of the selected areas were cut with a thickness of 80 nm using 
the same ultra tome. Finally, the ultra-thin sections were put into a transmission 
electron microscope (TEM) grid and stained with uranyl acetate and lead citrate. 
2.2.18.6.4  Scanning using a transmission electron microscopy (TEM) 
 Following staining, all the ultra-thin sections were examined using a JEOL 
JEM 1010 (Jeol Ltd., Tokyo, Japan) TEM. At least 100 axons from each mouse brain 
were counted. 
2.2.19 Statistical analyses  
Statistical analyses were performed using version 9 of SPSS and GraphPad 
Prism6. A standard error bar test (95 % confidence interval) and a Student’s t-test 
were performed. The results from the Student’s t-test were used to compare the means 
of the groups. All data are presented as mean ± standard error of mean (SEM). A 
difference of p<0.05 between the groups was considered to be statistically significant. 
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3 Chapter 3: Is there a CNS myelination phenotype in the TTR null mouse? 
3.1 Introduction 
Neuronal cells were originally thought to be the only brain cells until, in 1846, 
Virchow et al. proposed, for the first time, the coexistence of ‘nerve glue’, namely 
neuroglia or glial cells (Virchow, 1846). At the time, glial cells were described as a 
type of brain connective tissue. However, the evolution in microscopic techniques 
allowed for the accurate characterization of these cells. Thus, in 1913, using metallic 
impregnation techniques, astrocyte cells were characterized as the first type of glial 
cells (y Cajal, 1913). In 1921, del Rio-Hortega et al. identified the second type of glial 
cells, termed microglial cells (del Río-Hortega, 1921), and finally, oligodendrocyte 
cells were identified in 1928 (del Río-Hortega, 1928). 
Glial cells form approximately 90% of human brain cells and 65% of rodent 
brain cells (Pfrieger and Barres, 1995). They play an essential role in supporting 
neuronal cells in the brain and peripheral nervous system and maintaining neuronal 
homoeostasis, axon myelination, and normal maturation of the central nervous system 
(CNS). 
3.1.1 Oligodendrocyte development and maturation 
During the early stages of development of the CNS, oligodendrocyte precursor 
cells (OPCs) originate from two different areas: the medial ganglionic eminence and 
anterior entopeduncular area of the ventral forebrain (Bradl and Lassmann, 2010). 
Most newly developed OPCs will migrate from their location of origin into their final 
areas before differentiating into mature myelinated oligodendrocytes (Frost et al., 
1996, Levison and Goldman, 1993). However, some OPCs will remain 
undifferentiated in the adult CNS to compensate for any deficit in the 
oligodendrocytes’ number (Wolswijk and Noble, 1989). Interestingly, studies show 
that, OPCs can act as NSCs and differentiate into all neural lineages: astrocytes, 
oligodendrocytes and neurons. By using the immunopaning technique, the 
investigators isolated OPCs from a rat’s optic nerve (Kondo and Raff, 2000). They 
noticed that, after adding PDGF to the medium, the majority of the OPCs remained 
undifferentiated and expressed A2B5+. However, adding PDGF and fetal calf serum 
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(FCS) to the OPCs directed the majority of the cells to differentiate into astrocytes 
expressing glial fibrillary acidic protein (GFAP) astrocytes markers. Finally, culturing 
those OPCs in a medium supplemented with basic fibroblast growth factor (bFGF), 
FCS and bone morphogenetic proteins (BMPs) resulted in directing the cells to 
differentiate into neurons and express microtubule-associated protein 2 (MAP2) as a 
neuronal marker. 
3.1.2 Axon myelination 
Myelination is a process by which a layer of a special structure called myelin 
wraps around the neuron axon. In the central nervous system (CNS), oligodendrocytes 
are the myelin forming cells; whereas Schwann cells are the myelin forming cells in 
the peripheral nervous system (PNS) (Bunge et al., 1962). The main supportive role 
for the myelin sheath is to increase the efficiency and speed of impulse transmission 
along the neuron and allow transfer signalling for long distances. Insufficiency in the 
myelination process results in neuromas and neurological disease such as 
leukodystrophies and multiple sclerosis (MS) (Brosnan and Raine, 1996). Thus, 
normal myelination is essential for normal brain development. The myelination 
process starts by migration of oligodendrocytes to the neuron axons that need to be 
myelinated. Environmental cues, such as polysialylated-neural cell adhesion molecule 
(PSA-NCAM) control the migration step. Removing PSA-NCAM from the surface of 
the oligodendrocytes results in cessation of cell dispersion in cell culture models 
(Wang et al., 1994). The next step after migration is adhesion of the oligodendrocyte 
process to the targeted axon, followed by spiralling of the process around the axon to 
form myelin (Baumann and Pham-Dinh, 2001). 
A group of hormones and growth factors manipulate oligodendrocyte 
maturation, leading to myelin formation include T3, FGF, PDGF, EGF, insulin-like 
growth factor-I (IGF-I) and progesterone neurosteroid (Walters and Morell, 1981, 
Gard and Pfeiffer, 1993, Beck et al., 1995). Thus, T3 is essential for normal 
differentiation and maturation of oligodendrocytes. Cases of hypothyroidism show 
deficits in the myelination process in the brains of rodents (Rigual et al., 2005, Rocha 
et al., 2004, Walters and Morell, 1981) and humans (Mizuno et al., 2004, Wiseman et 
al., 2003). Likewise, acceleration in the myelination process emerges in cases of 
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hyperthyroidism (Wiseman et al., 2003, Brunaud et al., 2003, Ying et al., 2003). 
During postnatal development, hypothyroidism has a negative effect on expression of 
the myelin basic protein gene in the majority of the brain (Windebank et al., 1985).  
3.1.3 TTR and myelination 
As stated in chapter one, the first function described to TTR was that of TH 
binding (Ingbar, 1958). Newly suggested metabolic functions for TTR include, 
promotion of neuroregeneration (Fleming et al., 2007), plasma cryptic protease (Liz et 
al., 2009) and cleaving of amidated NPY (Liz et al., 2009). Despite the synthesis of 
TTR by most neural cells lineages, and despite the growing list of neurological 
diseases associated with altered levels of TTR in the CSF, including depression, 
Alzheimer’s disease, anxiety, memory and learning impairment and schizophrenia, no 
previous studies focused on studying myelination in TTR null mice brain. 
It is common knowledge that TTR helps move TH from the blood via the 
choroid plexus into CSF. Furthermore, Richardson and colleagues showed that TTR 
null mice had a reduction in apoptosis in the SVZ of the TTR null brain compared to 
wild type mice. The level of apoptosis was similar to that of hypothyroid wild type 
mice, implying a significant reduction of TH delivery to the NSCs in this niche 
(Richardson, 2007). 
 Therefore, studying and tracking the myelination (which is a TH dependent 
process) in the brain of TTR null mice could provide great insight into the 
bioavailability of TH in their brains as well as the role of TTR in normal brain 
development. Therefore, four different age groups (P7, P14, P21 and 12 weeks) that 
form the key time points for TH-regulated development in the brains of mice were 
selected and will be used in this chapter to: 
i. Investigate the differences in the brain weight of TTR null mice compared 
to age-matched wild type mice during development. 
ii. Evaluate the myelination process by measuring the thickness of the corpus 
callosum in TTR null mice and compared to wild type mice during 
development. 
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iii. Determine The G ratio of the myelin sheath of the nerve axons of TTR null 
mice compared to wild type mice during development. 
iv. Determine if there is a difference in the number of oligodendrocyte cells in 
the central part of the corpus callosum (CC) and anterior commissure (AC) 
between TTR null mice and wild type mice during postnatal development.  
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3.2 Results 
3.2.1 Comparison of the brain weights of wild type and TTR null mice during 
postnatal development 
Wild type and TTR null mice old ages P7, P14, P21 and 12 weeks were 
euthanized and their brains were weighed after resection of the medulla at the caudal 
end of pons and the olfactory bulbs (section 2.2.18.1). The brain weight of P7 TTR 
null mice (0.4145 ± 0.0067 g, n = 6) was heavier than that of P7 wild type mice 
(0.3793 ± 0.0029, n=6). Additionally, there was an approximately 12% increase in the 
brain weight of P14 TTR null mice (0.5138 ± 0.0074 g, n = 6) compared to age-
matched wild type mice (0.4582 ± 0.0072 g, n = 6). However, there was no significant 
difference in the brain weight of P21 old TTR null mice compared to wild type mice 
of the same age. Finally, the brain weight of 12 week old TTR null mice (0.5822 ± 
0.006 g, respectively, n = 6) was significantly increased compared to the wild type 
mice of the same age (0.5388 ± 0.0064 g, n = 6) (Figure 3-1). 
3.2.2 Comparison of the thickness of the myelin in the corpus callosum of wild type 
and TTR null mice during postnatal development 
Myelin in the corpus callosum was histochemically analysed using Luxol fast 
blue (LFB) staining (section 2.2.18.3). Coronal brain sections (10 µm-thick) 
corresponding to the area between 0.6 and 1.3 bregma, the area where the entire 
structure of the corpus callosum can be stained, was selected and stained. No myelin 
was detected in the corpus callosum of P7 and P14 mice in the corpus callosum with 
LFB staining (Figure 3-2). However, LFB weakly stained myelin along the 
mediolateral extent of the corpus callosum in P21 mice. At this age, the corpus 
callosum of TTR null mice had a significantly large myelinated area compared to wild 
type mice (Figure 3-3). Finally, for 12 week-old mice, LFB staining of myelin was 
homogenous and strong along the entire corpus callosum of both TTR null and wild 
type mice. However, the myelinated area was considerably larger and with stronger 
staining for TTR null mice compared to wild type mice (Figure 3-3). 
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3.2.3 Tracking the early myelination in the corpus callosum of P7 and P14 wild type 
and TTR null mice by IHC 
Myelin was not detected by LFB stain (histochemical method) in mice at an 
early age (P7 and P14; Figure 3-2). Thus, immunohistochemistry (which is more 
sensitive than LFB staining) was performed to detect myelin basic protein (MBP) in 
the corpus callosum (section 2.2.18.4) at age (P7 and P14; Figure 3-4). No myelin 
fiber was detected in the corpus callosum of P7 TTR null or wild type mice (Figure 3-
4 A and B). In contrast to the P7 mice, many MBP-positive fibers were detected in the 
medial region of the corpus callosum of both P14 TTR null and wild type mice 
(Figure 3-4 C and D). However, many MBP-immunoreactive myelinated fibres 
appeared stronger and more visible in TTR null mice compared to wild type mice 
(Figure 3-4 C and D). Also, there was significant increase in the size of the area 
stained positively with MBP for the P14 TTR null section compared to the P14 wild 
type section (Figure 3-4 E).  
3.2.4 Analysis of the thickness of the myelin sheath (G ratio) around the axons of 
the corpus callosum during postnatal development in wild type and TTR null 
mice. 
To investigate the G ratio of the myelinated axons of wild type and TTR null 
mice during postnatal development, the ultra-structure of the corpus callosum axons 
was analysed using electron microscopy (section 2.2.18.6). Thus, the G-ratio, which is 
calculated by dividing the value of the inner axonal diameter by the total outer 
diameter, was calculated and compared between TTR null and wild type mice during 
development from P7 until 12 weeks of age. The larger G ratio value is an indication 
for thinner myelin sheath and the vice versa. 
3.2.4.1 The thickness of the axonal myelin sheath of P7 mice 
 For the P7 group, electron microscopy images showed unmyelinated axons in 
the corpus callosum for both TTR null and wild type mice, which was expected since 
mouse CNS myelination starts after P8 (Figure 3-5). 
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3.2.4.2 The thickness of the axonal myelin sheath of P14 mice 
G-ratio analysis for the P14 group showed significant differences among the 
strains (P = 0.0001), with TTR null mice having a lower G ratio (0.73) than wild type 
mice (0.78). The normal range for G-ratio values in mouse corpus callosum has been 
shown to be 0.75–0.81 (Waxman and Swadlow, 1976, Arnett et al., 2001), thus 
indicating that hypermyelination occurred in TTR null mice (Figure 3-6).  
3.2.4.3 The thickness of the axonal myelin sheath of P21 mice  
For the P21 group, the G-ratio analysis showed significant differences among 
the strains (P = 0.0001), with a lower G-ratio in TTR null mice (0.72) compared to 
wild type mice (0.78). The values obtained indicate that hypermyelination occurred in 
TTR null mice (Figure 3-7). 
3.2.4.4 The thickness of the axonal myelin sheath of 12 weeks old mice 
For the 12 week-old group, the G-ratio analysis showed significant differences 
among the strains (P = 0.0001), with a lower G-ratio in TTR null mice (0.72) 
compared to wild type mice (0.80). The values obtained indicate that 
hypermyelination occurred in TTR null mice (Figure 3-8).  
3.2.5 Quantification the density of oligodendrocyte cell  
The first step to study the hypermyelination phenotype in the central nervous 
system of TTR null mice during postnatal development was to quantify the density of 
Olig2-positive cells, as Olig2 is a marker for oligodendroglial cell lineage. Thus, the 
density of Olig2-positive cells was calculated in the central part of the corpus 
callosum and the entire area of the anterior commissure of TTR null and wild type 
mice in the P7, P14, P21, and 12 week-old age groups (section 2.2.18.4) n= 6 mice for 
each genotype of each age group. Coronal brain sections with 10 µm-thicknesses 
corresponding to the area between 0.6 and 1.3 bregma were selected. (n=3 
sections/mouse). 
 For P7 TTR null mice, significant increases in the density of Olig2-positive 
cells of up to 23.89% and 15.64 % were observed in the corpus callosum and anterior 
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commissure, respectively, compared to P7 wild type mice (Figure 3-9 and 3-13). For 
P14 TTR null mice, the observed increases in Olig2-positive cell density were of 
41.42% and 22.69% in the corpus callosum (Figure 3-10) and anterior commissure 
(Figure 3-14), respectively, compared to P14 wild type mice. The largest Olig2-
positive cell density observed in the developing TTR null mice corpus callosum 
occurred at age P21, with an increase of 54.28% compared to wild type mice; 
nevertheless, the same group showed only a 15.67% increase in Olig2-positive cell 
density in the anterior commissure (Figures 3-11 and 3-15). Finally, an increase of 
47.57% and 24.59% in Olig2-positive cell density was observed in the corpus 
callosum and anterior commissure, respectively, of 12 week-old TTR null mice 
compared to age-matched wild type mice (Figure 3-12 and 3-16). The differences 
between the pairs of groups in the number of Olig2 positive in the CC and AC was 
tested be performing one-way ANOVA with post hoc analysis using Sidak’s test. A 
sifnificant different were found between these groups (Figure 3-18 A and B). The 
post hoc test was revealed significant differences between groups in the number of 
Olig2 in CC and AC. 
Comparison the differences between groups in the number of Olig2 positive cells in 
CC and AC. There were significant differences between groups in the number of 
Olig2 in CC and AC. All data were expressed as the mean ± SEM. Statistical 
comparisons were performed using a one-way ANOVA with post hoc analysis using 
Sidak’s test as appropriate.  P value < 0.05 was considered statistically significant. n= 
5 mice 
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Figure 3-1: Comparison of brain weights between TTR null and wild type mice. 
The brain weights of TTR null mice for age groups (P7, P14, and 12 week) were 
heavier than age-matched wild type mice but not for P21 age group. All data were 
expressed as the mean ± SEM. Statistical comparisons were performed using a one-
way ANOVA with post hoc analysis using Sidak’s test as appropriate.  P value < 0.05 
was considered statistically significant. n= 6 mice.   
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Figure 3-2: Comparison of myelinated corpus callosum size between P7 and P14 wild type and 
TTR null mice using a histological myelin stain (LFB). 
Coronal brain sections with 10 µm-thickness corresponding to the area between 0.6 and 1.3 bregma. 
Image A and B represent P7group and image C and D represent P14 age group. No myelin was 
detected in the corpus callosum of both age groups. Scale bar: 2 mm.  
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Figure 3-3: Comparison of myelinated corpus callosum size between P21 and 12 week old wild 
type and TTR null mice using a histological myelin stain (LFB). 
Coronal brain sections with 10 µm-thickness corresponding to the area between 0.6 and 1.3 bregma 
for A and B: P21 mice: the entire corpus callosum myelinated area was clearly stained in TTR null 
mice, but not for wild type mice. C and D: 12 week-old mice: LFB staining demonstrated the entire 
structure of myelinated corpus callosum, indicating hypermyelination. E: All data were expressed as 
the mean ± SEM. Statistical comparisons were performed using a one-way ANOVA with post hoc 
analysis using Sidak’s test as appropriate. P values < 0.05 was considered statistically significant. n= 
5 mice  
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Figure 3-4: Detecting myelin in P7 and P14 wild type and TTR null mice corpus 
callosum by using IHC. 
Coronal brain sections with 10 µm-thickness corresponding to the area between 0.6 
and 1.3 bregma for: A: P7 wild type mice corpus callosum stained with anti-MBP, 
indicating no myelin fibre detection. B: P7 TTR null mice corpus callosum stained with 
anti-MBP, indicating no myelin fibre detection. C: P14 wild type mice, showing MBP-
immunoreactive myelinated fibres (red arrows) in the corpus callosum. D: P14 TTR null 
mice, showing MBP-immunoreactive myelinated fibres (red arrows) in the corpus 
callosum. Scale bar: 200 µm. E: quantification the percentage of the stained area per high 
power field for P14 mice per high power field (HPF). All data were expressed as the mean 
± SEM. Statistical comparisons were performed using a Student’s t-test. P values < 0.05 
was considered statistically significant. n= 3 mice 
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Figure 3-5: Electron microscopy images of the corpus callosum of P7 wild type and 
TTR null mouse brains. 
A: Electron microscope image for corpus callosum of P7 wild type mice. B: Electron 
microscope image for corpus callosum of P14 TTR null mice. For both mice genotypes, no 
myelin was detected at this age (P7). 
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Figure 3-6: Measurement of myelin thickness and calculation of G-ratios in P14 wild type 
and TTR null mice. 
A: Electron microscope image for corpus callosum of P14 wild type mice. B: Electron 
microscope image for corpus callosum of P14 TTR null mouse. C: Graphical illustration of the 
relationship between G-ratio of individual axons and Axon diameter with, regression lines D: 
Summary histogram shows the G-ratio comparison between TTR null and wild type mice. All 
data were expressed as the mean ± SEM. Statistical comparisons were performed using a 
Student’s t-test. P values < 0.05 was considered statistically significant. n = 3 mice. G ratios 
were calculated from 100 exons per mouse and the statistics were performed on pooled data for 
each mouse. 
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Figure 3-7: Measurement of myelin thickness and calculation of G-ratios in P21 wild 
type and TTR null mice. 
A: Electron microscope image for corpus callosum of P21 wild type mice. B: Electron 
microscope image for corpus callosum of P21 TTR null mouse. C: Graphical illustration of 
the relationship between G-ratio of individual axons and Axon diameter with, regression 
lines. D: Summary histogram shows the G-ratio comparison between TTR null and wild 
type mice. All data were expressed as the mean ± SEM. Statistical comparisons were 
performed using a Student’s t-test. P values < 0.05 was considered statistically significant. 
n = 3 mice. G ratios were calculated from 100 exons per mouse and the statistics were 
performed on pooled data for each mouse. 
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Figure 3-8: Measurement of myelin thickness and calculation of G-ratios in 12 week old 
wild type and TTR null mice. 
A: Electron microscope image for corpus callosum of 12 week wild type mice. B: Electron 
microscope image for corpus callosum of 12 week TTR null mouse. C: Graphical illustration 
of the relationship between G-ratio of individual axons and Axon diameter with, regression 
lines. D: Summary histogram shows the G-ratio comparison between TTR null and wild type 
mice. All data were expressed as the mean ± SEM. Statistical comparisons were performed 
using a Student’s t-test. P values < 0.05 was considered statistically significant. n = 3 mice. G 
ratios were calculated from 100 exons per mouse and the statistics were performed on pooled 
data for each mouse. 
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Figure 3-9: Quantification of Olig2-positive cell density in the corpus callosum of 
P7 mice. 
Coronal brain sections with 10 µm-thickness corresponding to the area between 0.6 
and 1.3 bregma. A: Nuclei of P7 wild type mice corpus callosum tissue section 
stained with DAPI. B: Olig2-positive cells of P7 wild type mice corpus callosum 
tissue section stained with anti-Olig2 and detected using the anti-mouse Alexa-
Fluor555 conjugated antibody. C: merged. D: Nuclei of P7 TTR null mice corpus 
callosum tissue section stained with DAPI. E: Olig2-positive cells of P7 TTR null 
mice corpus callosum tissue section stained with anti-Olig2 and detected using the 
anti-mouse Alexa-Fluor555 conjugated antibody. F: merged. Scale bar: 200 µm 
G: Density of Olig2-positive cells in corpus callosum per mm2. All data were 
expressed as the mean ± SEM. Statistical comparisons were performed using a 
Student’s t-test. P values < 0.05 was considered statistically significant. n = 5 mice 
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Figure 3-10: Quantification of Olig2-positive cell density in the corpus callosum 
of P14 mice. 
Coronal brain sections with 10 µm-thickness corresponding to the area between 0.6 
and 1.3 bregma. A: Nuclei of P14 wild type mice corpus callosum tissue section 
stained with DAPI. B: Olig2-positive cells of P14 wild type mice corpus callosum 
tissue section stained with anti-Olig2 and detected using the anti-mouse Alexa-
Fluor555 conjugated antibody. C: merged. D: Nuclei of P14 TTR null mice corpus 
callosum tissue section stained with DAPI. E: Olig2-positive cells of P14 TTR null 
mice corpus callosum tissue section stained with anti-Olig2 and detected using the 
anti-mouse Alexa-Fluor555 conjugated antibody. F: merged. Scale bar: 200 µm 
G: Density of Olig2-positive cells in corpus callosum per mm2. All data were 
expressed as the mean ± SEM. Statistical comparisons were performed using a 
Student’s t-test. P values < 0.05 was considered statistically significant. n = 5 mice 
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Figure 3-11: Quantification of Olig2-positive cell density in the corpus callosum 
of P21 mice. 
Coronal brain sections with 10 µm-thickness corresponding to the area between 0.6 
and 1.3 bregma. A: Nuclei of P21 wild type mice corpus callosum tissue section 
stained with DAPI. B: Olig2-positive cells of P21 wild type mice corpus callosum 
tissue section stained with anti-Olig2 and detected using the anti-mouse Alexa-
Fluor555 conjugated antibody. C: merged. D: Nuclei of P21 TTR null mice corpus 
callosum tissue section stained with DAPI. E: Olig2-positive cells of P21 TTR null 
mice corpus callosum tissue section stained with anti-Olig2 and detected using the 
anti-mouse Alexa-Fluor555 conjugated antibody. F: merged. Scale bar: 200 µm 
G: Density of Olig2-positive cells in corpus callosum per mm2. All data were 
expressed as the mean ± SEM. Statistical comparisons were performed using a 
Student’s t-test. P values < 0.05 was considered statistically significant. n = 5 mice   
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Figure 3-12: Quantification of Olig2-positive cell density in the corpus callosum 
of 12 week-old mice. 
Coronal brain sections with 10 µm-thickness corresponding to the area between 0.6 
and 1.3 bregma. A: Nuclei of 12 week-old wild type mice corpus callosum tissue 
section stained with DAPI. B: Olig2-positive cells of 12 week-old wild type mice 
corpus callosum tissue section stained with anti-Olig2 and detected using the anti-
mouse Alexa-Fluor555 conjugated antibody. C: merged. D: Nuclei of 12 week-old 
TTR null mice corpus callosum tissue section stained with DAPI: E: Olig2-positive 
cells of 12 week-old TTR null mice corpus callosum tissue section stained with anti-
Olig2 and detected using the anti-mouse Alexa-Fluor555 conjugated antibody: F: 
merged. Scale bar: 200 µm. 
G: Density of Olig2-positive cells in corpus callosum per mm2. All data were 
expressed as the mean ± SEM. Statistical comparisons were performed using a 
Student’s t-test. P values < 0.05 was considered statistically significant. n = 5 mice. 
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Figure 3-13: Quantification of Olig2-positive cell density in the anterior 
commissure of P7 mice. 
Coronal brain sections with 10 µm-thickness corresponding to the area between 0.6 
and 1.3 bregma. A: Nuclei of P7 wild type mice anterior commissure tissue section 
stained with DAPI. B: Olig2-positive cells of P7 wild type mice anterior commissure 
tissue section stained with anti-Olig2 and detected using the anti-mouse Alexa-
Fluor555 conjugated antibody. C: merged. D: Nuclei of P7 TTR null mice anterior 
commissure tissue section stained with DAPI, E: Olig2-positive cells of P7 TTR null 
mice anterior commissure tissue section stained with anti-Olig2 and detected using 
the anti-mouse Alexa-Fluor555 conjugated antibody. F: merged. Scale bar: 200 µm.  
G: Density of Olig2-positive cells in anterior commissure per mm2. All data were 
expressed as the mean ± SEM. Statistical comparisons were performed using a 
Student’s t-test. P values < 0.05 was considered statistically significant. n = 5 mice. 
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Figure 3-14: Quantification of Olig2-positive cell density in the anterior 
commissure of P14 mice. 
Coronal brain sections with 10 µm-thickness corresponding to the area between 0.6 
and 1.3 bregma. A: Nuclei of P14 wild type mice anterior commissure tissue section 
stained with DAPI. B: Olig2-positive cells of P14 wild type mice anterior commissure 
tissue section stained with anti-Olig2 and detected using the anti-mouse Alexa-
Fluor555 conjugated antibody. C: merged. D: Nuclei of P14 TTR null mice anterior 
commissure tissue section stained with DAPI. E: Olig2-positive cells of P14 TTR null 
mice anterior commissure tissue section stained with anti-Olig2 and detected using 
the anti-mouse Alexa-Fluor555 conjugated antibody. F: merged. Scale bar: 200 µm.  
G: Density of Olig2-positive cells in anterior commissure per mm2. All data were 
expressed as the mean ± SEM. Statistical comparisons were performed using a 
Student’s t-test. P values < 0.05 was considered statistically significant. n = 5 mice.  
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Figure 3-15: Quantification of Olig2-positive cell density in the anterior commissure 
of P21 mice. 
Coronal brain sections with 10 µm-thickness corresponding to the area between 0.6 
and 1.3 bregma. A: Nuclei of P21 wild type mice anterior commissure tissue section 
stained with DAPI. B: Olig2-positive cells of P21 wild type mice anterior commissure 
tissue section stained with anti-Olig2 and detected using the anti-mouse Alexa-
Fluor555 conjugated antibody. C: merged. D: Nuclei of P21 TTR null mice anterior 
commissure tissue section stained with DAPI. E: Olig2-positive cells of P21 TTR null 
mice anterior commissure tissue section stained with anti-Olig2 and detected using 
the anti-mouse Alexa-Fluor555 conjugated antibody. F: merged. Scale bar: 200 µm.  
G: Density of Olig2-positive cells in anterior commissure per mm2. All data were 
expressed as the mean ± SEM. Statistical comparisons were performed using a 
Student’s t-test. P values < 0.05 was considered statistically significant. n = 5 mice. 
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Figure 3-16: Quantification of Olig2-positive cell density in the anterior 
commissure of 12 week-old mice. 
Coronal brain sections with 10 µm-thickness corresponding to the area between 0.6 
and 1.3 bregma. A: Nuclei of 12 week-old wild type mice anterior commissure tissue 
section stained with DAPI. B: Olig2-positive cells of 12 week-old wild type mice 
anterior commissure tissue section stained with anti-Olig2 and detected using the anti-
mouse Alexa-Fluor555 conjugated antibody. C: merged. D: Nuclei of 12 week-old 
TTR null mice anterior commissure tissue section stained with DAPI. E: Olig2-
positive cells of 12 week-old TTR null mice anterior commissure tissue section 
stained with anti-Olig2 and detected using the anti-mouse Alexa-Fluor555 conjugated 
antibody. F: merged. Scale bar: 200 µm.  
G: Density of Olig2-positive cells in anterior commissure per mm2. All data were 
expressed as the mean ± SEM. Statistical comparisons were performed using a 
Student’s t-test. P values < 0.05 was considered statistically significant. n = 5 mice. 
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Figure 3-17: Negative control sections for the Olig2 antibody. 
Coronal brain sections with 10 µm-thickness corresponding to the area between 0.6 
and 1.3 bregma. A: Nuclei of negative control tissue section (CC area) stained with 
DAPI. B: Wild type mouse brain sections (CC area) were used as negative control 
after omitting primary antibody. C: merged. D: Nuclei of negative control tissue 
section (AC area) stained with DAPI. E: Wild type mouse brain sections (AC area) 
were used as negative control after omitting primary antibody. F: merged. Scale bar: 
200 µm 
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Figure 3-18: Comparison the differences between groups in the number of Olig2 
positive cells in CC and AC.  
A and B: There were significant differences between groups in the number of Olig2 in 
CC and AC. All data were expressed as the mean ± SEM. Statistical comparisons 
were performed using a one-way ANOVA with post hoc analysis using Sidak’s test as 
appropriate.  P value < 0.05 was considered statistically significant. n= 5 mice.  
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3.3 Discussion 
It is well known that THs play an essential role in regulating growth and 
development, particularly of the CNS (Escobar et al., 2004, de Escobar et al., 2007). 
Never-the-less, there has been heated debate on the role of TTR synthesised by the 
choroid plexus whether it has a role in the movement of THs from the blood to the 
brain and in distributing THs in the blood and cerebrospinal fluid (CSF) (Alshehri et 
al., 2015). Some reports state that TTR null mice have a reduction in apoptosis in the 
SVZ of the TTR null brain compared to wild type mice. The level of reduction ranked 
as similar to that of hypothyroid wild type mice (Richardson, 2007). Therefore, 
studying and tracking myelination (which is a TH dependent process) in the brain of 
TTR null mice is essential for studying hypothyroidism. It would provide great insight 
into the bioavailability of TH in their brain and the role of TTR in brain development 
Accordingly, four different age groups (12 week, P21, P14 and P7) which form Key 
time points for TH-regulated development in the brains of mice were selected and in 
our study. 
Our analysis of the TTR null phenotype in mice yielded new and exciting 
findings. Firstly, a comparison of TTR null mice brains with those from wild type 
mice showed a significant increase in the size of the TTR null mice brain during 
development for age groups (P7, P14 and 12 weeks), which was different than 
expected. Interestingly, Data from the LFB and MBP stains and electron microscopy 
(EM) analysis of the G ratio of the CC axons showed a significant increase in the 
amount of myelination during development. These findings clearly indicate that 
hypermyelination of the axons occurs in the corpus callosum of TTR null mice brain 
at ages P14, P21 and 12 weeks. 
Myelination is a process by which a layer of a special structure called myelin 
wraps around the neuron axon. Axonal demyelination is associated with several 
neurological diseases, including leukodystrophies (Aboul-Enein et al., 2003) and 
multiple sclerosis (MS)  in the CNS, as well as peripheral neuropathies (Baumann and 
Pham-Dinh, 2001, Brosnan and Raine, 1996), which highlight the critical role of 
myelination in the development of the human brain and the nervous system. 
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There is a direct correlation between myelogenesis and brain size. Thus, 
knocking down the IGF-I gene in mice, a myelination regulatory gene, caused a 
significant decreased the in their brain weights due to hypomyelination, compared to 
wild type mice (Beck et al., 1995). Likewise, overexpressed IGF-I gene in rodent 
resulted in significant increases in their brain weight with the hypermyelination 
phenotype (McMorris et al., 1990). Consequently, the hypermyelination phenotype in 
the brain of the TTR null mice is our principal explanation for the increase in brain 
weight.  
To investigate the cause of that hypermyelination in the brains of TTR null 
mice, we must evaluate the status of the myelinating cells in the CNS which are 
oligodendrocytes. They are TH-dependent cells. For the period of embryogenesis and 
early postnatal life, restricted periventricular germinal regions form the main source 
for most of the oligodendrocytes (Warf et al., 1991, Pringle and Richardson, 1993, 
Timsit et al., 1995). Interestingly, oligodendrocytes can be continue to be produced 
during adult life (Blakemore, 1972, Prineas and Connell, 1979, McCarthy and 
Leblond, 1988) and they then contribute in myelin repair (Chari and Blakemore, 
2002). Oligodendrocytes are the myelinating cells of the CNS and are crucial for 
appropriate brain function. Accordingly, the number of oligodendrocytes was 
quantified in the two major myelinated areas in the brain which are CC and CA. Our 
finding revealed that there was a substantial increase in the number and density of 
Olig2-positive cells in the corpus callosum and anterior commissure of TTR null 
mouse brains aged P7, P14, P21 and 12 weeks. The expansion in brain size of TTR 
null mice may be a result of the increase in the number of oligodendrocyte cells in the 
age group (P7, P14, P21 and 12 weeks) as well as the increase in myelination of the 
corpus callosum of each mouse in the myelinated age group (P14, P21 and 12 weeks). 
Explaining the role of TTR in modulating the amount of myelination is therefore 
important. 
TTR is the main T4 distrbutor in humans (Hagen and Solberg, 1974), and it is 
an important factor for moving T4 into the CSF and in the brains of rodents (Dickson 
et al., 1987). Despite the many studies conducted to understand the function of TTR 
as an extracellular TH distributor, the full function of TTR as a TH distributor has yet 
to be completely understood. Therefore, the absence of TTR expectedly means a 
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reduction in the availability of TH in the brain. Such a reduction would in turn be 
expected to decrease the number of oligodendrocytes and result in hypomyelination. 
However, our findings show an increase (and not a decrease) in the number of 
oligodendrocytes cells and an increase in the amount of myelination; furthermore, the 
phenotype of TTR null mice was not as severe as originally anticipated (Episkopou et 
al., 1993). We suggest that TH transporter proteins may be the key to answering this 
conflict. Thus, we hypothesised that TH transmembrane transporter proteins may up-
regulated in the choroid plexus and blood-brain barriers of TTR null mice. An 
intensive study of the expression and distribution of these transporters in the brain of 
TTR null mice is needed to examine such a hypothesis.  
Roles of neuropeptide NPY protein also cannot be excluded in maintain 
myelination in TTR null mice. It has been reported TTR null mice can be used as 
model for NPY overexpression (Nunes et al., 2006). Thus, a recent study suggested a 
novel function for NPY in inducing myelination in mice brains (Hashimoto et al., 
2011). Administering NPY to C57BL/6 mice resulted in an increase in the amount of 
myelination in neonatal mice brains during development from P7 to P14. Anti-MBP 
staining data showed a significant increase in myelinated fibres in the brain coronal 
sections corresponding to the parietal region of the cerebrum of P14 NPY mice 
compared to wild type control group (Hashimoto et al., 2011). Also, the real time 
polymerase chain reaction (qRT-PCR) results showed a significant increase in 
cerebrum MBP mRNA in the NPY administrated group compared to the wild type 
group. Additionally, electron microscope images and G-ratio calculations for neuronal 
axons from cross sections of the parietal part of the cerebra confirmed an increase in 
the rate of the axonal myelination and a decrease in the axonal G-ratio in the brains of 
mice in the NPY administrated group compared to the control group. The authors 
concluded that NPY, partially via Y1R, induces NT3 via TrkC phosphorylation, 
which induces myelination by oligodendrocytes in mice brains during development 
(Hashimoto et al., 2011). Thus, based on our findings in regard to TTR null mice, 
which showed a significant increase in myelinated fibres by MBP 
immunohistochemistry and a significant decrease in the axonal G-ratio by electron 
microscopy, the same myelin-inducing mechanism for NPY in the TTR null mice 
cannot be excluded.  
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Until now, TTR has been known as an extracellular TH binding protein that 
helps distribute THs throughout the body via the blood and cerebrospinal fluid. This 
novel hypermyelination phenotype in the TTR null mice brain suggests a paradigm 
shift in understanding the function of TTR and may further our understanding of the 
myelination process. Oligodendrocyte is the myelinating cells in the CNS. Thus, we 
hypothesized that the cause of the hypermyelination phenotype was the alteration in 
oligodendrocyte maturation; therefore, the next chapter will describe isolation of 
oligodendrocyte precursor cells and NSCs from the TTR null mouse brain. Then, 
proliferation, migration and apoptosis rate of these cells will be evaluated and 
compared to the data from age-matched wild type mice.  
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3.4 Conclusion 
From the data presented in this chapter we concluded that there was a 
significant increase in the size of TTR null mouse brains during development for all 
age groups (P7, P14, P21 and 12 weeks) compared to the wild type mice. Also, there 
was significant increase in the number and density of Olig2-positive cells in the 
corpus callosum and anterior commissure of TTR null mouse brains aged P7, P14, 
P21 and 12 weeks compared to wild type mice. Finally, data from the LFB and MBP 
stains and electron microscopy (EM) analysis of the G ratio of the corpus callosum of 
the TTR null mice axons showed a significant increase in the amount of myelination 
during development compared to the wild type mice. These findings clearly indicate 
that hypermyelination of the axons occurred in the corpus callosum of TTR null 
mouse brains at ages P14, P21 and 12 weeks. The next chapter will aim to answer the 
question whether the hyper-myelination phenotype is regulated by altered 
oligodendrocyte maturation or not.  
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4 Chapter 4: Is the hypermyelination phenotype regulated by altered 
oligodendrocyte maturation? 
4.1 Introduction 
The neural stem cells (NSCs) in the mature central nervous system (CNS) are 
known to be a self-renewing cells with the potential to differentiate into a three-
neuronal cell lineages: neurons, astrocytes and oligodendrocytes (Lois and Alvarez 
buylla, 1993). It was originally thought that the adult brain was free from stem cells 
and that new neuronal network connections could not be aadded. That was until 1969, 
when Altman used a tritiated thymidine to demonstrate the adult rat brain has actively 
dividing cells (Altman, 1962, Altman and Das, 1965, Alvarez-Buylla and Lois, 1995, 
Rietze et al., 2001). Later, the discoveries of specific neuronal antibodies and 
thymidine bromodeoxyuridine (BrdU) allowed for the confirmation of Altman’s 
hypothesis, as well as for the study of NSC properties in the adult brain (Kuhn et al., 
1996). 
4.1.1 Subventricular zone (SVZ) and subgranular zone (SGZ) niches 
In the healthy adult mammalian brain, the SVZ and the SGZ are the main two 
areas with NSCs, active in neurogenesis (Gage, 2000). Interestingly, a number of 
studies have successfully isolated and cultured NSCs from areas outside of SVZ and 
SGZ sites, such as the spinal cord (Shihabuddin et al., 2000), neorcortex (Gould et al., 
1999), temporal cortex tissue (Walton et al., 2006) and substantia nigra (Lie et al., 
2002). The potencies of these cells vary based on their site of isolation. In vivo 
experiments showed the NSCs in SGZ have the capability to produce mature neurons 
or astrocytes cells that functionally integrate into the hippocampal neuronal circuitry, 
but cannot produce oligodendrocytes (van Praag et al., 2002, Liu et al., 2003). 
However, SVZ NSCs can differentiate into neurons, astrocytes and oligodendrocytes 
(Gage, 2000). The common feature between the NSCs harvested from neurogenic 
regions (SVZ and SGZ) or non-neurogenic regions is the ability of these progenitor 
cells in vitro to exhibit self-renewal, as well as to differentiate into the full neuronal 
lineage: astrocytes, oligodendrocytes and neurons (Gould et al., 1999, Shihabuddin et 
al., 2000, Lie et al., 2002, Walton et al., 2006). 
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4.1.2 The microenvironment of adult NSCs influences their differentiation 
There are different signal molecules known to regulate the development of 
NSCs in the adult brain and provide a suitable microenvironment to maintain the 
behaviours of NSCs. These factors can be intrinsic or extrinsic. The transcription 
factors form the main intrinsic signals, including basic-helix-loop-helix (bHLH) 
transcription factors (Kageyama et al., 2005), SRY-related HMG box (SOX) family 
transcription factors (Episkopou, 2005), oestrogen receptor (Brännvall et al., 2002), 
peroxisome proliferator activated receptor γ (Wada et al., 2006) and N-CoR, a nuclear 
receptor co-repressor (Hermanson et al., 2002). On the other hand, a number of 
extrinsic signals have been discovered, which play major roles in regulating the 
behaviours of NSCs. These molecules include the bone morphogenetic proteins 
growth factors (BMPs 2 and 4) (Bond et al., 2012), fibroblast growth factors (FGF 8 
and 3), the sonic hedgehog (Shh) signal pathway (Ericson et al., 1995), the Wnt 
signalling pathway (Chenn and Walsh, 2002) and thyroid hormones (THs) (Montero-
Pedrazuela et al., 2006, Lemkine et al., 2005) . 
4.1.3 The effect of hypothyroidism on NSCs 
THs are essential for normal brain development including optimal 
neurogenesis in the brain of a mammalian embryos and during perinatal growth 
(Escobar et al., 2004, de Escobar et al., 2007). T3 is involved in the regulation of 
different neurogenesis processes, including proliferation, differentiation, migration, 
apoptosis, synaptogenesis, plasticity and myelination (Lemkine et al., 2005, Bernal, 
2007). Despite the importance of T3 for neurogenesis, the correlation between 
hypothyroidism and control of the NSC cycle remains incompletely understood. A 
few studies have shown that hypothyroidism results in a significant decrease in the 
number of proliferating cells in the SVZ area of the adult mice brains, and that 
reduction has been reversed through T3 treatment (Montero-Pedrazuela et al., 2006, 
Lemkine et al., 2005). On the other hand, another two studies found no observable 
difference in the number of proliferative cells in the SGZ of hypothyroidism in adult 
mice brains (Ambrogini et al., 2005, Desouza et al., 2005).  
  
139 
THs provide one of the main extracellular signals to direct and restrict the 
differentiation of the precursor cells (PCs) (Johe et al., 1996). In vitro experiments on 
OPCs harvested from rat optic nerves showed that in the presence of the THs, the 
OPCs proliferated in division up to eight times and then differentiated. However, 
removing THs forced the OPCs to proliferate and divide for an indefinite time (Barres 
and Raff, 1994). Moreover, the expressions of all myelin genes (myelin basic protein 
[MBP], proteolipid protein [PLP] and myelin-associated glycoprotein [MAG]) were 
influenced by THs (Barres et al., 1994). 
4.1.4 Oligodendrocyte cell lineage and THs 
Oligodendrocyte progenitor cells (OPCs) are the progenitors that form 
oligodendrocytes, the myelinating cells in the CNS (Gage, 2000). T3 plays a key role 
in maintaining OPC proliferation, migration and differentiation (Rogister et al., 1999, 
Rodriguez-Pena, 1999). T3 has nuclear receptors that regulate transcription of specific 
genes. Two isoforms of TH receptors (TRs): TRα and TRβ are encoded by two 
different genes. TRα1&2 are the unique TR isoforms expressed by OPCs (Billon et 
al., 2001), while TRβ1 is expressed by differentiating oligodendrocytes (Rodriguez-
Pena, 1999). Thus, the action of T3 in OPCs is mainly mediated by binding to the 
TRα1 nuclear receptors and not TRα2 (Forrest et al., 1991). Various studies have been 
conducted on the effects of hypothyroidism on OPC biology. The expression of NG2 
(marker for proliferative OPCs) was also slightly decreased in the olfactory bulb of 
hypothyroid rats, as well as significantly increased in the same area of hyperthyroid 
rats compared to euthyroid control rats (Fernandez et al., 2004b). A role for T3 in 
controlling oligodendrocyte differentiation has been suggested. In vivo and in vitro 
experiments showed that T3 controls the timing of oligodendrocyte differentiation via 
TR mediators (Billon et al., 2001). The over-expression of TRα1 resulted in the 
acceleration of OPC differentiation, while OPCs isolated from TRα1-/- mice were 
unable to stop dividing and differentiating (Billon et al., 2002).  
OPC migration is important, especially during early brain development. 
Postnatally, the OPCs develop in the SVZ migrate radially for a long distance into the 
cortex, corpus callosum, striatum and fimbria fornix before starting to differentiate 
into mature myelinating oligodendrocytes (Frost et al., 1996, Levison and Goldman, 
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1993). The role of THs in OPC migration is not fully understood. However, some 
extracellular molecules involved in cell migration are regulated by THs, such as 
Reelin protein, which is secreted by the Cajal-Retzius cells of the cortex and 
hippocampus (Del Río et al., 1997). Further studies are needed to elucidate the exact 
role of THs in OPC migration. We are unaware of any study that has focused on the 
role of THs in OPC apoptosis. However, one study focused on the rate of apoptosis in 
the SVZ area of adult hypothyroid mice (Richardson et al., 2007) using four different 
groups: TTR null mice, hypothyroid TTR null mice, hypothyroid wild type mice and 
euthyroid wild type mice. There were 50% fewer apoptotic cells in the SVZ of the 
TTR null mice compared to the euthyroid wild type mice. Furthermore, the SVZ of 
TTR null mice had a similar number of apoptotic cells as in the SVZ of hypothyroid 
wild type mice. However, there was no difference in the number of apoptotic cells in 
the SVZ of hypothyroid wild type and hypothyroid TTR null mice. They concluded 
that THs played a critical role in controlling apoptosis of progenitor cells in the SVZ 
of the adult mice. They hypothesised that absence of TTR in TTR null mice reduced 
the availability of THs in the mouse brains, which explained the similarity in the 
number of apoptotic cells in the SVZ of the TTR null mice and hypothyroid wild type 
mice. 
4.1.5 The role of TTR in the CNS 
As stated previously, TTR is a thyroid hormone distributor protein. In addition 
to its role as a TH distributor, a few studies suggested a neurobiological role for TTR 
in the promotion of neuroregeneration (Fleming et al., 2007) (Liz et al., 2009). 
Moreover, a wide expression of TTR in the nervous system has been revealed. TTR 
mRNA was detected in cultured primary neurons isolated from the cortex of adult 
mice and the hippocampus of embryonic mouse brains (Li et al., 2011). A similar 
observation was revealed for brain astrocytes and transit-amplifying cells (type-C 
cells) (Lee et al., 2012) and peripheral nerve Schwann cells (Murakami et al., 2010). 
However, the precise roles and mechanism(s) of action of TTR in these cells have not 
yet been revealed. 
 In the previous chapter, by using TTR null mice as an animal model, Luxol 
fast blue (LFB) stain and immunohistochemistry data for myelin basic protein 
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revealed significant increases in corpus callosum myelination for the P14, P21 and 12 
week age groups. Furthermore, a G-ratio analysis using electron microscopy revealed 
an increase in myelination of the central nervous system axons in the TTR null mice 
compared to the wild type mice for the same age groups. Finally, we found a 
substantial increase in the number of oligodendrocytes in the corpus callosum and 
anterior commissure when compared to wild type mice at P7, P14, P21 and 12 weeks 
old. Thus, it is plausible that TTR plays a significant role in oligodendrocyte 
precursor cell biology. 
Therefore, to study the cause of the hypermyelination phenotype in the TTR 
null mouse brains and whether it happened as a consonance of alteration in NSCs and 
OPCs. The maturation of NSCs and OPCs isolated from the brains of TTR null mice 
and wild type mice were used to:  
i. Evaluate the potency of NSCs, from TTR null mice compared to NSCs from 
wild type mice. 
ii. Determine if the isolated NSCs from the SVZ of TTR null mice differentiate 
differently to those from wild type mice 
iii. Determine if the isolated OPCs from TTR null mice proliferate differently to 
those from wild type mice. 
iv. Determine if the isolated OPCs from TTR null mice migrate differently to 
those from wild type mice. 
v. Determine if the rate of OPC apoptosis in TTR null mice is different to that in 
wild type mice.  
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4.2 Results 
4.2.1 Absence of TTR enhances the proliferation rate of NSC neurosphere colonies 
isolated from the SVZ of P21 TTR null mice  
In order to study the role of TTR in the proliferative potential of NSCs, NSCs 
isolated from the SVZ of P21 wild type and TTR null mice were used to perform 
neural-colony forming assay (NCFC) (section 2.2.5). NSCs were plated in uncoated 
six-well plates to proliferate and make small colonies of cells within one week after 
plating. After two weeks, colonies of different sizes were able to be distinguished. 
Thus, after 14 days colonies were classified into two categories: (1) less than 2 mm in 
diameter, (2) ≥2 mm in diameter. Practically, colonies smaller than 2 mm diameter are 
referred to as progenitor derived and colonies ≥2 mm in diameter are referred to as 
NSC derived (Figure 4-1 A and B). The proportion of colonies ≥2 mm in diameter to 
the total number of colonies in each well was calculated. A significant increase in the 
fraction of TTR null NSC colonies with a size ≥2 mm in diameter was present 
compared to the wild type data (Figure 4-1 C). That means the NSCs isolated from the 
SVZ of P21 TTR null NSCs have more potential to proliferate compared to NSCs 
isolated from the SVZ of P21 wild type mice. 
4.2.2 Absence of TTR promotes NSC differentiation into glial lineages in vitro. 
Since NSCs are an important endogenous source of OPCs and subsequently 
oligodendrocytes (Gonzalez-Perez and Alvarez-Buylla, 2011), we next investigated 
whether the absence of TTR could affect the differentiation of NSCs into OPCs and 
oligodendrocytes and other neural lineages. Thus, the NSCs were harvested from the 
SVZ of P21 wild type and TTR null mice (section 2.2.4), then cultured, proliferated 
and differentiated into the three neuronal lineages (section 2.2.6). The NSCs isolated 
from the SVZ of P21 mouse brains were cultured using two different systems: 
monolayer and neurosphere culture system for two weeks (Figure 4-2). The cells were 
directed to differentiate into astrocytes, neurons or oligodendrocytes for three week 
(Figure 4-3). Flow cytometry was performed to quantify the degree of differentiation 
of NSCs into each of the cell types (Figure 4-4). The percent of NSCs from TTR null 
NSCs that differentiated into Olig2 (+) oligodendrocytes was significantly increased 
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by about 25% compared to those from wild type mice (19 %) (Figure 4-5). Also, there 
was a significant increase in the number of TTR null NSCs that differentiated toward 
glial fibrillary acidic protein GFAP (+) astrocytes (39 %) compared to NSCs isolated 
from wild type mice (33 %) (Figure 4-5). Importantly, there was a significant 
decrease in the number of beta-III tubulin (+) neurons in the TTR null cultured cells 
(4 %) compared to wild type cells (8.6%) (Figure 4-5). These data indicate that the 
absence of TTR promotes differentiation of the NSCs into the glial lineage at the 
expense of differentiation into the neuronal lineage.   
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Figure 4-1: Quantitation of the potency of the NSC colonies isolated from the 
SVZ of P21 mouse brains by performing neural-colony forming cell assays. 
Representative photomicrographs of NSC colonies isolated from the SVZ of P21 (A) 
wild type and (B) TTR null mice cultured in uncoated plates.  
(C) There was a significant increase in the number of colonies with an average 
diameter ≥ 2 mm that were isolated from P21 TTR null mouse SVZ compared to wild 
type. That increase corresponded with a significant decrease in the number of colonies 
with an average diameter < 2 mm that were isolated from TTR null mouse SVZ 
compared to wild type. The colonies ≥2 mm in diameter are referred to as “NSC 
derived” cells that have self-renewal and multi-potential capabilities. However, the 
colonies < 2 mm diameter are referred to as “progenitor derived”. All data were 
expressed as the mean ± SEM. Statistical comparisons were performed using a one-
way ANOVA with post hoc analysis using Sidak’s test as appropriate.  P value < 0.05 
was considered statistically significant. n=4 independent experiments. 
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Figure 4-2: Characterization of NSCs isolated from the SVZ of P21 TTR null 
mice and stained with NSC proliferation markers. 
Images A to D: NSCs cultured using the monolayer culture system. (A): NSC nuclei 
stained with DAPI; (B) NSCs stained with polyclonal Sox2 antibody, labeled with 
Alexa-Fluor488; (C) NSCs stained with anti Nestin monoclonal antibody; detected 
using the anti-mouse Alexa-Fluor555 conjugated antibody; (D) merged. Images; E to 
L: NSCs cultured using neurosphare culture system (E) NSCs nuclei stained with 
DAPI; (F) NSCs stained with polyclonal Sox2 antibody, labeled with Alexa-
Fluor488; (G) NSCs stained with anti Nestin monoclonal antibody; detected using the 
anti-mouse Alexa-Fluor555 conjugated antibody; (H) merged. (I) NSC nuclei stained 
with DAPI; (J) NSCs stained with polyclonal Ki67 antibody, detected using the anti-
rabbit labeled with Alexa-Fluor488; (K) NSCs stained with anti PCNA monoclonal 
antibody; detected using the anti-mouse Alexa-Fluor555 conjugated antibody; (L): 
merged. Scale bar: 50 µm 
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Figure 4-3: Characterization of NSCs isolated from the SVZ of P21 TTR null 
mice and differentiated into the three neural lineages: oligodendrocytes, 
astrocytes and neurons. 
Images (A) oligodendrocytes nuclei stained with DAPI; (B): oligodendrocytes stained 
with Olig2 marker labeled with Alexa-Fluor555; (C) Merged; (D) Oligodendrocytes 
nuclei stained with DAPI; (E): oligodendrocytes stained with MBP marker labeled 
with Alexa-Fluor488; (F) Merged; (G) neurons nuclei stained with DAPI; (H) 
neurons stained with β-tubulin III marker labeled with Alexa-Fluor555; (I) Merged; 
(J) Astrocytes nuclei stained with DAPI; (K): Astrocytes stained with GFAP marker 
labeled with Alexa-Fluor555; (L) Merged. Scale bar= 50 µm 
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Figure 4-4: Absence of TTR influences the differentiation of NSCs. 
Images (A-F) Representative flow cytometry contour plots are shown to illustrate 
expression of individual phenotypic markers for the three neuronal lineages. In each 
plot, the percentage of cells positive for a given marker is shown on the right, and the 
percentage of cells negative for the same marker is shown on the left. (A) Wild type 
OPCs were labeled with anti Olig2 (OPC marker) conjugated with 
Phycoerythrin (PE). A control plot was gated to define the two regions lying within 
the quadrants. About 20.49 % of the total number of cells were positive for Olig2. (B) 
TTR null OPCs were labeled with anti Olig2 conjugated with PE. A control plot was 
gated to define the two regions lying within the quadrants. The total number of the 
Olig2 positive cells was 25.93 %. (C) Wild type OPCs were labeled with anti β-
tubulin conjugated with PE. A control plot was gated to define the two regions lying 
within the quadrants. The total number of the Olig2 positive cells was 8.33 %. (D) 
TTR null OPCs were labeled with anti β-tubulin conjugated with PE. A control plot 
was gated to define the two regions lying within the quadrants. The total number of 
the β-tubulin III positive was 3.82 %. (E) Wild type OPCs were labeled with anti 
GFAP conjugated with PE. A control plot was gated to define the two regions lying 
within the quadrants. The total number of the GFAP positive cells was 32.29 %. (F) 
TTR null OPCs were labeled with anti GFAP conjugated with PE. A control plot was 
gated to define the two regions lying within the quadrants. The total number of the 
GFAP marker was 38.79 %. n=3 independent experiments. 
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Figure 4-5: TTR promotes NSCs to differentiate into glial precursor cells. 
Differentiation assay for NSCs isolated from SVZ of P21 TTR null mouse brains 
showed a greater proportion differentiating into the glial cell lineage, whereas the 
equivalent cells from wild type mice had a greater proportion differentiating into the 
neuronal lineage. All data were expressed as the mean ± SEM. Statistical comparisons 
were performed using a one-way ANOVA with post hoc analysis using Sidak’s test as 
appropriate.  P value < 0.05 was considered statistically significant. n= 3 independent 
experiments. 
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4.2.3 Absence of TTR promotes OPC proliferation in vitro 
In order to confirm the effects of TTR absence in vitro for OPC proliferation, 
OPCs were isolated from cortices of E18 and P7 wild type and TTR null and mouse 
brains (section 2.2.4). The isolated and purified OPCs were cultured and proliferated 
in vitro for one week and just for a single passage, to limit the chance of any genetic 
or phenotypic drift that could be developed with additional passages. The OPCs were 
then stained to observe proliferation with double staining of Olig2 (a marker for 
OPCs) and Ki67 (a marker for proliferating cells) (section 2.2.7) (figure 4-6 and 4-7). 
The results showed that compared with OPCs isolated from the cortex of the E18 wild 
type mice, there was significant increase (23%) in the number of proliferating cells 
isolated from the cortex of E18 TTR null mouse brain (Figure 4-6 I). Also, there was 
a substantial increase in the number of proliferating cells isolated from the cortex of 
P7 TTR null compared to the wild type mice (figure 4-7 I). These result are consistent 
with the results in chapter 3 which described an increase in the number of OPCs in 
brains of TTR null mice brain compared to wild type control mice (Section 3.2.6).  
4.2.4 Absence of TTR affects progression of OPCs cycle 
To determine whether the absence of TTR affects the OPC cycle, we 
performed transfection, bromodeoxyuridine (BrdU) incorporation and flow cytometric 
analysis using OPCs isolated from P7 mouse cerebral cortex which had been 
proliferated for one week (section 2.2.9). As shown in Figure 4-8, there was a 
significant increase in the population of OPCs in S phase for OPCs isolated from TTR 
null mice (15 %) compared to OPCs isolated from wild type mice (7 %). This was 
accompanied by significant increase population in G2/M phase (6 % in TTR null 
OPCs versus 4 % in wild type OPCs), consistent with increased progression from S 
phase to G2/M phase. Also, there was a significant decrease in the population of 
OPCs cells in G0/G1 phase for OPCs isolated from TTR null mice versus (77 %) 
OPCs isolated from wild type mice (84 %). Finally, there was a decrease in the 
number of apoptotic cells in TTR null OPCs (4 %) versus wild type OPCs (6 %), 
however; the decrease was not statistically significant. Nonetheless, these results 
imply that the absence of TTR may affect the progression from S phase to G2/M 
phase, which, in turn, accelerates OPC proliferation. 
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Figure 4-6: Absence of TTR enhances proliferation of OPCs isolated from the 
cerebral cortices of E18 TTR null mice. 
Images A - D Representative OPCs isolated from the cortices of wild type mice. A: 
OPC nuclei stained with DAPI; B: OPCs stained with polyclonal Ki67 antibody 
(proliferation marker) labeled with Alexa-Fluor488; C: OPCs stained with anti Olig2 
monoclonal antibody (OPC marker) detected using the anti-mouse Alexa-Fluor555 
conjugated antibody; D: merged. 
Images E - H Representative OPCs isolated from cortices of TTR null mice. E: OPC 
nuclei stained with DAPI; F: OPCs stained with polyclonal Ki67 antibody 
(proliferation marker) labeled with Alexa-Fluor488; G: OPCs stained with anti Olig2 
monoclonal antibody (OPC marker) detected using the anti-mouse Alexa-Fluor555 
conjugated antibody; H: merged. Scale bar: 100 µm. 
I: Quantitation of the number of cells double labelled positively for Ki67 and Olig2. 
There was a significant increase in the number of proliferating Olig2 positive cells 
isolated from the cortices of E18 TTR null mice compared to those from cortices of 
E18 wild type mice. All data were expressed as the mean ± SEM. Statistical 
comparisons were performed using Student’s t-test (P values < 0.05 were considered 
to be statistically significant). n=4 
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Figure 4-7: Absence of TTR enhances proliferation of OPCs isolated from 
cortices of P7 TTR null mice. 
Images A – D Representative OPCs isolated from cortices of wild type mice. A: OPC 
nuclei stained with DAPI; B: OPCs stained with polyclonal Ki67 antibody 
(proliferation marker) labeled with Alexa-Fluor488; C: OPCs stained with anti Olig2 
monoclonal antibody (OPC marker) detected using the anti-mouse Alexa-Fluor555 
conjugated antibody; D: merged. Scale bar: 100 µm. 
Images E - H Representative OPCs isolated from cortices of TTR null mice. E: OPC 
nuclei stained with DAPI; F: OPCs stained with polyclonal Ki67 antibody 
(proliferation marker) labeled with Alexa-Fluor488; G: OPCs stained with anti Olig2 
monoclonal antibody (OPC marker) detected using the anti-mouse Alexa-Fluor555 
conjugated antibody; H: merged. Scale bar: 100 µm 
I: Quantitation of the number of cells double labelled positively for Ki67 and Olig2. 
There was a significant increase in the number of proliferating Olig2 positive cells 
isolated from the cortices of P7 TTR null compared to those from cortices of P7 wild 
type mice. All data were expressed as the mean ± SEM. Statistical comparisons were 
performed using Student’s t-test (P values < 0.05 were considered to be statistically 
significant) n=4. 
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Figure 4-8: Flow cytometric analyses of cell cycle for OPCs isolated from P7 
TTR null and wild type mice. 
A: There was a significant decrease in the population of OPCs cells in G0/G1 phase 
for OPCs isolated from cortices of TTR null mice (77 %) versus 84 % of OPCs 
isolated from cortices of wild type mice. B: There was a substantial increase in the 
population of OPCs in G2/M phase in TTR null OPCs (6 %) versus 4 % in wild type 
OPCs. : There was a major increase in the population of OPCs in the S phase for 
OPCs isolated from TTR null (15 %) versus 7 % in OPCs from wild type mice. D: 
There was no significant decrease in the number of apoptotic cells in TTR null OPCs 
(4 %) versus 6 % in wild type OPCs. All data were expressed as the mean ± SEM. 
Statistical comparisons were performed using Student’s t-test (P values < 0.05 were 
considered to be statistically significant). n=3 
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4.2.5 Absence of TTR accelerates OPC migration in vitro 
After having observed the increase in the number of oligodendrocytes in the 
corpus callosum and anterior commissure of TTR null mice in vivo (Chapter 3), it was 
of interest to evaluate the migration process of the TTR null OPCs in vitro. Thus, the 
OPCs isolated from E18 and P7 wild type and TTR mull mice cortices were used to 
perform chemotaxis migration assays in vitro (section 2.2.10). After 12 hours of 
culturing OPCs in the migration chamber, seven randomly selected fields of the 
chamber were chosen and the numbers of migrating cells were counted. For each cell 
genotype the experiment was performed 5 times and a total of 35 counts were made (7 
counts for each chamber) which were then averaged in order to give an estimation of 
the number of migrating cells (Figure 4-9 A-D). The number of migratory cells for 
OPCs isolated from cortices of E18 and P7 TTR null mice was significantly higher 
compared to the number of migratory wild type OPCs (Figure 4-9 E). The results 
obtained showed that lack of TTR increased OPC migration.  
4.2.6 Affects of TTR on apoptosis of OPCs in vitro 
In order to study the role of TTR on apoptosis, a Terminal-deoxynucleotidyl 
Transferase Biotin-dUTP Nick End Labeling (TUNEL) assay was performed on 
OPCs isolated from cortices of E18 and P7 mice and then proliferated for one week 
(section 2.2.8). This assay quantitates a hallmark end stage of apoptosis, DNA 
fragmentation, by incorporating a biotinylated nucleotide (dUTP) onto the 3’OH end 
of fragmented DNA catalyzed by recombinant Deoxynucleotidyl Transferase (rTDT). 
The incorporated biotinylated dUTP was labeled with Alexa flour 488 and double 
labeled with Olig2 marker (Figures 4-10 and 4-11). Quantitation of the data from four 
experiments showed a clear decrease in the population of OPCs positive for TUNEL 
for OPCs isolated from the cortices of E18 and P7 TTR null mice compared to OPCs 
isolated from cortices of wild type mice (Figure 4-10 I and 4-11 I). These results may 
suggest a role for TTR in promoting the rate of apoptosis of OPCs.  
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Figure 4-9: Absence of TTR increases the migration of OPCs isolated from the 
cerebral cortices of E18 and P7 TTR null mice. 
The migratory rates of TTR null OPCs compared to wild type OPCs were analyzed 
using the modified Boyden chamber assay (migration assay). Images A to D are 
representative (400X) photomicrographs high power field (HPF) of migrated OPCs 
cells isolated from cortices of E18 and P7 wild type and TTR null mice and stained 
with crystal violet.  
(E) Data were analyzed for 3 independent experiments for the E18 group and 5 
independent experiments for the P7 group. All data were expressed as the mean ± 
SEM. Statistical comparisons were performed using a one-way ANOVA with post 
hoc analysis using Sidak’s test as appropriate.  P value < 0.05 was considered 
statistically significant. 
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Figure 4-10: Absence of TTR decreases the rate of apoptosis of OPCs isolated 
from cerebral cortices of E18 TTR null mice. 
Images A - D; Representative OPCs stained with TUNEL and anti-Olig2. OPCs were 
isolated from the cortices of E18 wild type mice. A: OPC nuclei stained with DAPI; 
B: OPCs stained with TUNEL, labeled with Alexa-Fluor488; C; OPCs stained with 
anti Olig2 monoclonal antibody (OPC marker), detected using the anti-mouse Alexa-
Fluor555 conjugated antibody; D: merged. Scale bar: 100 µm. 
Image E – H; Representative OPCs stained with TUNEL and Olig2. OPCs were 
isolated from the cortices of E18 TTR null mice. E: OPC nuclei stained with DAPI; 
F: OPCs stained with TUNEL, labeled with Alexa-Fluor488; G: OPCs stained with 
anti Olig2 monoclonal antibody (OPC marker), detected using the anti-mouse Alexa-
Fluor555 conjugated antibody; H: merged. Scale bar: 100 µm. 
I: Quantitation of the OPCs isolated from cortices of E18 TTR null and wild type 
mice double labeled for TUNEL and Olig2. There was a significant decrease in the 
number of double labelled Olig2 and TUNEL OPCs isolated from cortex of E18 TTR 
null mice compared to those from wild type mice. All data were expressed as the 
mean ± SEM. Statistical comparisons were performed using Student’s t-test (P values 
< 0.05 were considered to be statistically significant). n=4   
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Figure 4-11: Absence of TTR decreases the rate of apoptosis of OPCs isolated 
from cerebral cortices of P7 TTR null mice. 
Images A - D; Representative OPCs stained with TUNEL and anti-Olig2. OPCs were 
isolated from the cortices of P7 wild type mice. A: OPC nuclei stained with DAPI; B: 
OPCs stained with TUNEL, labeled with Alexa-Fluor488; C: OPCs stained with anti 
Olig2 monoclonal antibody (OPC marker), detected using the anti-mouse Alexa-
Fluor555 conjugated antibody; D: merged. Scale bar: 100 µm. 
Image E – H; Representative OPCs stained with TUNEL and anti-Olig2. OPCs were 
isolated from the cortices of P7 TTR null mice. E: OPC nuclei stained with DAPI; F: 
OPCs stained with TUNEL, labeled with Alexa-Fluor488; G: OPCs stained with anti 
Olig2 monoclonal antibody (OPC marker), detected using the anti-mouse Alexa-
Fluor555 conjugated antibody; H: merged. Scale bar: 100 µm. 
I: Quantitation of the OPCs isolated from cortices of P7 TTR null and wild type mice 
double labeled for TUNEL and Olig2. There was a significant decrease in the number 
of double labelled Olig2 and TUNEL OPCs isolated from cortex of P7 TTR null mice 
compared to those from wild type mice. All data were expressed as the mean ± SEM. 
Statistical comparisons were performed using Student’s t-test (P values < 0.05 were 
considered to be statistically significant). n=5  
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4.3 Discussion 
The previous chapter presented evidence for our discovery that the corpus 
callosum and anterior commissure of TTR null mice brain, compared to that of the 
wild type, had a significant increase in the number of the Olig2 (+) cells and was 
accompanied by an increase in the rate of axon myelination (hypermyelination) in the 
corpus callosum. To confirm in vitro the effects of TTR on OPC biology and to 
understand the role of TTR in NSCs in general and in OPCs specifically, OPCs/NSCs 
were isolated from TTR null mice and compared OPCs/NSCs from wild type mice.  
The first set of data considered in this chapter concerned the differences in the 
potential of TTR null NSCs to differentiate into the three neural lineages. NSCs in the 
SVZ are known to be an important source of endogenous oligodendrocytes 
(Gonzalez-Perez and Alvarez-Buylla, 2011). During development and during some 
diseases, NSCs in the SVZ area differentiate into glia precursor cells and neuroblast 
cells (Lois and Alvarez buylla, 1993). Importantly, the present study’s in vitro data 
show that a lack of TTR can promote the differentiation of cultured NSCs into glial 
precursor cells which contain oligodendrocytes and astrocytes at the expense of 
neurons (Figure 4-4). This finding agrees with the in vivo data indicating a significant 
increase in the number of oligodendrocytes cells in the corpus callosum and anterior 
commissure of TTR null mouse brains compared with wild type mouse brains during 
development (Section 3.2.6). 
 Groups of extracellular factors play a major role restrict the differentiation of 
the NSCs. These growth factors are of significant importance as fate determining 
extracellular factors. For instance, both neurotrophin-3 (NT3) and retinoic acid form 
the major promoters of neuronal differentiation (Guigon and Cheng, 2009). The 
cytokines’ leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF) 
(Ishihara et al., 2008, Ye et al., 2008), FGF2, serum (Leonard, 2008) and bone 
morphogenetic proteins (BMPs) (Stoler et al., 2007) are essential for the production of 
astrocytes. In cases of oligodendrocyte differentiation, CNTF and T3 are two of the 
main extracellular signals that direct and restrict the differentiation and maturation of 
the oligodendrocytes (Ye et al., 2008). Thus, T3 is essential for normal differentiation 
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and maturation of oligodendrocytes. So, if the TTR acts as an extracellular TH 
distributor protein that delivers the TH to the NSCs, a decrease in the number of glia 
cells especially oligodendrocytes cell lineage will be seen in the brain of TTR null 
mice. Therefore, a novel function for TTR in the brain cannot be excluded. It is 
extremely difficult to extrapolate from in vitro conditions, as multiple factors might 
act in concert to achieve the exquisitely fine regulation of the complex process of 
NSC differentiation. Illustrating the function of TTR in NSC differentiation could be 
a first step to discover a possible beneficial role for TTR in mobilizing endogenous 
NSCs. The next chapter data will help to interpret this finding.  
The NCF assay data showed that the NSCs isolated from the SVZ of P21 TTR 
null NSCs have more potential to proliferate comparing to wild type NSCs. In 
agreement with our finding, a recent study showed that adding exogenous TTR to the 
NSC neurosphere culture resulted in a decrease in the NSC proliferation rate (Lee et 
al., 2012). This may an indication that the presence of TTR may act as a negative 
regulator for NSC proliferation. Regarding TTR-mediated OPC proliferation, the 
Ki67 and BrdU data revealed a significant increase in the proliferation rates of OPCs 
harvested from E18 and P7 TTR null mice compared to those from wild type mice 
(Figures 4-6 and 4-7). We next tested whether the rate of OPC apoptosis changed as a 
result of lack of TTR. According to the TUNEL assay data, the lack of TTR synthesis 
resulted in a significant reduction in the number of OPCs undergoing apoptosis in 
vitro (Figures 4-10 and 4-11). This finding agrees with in vivo data suggesting an 
decrease in the apoptosis rate of NSCs in the SVZ of adult TTR null mice compared 
to wild type mice (Richardson et al., 2007). The last set of data presented in this 
chapter supports the effect of the absence of TTR on OPC migration. The data 
showed an increase in the migration rate of OPCs isolated from TTR null mice 
compared to those isolated from wild type mice. As it is known that various growth 
factors, hormones and signal molecules play different roles in controlling OPC 
proliferation, migration and apoptosis and survival such as T3, FGF, PDGF, EGF, 
insulin-like growth factor-I (IGF-I) and progesterone neurosteroid (Walters and 
Morell, 1981, Gard and Pfeiffer, 1993, Beck et al., 1995). The TH is one of the factors 
that considerably affect OPC maturation. TTR is an extracellular TH distributor, and 
it has an important role in the movement of the TH from the blood to the CSF. Thus, 
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we hypothesised that the absence of TTR in the TTR null mice results in the reduction 
of TH delivery to the OPCs, which in turn causes the delayed maturation and 
development of these cells. Surprisingly, the opposite occurred. The OPCs isolated 
from the TTR null mice proliferated and migrated faster than the wild-type OPCs. 
These findings are in agreement with the in vivo data, which show a hypermyelination 
phenotype in the brain of the TTR null mice, as well as an asynchronous significant 
increase in the number of Olig2 (+) cells in the corpus callosum and anterior 
commissure of the TTR null mice compared with the wild-type ones (Section 3.2.6). 
This increase can be due to the high proliferation and cell survival rates, as well as the 
decrease in apoptosis rate, of the OPCs of the TTR null mice. Therefore, if the TTR 
functions as an extracellular TH distributor protein that delivers the TH to the OPCs 
and NSCs, a hypothyroid phenotype can be expected in the TTR null mice. However, 
this is not what the data showed. An alternative explanation will be explored in the 
next chapter.  
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4.4 Conclusion 
As illustrated and discussed in chapter1, the main known function of TTR is as 
an extracellular TH distributor protein, distributing thyroid hormones throughout the 
body via the blood stream to the cerebrospinal fluid and, finally, to the brain’s cells 
(Dickson et al., 1987, Schreiber et al., 1990). Subsequently, other roles have been 
suggested including promotion of neuroregeneration and protection against 
neurodegeneration (Fleming et al., 2007), involvement in schizophrenia (Huang et al., 
2006), behavior (Sousa et al., 2004) and in memory and learning (Sousa et al., 2007). 
Moreover, the data from this chapter showed that the absence of TTR enhanced the 
proliferation of NSC neurosphere colonies and promoted NSCs in differentiating into 
glial precursor cells for the OPCs isolated from SVZ of P21 TTR null mice compared 
to wild type OPCs. 
Furthermore, the data from this chapter suggested that the lack of TTR 
synthesis influenced the OPC cycle. A reduction in the number of OPCs undergoing 
apoptosis and an increase in the number of OPCs undergoing proliferation was seen. 
In addition, the migratory potentials of TTR null OPCs were increased compared to 
the wild type OPCs.  
The next chapter will aim to answer the question if there is a role for TTR 
other than as an extracellular TH distributor protein?  
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Chapter 5 
A role for TTR other 
than an extracellular TH 
distributor protein?   
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5 Chapter 5: A role for TTR other than an extracellular TH distributor protein? 
5.1 Introduction 
5.1.1 Synthesis of TTR by the choroid plexus 
TTR mRNA was first described in the brain in 1985 (Soprano et al., 1985). 
Later that year, Schreiber’s group found TTR mRNA only in the choroid plexus of the 
brain (Dickson et al., 1985a) and then specifically in the choroid plexus epithelial 
cells (Stauder et al., 1986). As mentioned previously (section 1.4.4.1) the TTR 
synthesised by the choroid plexus is believed to be involved in moving T4 from the 
blood into the CSF. Furthermore, TTR was found to be the major protein synthesised 
and secreted by the choroid plexus from representative species of mammals, birds and 
reptiles (Harms et al., 1991), implying strong evolutionary selection pressure, 
implying an important function of TTR synthesis by the choroid plexus. 
5.1.2 Onset of TTR synthesis in the choroid plexus of precocial and altricial animals 
 The onset of TTR gene expression during the embryonic stage of vertebrate 
choroid plexus varies across species. Vertebrates can be classified according to the 
degree of the brain development at birth, into precocial and altricial. The brain of 
precocial animals, such as chickens and sheep, is characterised by significant 
development at birth compared with that of altricial animals, such as rats and mice. In 
sheep, the total gestation period for sheep is 155 days and the brain reaches its 
maximal increase in weight 50 days before birth (Tu et al., 1990). Also, the TTR 
synthesis starts at very early embryos and reach the peak during the first half of 
gestation (Tu et al., 1990). On the other hand, in rat the total gestation period for rats 
is 23 days and the brain reaches its maximal increase in weight 9 days after birth 
(Fung et al., 1988). The TTR mRNA starts to be detected at E12.5 age and reaches the 
maximum only 2 days prior to birth (Fung et al., 1988).  
5.1.3 Sites of TTR synthesis in the nervous system 
It was suggested that TTR gene may be expressed by human and rodent dorsal 
root ganglia (DRG) (Murakami et al., 2008). However, that finding was questioned by 
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other investigators (Sousa and Saraiva, 2008), who stated that TTR gene is not 
expressed by mice DRG and the presence of the TTR mRNA was probably due to 
contamination from TTR in the meninges (Sousa and Saraiva, 2008). Thus, Laser 
capture micro dissection (LCM) to dissect muse DRG and to minimize the chance of 
contamination by meninges (Murakami et al., 2010). They confirmed that the TTR 
gene is not only expressed in DRG but also in the sciatic nerve of mice. The level of 
detected TTR mRNA in the mice sciatic nerve was one-fifth of the TTR mRNA in 
DRG (Murakami et al., 2010). The large difference in the ratio of TTR gene 
expression between DRG and the sciatic nerve may support the theory of 
contamination by meninges TTR. Thus, culture of dissociated sensory neurons 
from the dorsal root ganglia in vitro, followed by their use to study TTR expression, 
would resolves the debate on TTR gene expression in DRG.  
TTR mRNA was also detected in the primary cell culture of Schwann cells 
isolated from different sources, such as in the Schwann cells isolated from sciatic 
nerves of mice (Murakami et al., 2010), immortalized murine Schwann cells raised 
from DRG (Watabe et al., 1995), and rat Schwann cells (Freeman and Sueoka, 1987, 
Matsumura et al., 1997). A significant decrease in the level of TTR mRNA in the rat 
Schwann cells culture was detected after differentiating Schwann cells by adding 
forskolin. Murakami et al. suggested that the expression of TTR gene by Schwann 
cells began to decrease when the cells started to differentiate (Murakami et al., 2010). 
Moreover, Secretory molecule expression profile data showed that SVZ astrocyte and 
transit-amplifying cells (type-C cells) have the ability to express TTR (Lee et al., 
2012). The function of TTR synthesis by the nervous system could be related to its 
known function as THDPs or may be related to a “new” biological function for TTR. 
Until now, no function of TTR expressed by the nervous system has been revealed. 
Despite previous studies describing hypothyroid phenotype in TTR null mice, 
(Richardson et al., 2007, Monk et al., 2013), data from this investigation has revealed 
a hyperthyroid phenotype; hypermyelination in the TTR null mouse brains during 
development. Moreover, that Hypermyelination phenotype appeared to be regulated 
by altered Oligodendrocyte (OL) maturation. Thus, this present chapter will 
investigate an alterative role for TTR in OL maturation. In this chapter we will: 
1. Investigate if TTR is synthesised by OPCs. 
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2. Investigate if the TTR synthesised by OPCs is secreted. 
3. Track the expression of TTR during OPC differentiation. 
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5.2 Results 
5.2.1 TTR mRNA is present in OPCs and OLs 
To determine if OPCs derived from NIH approved H9 human embryonic stem 
cells (hESCs) and cultured in proliferation and differentiation media, synthesise TTR, 
a series of reverse transcription-polymerase chain reactions (RT-PCRs) were 
performed (section 2.2.13.1). The mRNA was extracted from proliferated hOPCs, 
which had been expanded for four weeks (section 2.2.2), and from hOPCs that had 
been under differentiation condition for two weeks (section 2.2.3). For each cell type, 
RT-PCRs were performed. Primers to Olig2 were used to confirm the cell type, 
primers for GAPDH were used as the internal control, and primers for TTR were used 
to detect the presence of TTR mRNA. For the list of primers and their sequences see 
(Table 2.5). The results showed that TTR mRNA was present in OPCs cultured in 
proliferation media and in OPCs cultured in differentiation media (Figure 5-1). 
Electrophoresis of the PCR products showed that TTR bands with size 240 bp 
appeared more intense during the OPC proliferation phase compared to the OPCs 
under differentiation conditions. The bands’ intensities were normalized to these of 
GAPDH cDNA and quantified using ImageJ software. The intensity of the TTR 
cDNA in OPCs under differentiation condition was just 0.6 compared to those from 
proliferated OPCs. This means that more TTR mRNA was present during the 
proliferation phase of OPCs compared to the differentiation phase. As a negative 
control, the DNA template was omitted from the PCR reaction mixture.  
5.2.2 Confirmation of the identity of PCR bands as TTR cDNA 
To verify the identity of PCR bands detected in (Figure 5-1), bands were 
excised and extracted from the gels and sent for DNA sequencing (section 2.2.13.1.8). 
Messy data that appeared distorted at the beginning or ending of the sequence were 
excluded, and the rest of the sequence peaks that were normal were matched. Thus, 
198 bp were matched for TTR cDNA, and 138 bp were matched for Olig2 cDNA. 
The sequencing results were 100% identical with the expected amplified section of 
human TTR cDNA and human Olig2 cDNA (Figure 2-2). The sequenced RT-PCR 
product straddles two exons of the TRR gene but not the intervening intronic 
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sequence, as this is clear evidence that the bands are not merely the result of genomic 
DNA contamination in the RT-PCR reaction. 
5.2.3 Detection of TTR in OPCs and OLs using immunocytochemistry 
To determine the ability of OPCs derived from NIH approved H9 hESCs 
cultured in proliferation and differentiation media to synthesise TTR and localize it, 
an OPC line were used (section 2.2.1). The OPCs were cultured to proliferate for four 
weeks in an expansion medium (section 2.2.2). Next, immunocytochemistry (ICC) 
was performed (section 2.2.11). Markers for proliferating OPCs, such as monoclonal 
neuron-glial antigen 2 (NG2) and platelet-derived growth factor receptor alpha 
(PDGFRα) antibodies, were used to verify the maturation phase. OPCs characterized 
with a small oval cell body and bipolar processes were positively stained with both 
proliferating markers (NG2 and PDGFRα) (Figure 5-3 C and G). TTR was detected in 
the cytoplasm of OPCs (Figure 5-3) and there were no obvious differences in the 
distribution of the TTR associated florescence within the cells (Figure 5-3 B and F). 
Next, the hOPCs were cultured and differentiated in a differentiation medium over 
two weeks (section 2.2.3). Markers for differentiated hOPCs, such as monoclonal 
NG2, PDGFRα and myelin basic protein (MBP) antibodies, were used to verify the 
maturation of the oligodendrocytes. Oligodendrocytes characterized with oval cell 
body and multiple long processes were positively stained with all differentiation 
markers (Figure 5-4 C, G, K and O). Similar to the OPCs, TTR was detected in OL 
(Figure 5-4 B, F, J and N), and the TTR associated florescence specifically appeared 
to be present in the process and soma of OPCs of OL.                                                                                 
5.2.4 Detection of TTR by western blotting 
To confirm the above ICC results, that showed that TTR was synthesised by 
OPCs derived from NIH approved H9 hESCs proteins were extracted (sections 
2.2.14) from the culture of OPCs which had proliferated and expanded for four weeks 
(section 2.2.2) and from OPCs which had been cultured in differentiation media for 
two weeks (section 2.2.3). After the proteins were extracted from the cells (section 
2.2.14), the western blot was performed using a TTR antibody (section 2.2.17). 
Albumin was used as a negative control and human TTR was used as a positive 
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control. TTR protein was detected in both proliferated OPCs and differentiated OPCs 
(Figure 5-5 A and B). Two protein bands were identified corresponding to monomer 
(~15 kDa) and dimmer TTR (~30 kDa). Moreover, no secreted TTR was detected in 
the proliferation and differentiation culture media. Also, No TTR was detected in the 
ingredient of the fresh proliferation and differentiation media (figure 5-5 C). 
5.2.5 The majority of mouse embryonic OPCs express TTR 
OPCs isolated from the brain of E12.5 mice (Cells were obtained from other 
lab) were used to quantify the number of OPCs that synthesized TTR by flow 
cytometry (section 2.2.12). Figure 5-6 (A) shows the flow cytometry results, Cells 
were labeled with one marker “anti TTR conjugated with fluorescein Isothiocyanate 
(FITC)”. A control plot was gated to define the two regions lying within the following 
quadrants: Q4R18 (negative FITC); Q4R17 (positive FITC). It has been noticed that 
eighty percent of the total number of the cells is positive for TTR (quadrants: Q4R17). 
Moreover, the purified OPCs were stained with double labeled antibodies markers; 
anti TTR conjugated with FITC, and anti PDGFRα conjugated with phycoerythrin 
(PE) (Figure 5-6 B). A control plot is gated to define the four regions lying within the 
following quadrants: Q1R3 (negative FITC, positive PE); Q1R4 (positive FITC, 
positive PE); Q1R6 (negative FITC, negative PE); and Q1R5 (positive FITC, low 
PE). Nine percent of the PDGFRα positive OPCs were positive for TTR (quadrants: 
Q1R4), and 27.7% of the total number of cells were positive for TTR (quadrant: 
Q1R5). 
5.2.6 TTR gene expression is variable and depends on the maturation stages of OLs.  
Expression of TTR has been tracked by flow cytometry (section 2.2.12) 
through differentiation of hOPCs derived from h9 HESCs for four weeks (figure 5-6). 
Cells were labeled with anti TTR conjugated with FITC. During week0 of 
differentiation, about 4.7 % expressed TTR and about 15.4 % during week1. The peak 
of TTR expression was within week 2 of differentiation (56.1). The number of OPCs 
expressed TTR then reduces to 30.1 % during week 3 then increases again within 
week 4 to 38 %. 
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Figure 5-1: TTR mRNA was detected in OPCs derived from NIH approved H9 
hESCs cultured in proliferation and differentiation media.  
A: GAPDH cDNA was used as the internal control. The GAPDH cDNA band size is 
202bp; B: Olig2 cDNA was detected as the oligodendrocyte marker. The Olig2 band 
size is 178 bp; C: TTR cDNA was detected in both proliferating and differentiating 
oligodendrocyte. The TTR band size is 240 bp. The DNA template was omitted in 
negative control reaction. The relative ratio of TTR cDNA were calculated and 
normalized to the GAPDH band. D: The intensity of the TTR cDNA in OPCs under 
differentiation condition was just 0.6 compared to those from proliferated OPCs. n=1 
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Figure 5-2: Confirmation of identity of PCR bands by DNA sequencing. 
A: Sequencing result was 100 % identical to the expected amplified human TTR cDNA. B: 
Sequencing result was 100 % identical to the expected amplified Olig2 cDNA. Messy data that 
appeared distorted at the beginning or end of the sequence were excluded, and the rest of the 
sequence peaks that were normal have been matched. Thus, 198 bp have been matched for TTR 
cDNA, and 138 bp were matched for Olig2 cDNA.  
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Figure 5-3: TTR is localized within proliferating OPCs derived from NIH approved H9 hESCs 
and cultured in proliferation medium. 
A: OPC nuclei stained with DAPI; B: OPCs stained with polyclonal TTR antibody, detected using 
the anti-rabbit Alexa-Fluor488 conjugated antibody; C: OPCs with small oval cell body with bipolar 
processes stained with monoclonal NG2 antibody, a marker for proliferating OPC; detected using the 
anti-mouse Alexa-Fluor555 conjugated antibody D: merged. E: OPC nuclei stained with DAPI; F: 
OPCs stained with polyclonal TTR antibody, detected using the anti-rabbit Alexa-Fluor488 
conjugated antibody; G: OPCs with small oval cell body with bipolar processes stained with 
monoclonal PDGFRα antibody, a marker for proliferating OPC; detected using the anti-mouse 
Alexa-Fluor555 conjugated antibody H: merged. TTR is present in the cytoplasm of proliferating 
OPCs. Scale bar= 100 µm 
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Figure 5-4: TTR is localized within OPCs derived from NIH approved H9 hESCs and 
cultured in differentiation media. 
A: OL nuclei stained with DAPI; B: OL stained with polyclonal TTR antibody, detected using the 
anti-rabbit Alexa-Fluor488 conjugated antibody; C: OL stained with an oval cell body and 
multiple long processes stained with monoclonal MBP antibody, a marker for differentiated OC; 
detected using the anti-mouse Alexa-Fluor555 conjugated antibody; D: merged. E: OC nuclei 
stained with DAPI; F: OL stained with polyclonal TTR antibody, detected using the anti-rabbit 
Alexa-Fluor488 conjugated antibody; G: OL stained with an oval cell body and multiple long 
processes stained with monoclonal CNPase antibody, a marker for differentiated OC; detected 
using the anti-mouse Alexa-Fluor555 conjugated antibody; H: merged; I: OC nuclei stained with 
DAPI; J: OL stained with polyclonal TTR antibody, detected using the anti-rabbit Alexa-Fluor488 
conjugated antibody; K: OL stained with an oval cell body and multiple long processes stained 
with monoclonal NG2 antibody, a marker for early differentiated OC; detected using the anti-
mouse Alexa-Fluor555 conjugated antibody; L: merged. M: OPC nuclei stained with DAPI; N: 
OL stained with polyclonal TTR antibody, detected using the anti-rabbit Alexa-Fluor488 
conjugated antibody; O: OL stained with an oval cell body and multiple long processes stained 
with monoclonal PDGFRα antibody, a marker for early differentiated OC; detected using the anti-
mouse Alexa-Fluor555 conjugated antibody; P: merged. Scale bar= 100 µm 
  
183 
 
 
 
 
 
 
Figure 5-5: Western blot analysis revealing TTR in OPCs derived from NIH 
approved H9 hESCs. 
A: western blot bands for protein samples extracted from OPCs cultured in 
proliferation media. B: western blot bands for OPCs cultured in differentiation 
media. Human albumin was used as the negative control and human TTR was 
used as the positive control for both experiments. C: fresh proliferation and 
differentiation media were tested for the presences of TTR. Proliferation and 
differentiation media that had been used to expand and differentiate OPCs, 
respectively were concentrated 20 fold and tested for TTR. 
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Figure 5-6: Quantification of the number of OPCs derived from H9 hESCs that 
synthesise TTR during differentiation by flow cytometry.  
Cells were labeled with anti-TTR conjugated with FITC. During week 0 of 
differentiation, about 4.7 % expressed TTR and about 15.4 % during week 1. The 
peak of TTR expression was within week 2 of differentiation (56.1). The number of 
OPCs that expressed TTR then reduced to 30.1 % during week 3 then increased 
again during week 4 to 38 %. n=1 
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Figure 5-7: Quantification of primary embryonic mouse OPCs that synthesise 
TTR, by flow cytometry. 
A: Cells were labeled with anti TTR conjugated with FITC. A control plot was gated 
to define the four regions lying within the following quadrants: Q4R18 (negative 
FITC); Q4R17 (positive FITC). Eighty percent of the total number of the cells was 
positive for TTR (quadrants: Q4R17). 
B: Cells were double labeled with anti TTR conjugated with FITC, and anti 
PDGFRα conjugated with PE. A control plot was gated to define the four regions 
lying within the following quadrants: Q1R3 (negative FITC, positive PE); Q1R4 
(positive FITC, positive PE); Q1R6 (negative FITC, negative PE); and Q1R5 
(positive FITC, low PE). Nine percent of OPCs were positive for TTR and PDGFRα 
(OPC marker) (quadrant: Q1R4), and 27.7 % of the total number of the cells was 
positive for TTR (quadrant: Q1R5). 
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5.3 Discussion 
Given the apparently contradictory data of TTR null mice having a 
hypothyroidism in CNS phenotype (Richardson et al., 2007, Monk et al., 2013) yet 
hypermyelination in the corpus callosum (chapter 3) and the fundamental importance 
of THs in oligodendrocyte maturation, we screened OPCs for TTR synthesis. We 
detected TTR mRNA in OPCs derived from NIH approved H9 hESCs that had been 
cultured in proliferation and differentiation media. We showed that the TTR 
synthesized by OPCs is not secreted into the culture media (Figure 5.5), and that the 
level of TTR gene expression was variable and depended on the proliferation and 
differentiation stages (Figure 5-6). 
In the previous chapter we found an alteration in the status of the NSC and 
oligodendrocyte biology isolated from TTR null mice. TTR synthesised by OPCs 
could be a factor with a direct or an indirect role in mediating that alteration. The first 
possible mechanism for TTR influencing cell cycle is via TH, which control OPC cell 
cycle (Lemkine et al., 2005). Compared to other thyroid hormone distributor proteins, 
TTR has an intermediate affinity for T3 and T4 (7.0 x 107 and 1.4 x 107 M-1, 
respectively) (Robbins, 1996). Therefore, it is possible that endogenous TTR, which 
has been shown to be synthesized by OPCs and neurons cells, binds T4 inside these 
cells, which controls the level of T4 available for deiodinated to T3, the functional 
form of THs. In TTR null mice, the absence of TTR could result in an increase in the 
level of tissue T4 and, consequently, the level of deiodinated T3, which will affect the 
rate of OPCs proliferation, apoptosis and cell survival. The same mechanism can be 
suggested for the in vitro data. Typically thyroid hormone is added to media 
supplements of the cultures. The absence of TTR could result in an increase in the 
level of cellular T4 and consequently in the level of deiodinated T3.   
Moreover, in the chapter 4 we found an increase in the proliferation rate of 
neurosphere colonies isolated from cerebral cortex of P21 TTR null mice, compared 
to control group of wild type mice (section 4.2.1). Accordingly, flow cytometry cell 
cycle analysis showed a pronounced increase in the population of TTR null OPCs in 
G2/M phase, consistent with the increased progression of TTR null OPCs in S phase, 
compared to wild type OPCs (section 4.2.4). These results imply that the absence of 
TTR might affect the progression from S phase to G2/M phase, which, in turn, 
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accelerates OPCs proliferation. In agreement with our finding, a recent study showed 
that adding exogenous TTR to the NSC neurosphere culture resulted in a decrease in 
the NSC proliferation rate (Lee et al., 2012). This indicates that the presence of TTR 
may act as a negative regulator for NSC proliferation. Thus, in our case, the absence 
of TTR from our cells signified the absence of the proliferation negative regulator. 
Given that TTR-like protein (the evolutionary precursor to vertebrate TTR) 
was an intracellular protein, it is tantalising to consider that TTR could have an 
intracellular function in the CNS in addition to being an extracellular distributor for 
THs and RBP-retinol in the CSF. A study based on TTR null mice revealed that TTR 
might play a critical role in the promotion of neuroregeneration (Fleming et al., 2007). 
After crushing the sciatic nerve, the investigators observed a lower capacity of the 
sciatic nerve to regenerate in the TTR null mice compared with wild type mice. 
Further support for the role of TTR in neuroregeneration came from a study 
investigating the proteolytic (cleavage of apolipoprotein AI) function of TTR. A 
glutathionylated variant of TTR, in which the proteolytic function was lost (TTRprot-
), was prepared. The ablation of proteolytic activity did not affect the binding of T4 or 
RBP but did reduce the neurite length of PC12 cells in culture (Liz et al., 2009). The 
neuritogenic activity of TTR was found to be dependent on its internalisation into 
dorsal root ganglia cells via receptor-mediated endocytosis, specifically, by the 
megalin receptor (Fleming et al., 2009). Interestingly, megalin is also expressed by 
oligodendrocytes (Wicher et al., 2006a); thus, it is possible that megalin is the key 
receptor for TTR oligodendrocytes, and the molecular mechanism for TTR in 
oligodendrocytes cells could be initiated via that receptor. This supports the 
hypothesis that TTR might have further natural substrates in the nervous system, in 
addition to THs and RBP-retinol, and strengthens the evidence for the role of TTR in 
neuroregeneration (Fleming et al., 2007). 
The expression of the TTR gene in oligodendrocytes may have 
neuroprotective role against Alzheimer's disease (AD). It was revealed that TTR 
could protect an individual from AD by interacting with a β-amyloid protein (Aβ) 
because TTR sequesters Aβ proteins and prevents amyloid formation (Schwarzman et 
al., 1994), which in turn results in a reduction of Aβ protein formation and 
accumulation, inevitably suppressing AD (Buxbaum et al., 2008). Thus, it has been 
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proposed that in late onset AD patients, the lack of a sufficient concentration of TTR 
in their CSF occurs as a result of an increase in the Aβ fibre formation (Serot et al., 
1997). The two main pathological features of AD are (i) increase in Aβ accumulation 
and (ii) abnormal process of the amyloid precursor protein (APP) (reviewed in (Hardy 
and Selkoe, 2002). Normally, alpha-secretase cleaved APP (sAPPα) acts 
neuroprotectively against Aβ toxicity (Stein et al., 2004). It has been proposed that the 
levels of sAPPα decrease as the level of Aβ protein increases (Stein and Johnson, 
2003). A number of studies have suggested that sAPPα protects against AD by 
inducing the expression of TTR (Stein and Johnson, 2003, Stein et al., 2004). In vitro 
and in vivo models of experiments have shown that sAPPα is able to stimulate TTR 
expression, which is necessary for protection against Aβ induced neural death (Stein 
et al., 2004). Backcrossing of the TTR null mice with AD mice model resulted in an 
increase in the deposition of Aβ in the brains of the transgenic mice with the 
hemizygous deletion of TTR (Choi et al., 2007). 
The expression of the TTR gene in oligodendrocytes could have negative 
impact in the progress of some disease. Increased TTR expression has been shown to 
be a major contributor to neural degeneration in a variety of diseases and to 
have cellular effects on neuronal function. Such diseases include FAP, 
cerebral amyloid angiopathy and generalised vasculopathic injuries (Hou et al., 2007). 
The wide expression of the TTR gene in areas other than the liver and choroid plexus 
such as cortex neurons (Li et al., 2011), dorsal root ganglia (DRG) cells (Murakami et 
al., 2008), human intercostal nerves (Murakami et al., 2011), sciatic nerves of mice 
(Murakami et al., 2010), Schwann cells isolated from the sciatic nerves of 
mice (Murakami et al., 2010), SVZ astrocytes and oligodendrocytes could be the 
source of the overexpression of TTR in the nervous system and the main source for 
the deposition of mutant TTR. Interestingly, the immunocytochemistry results of TTR 
in differentiated OL (Figure 5-4) showed that TTR appears more concentrated at the 
end parts of the cells’ processes. The function of oligodendrocyte processes is to wrap 
the neuron axon and begin to myelinate it. The accumulation of TTR at the end of the 
oligodendrocyte processes may be an indication for the secretion of TTR which hasn’t 
been identified yet. 
  
  
189 
 
5.4 Conclusion 
 For the first time we have shown definitively that oligodendrocytes cultured 
in proliferation and differentiation media synthesise TTR. Also, we showed that the 
TTR synthesized by OPCs is not secreted into the culture media, and the level of TTR 
gene expression is variable depending on the proliferation and differentiation stages. 
The discovery of TTR synthesis in OPCs could explain why TTR null mice have 
hypermyelination; once T4 enters a cell it can be bound by TTR until released and 
deiodinated to T3 to regulate gene transcription. Thus, the absence of intracellular 
TTR, T4 entering the cell can be immediately deiodnated to T3 and activate 
transcription of TH-regulated genes, resulting in hypermyelination phenotype.  
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Chapter 6 
General discussion 
and future directions 
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6.1 Chapter 6: General discussion 
In this thesis, we identified a novel hypermyelination phenotype in the brains 
of TTR null mice during development, for the P14, P21 and 12 week age groups. The 
hypermyelination phenotype was synchronous with a substantial increase in the 
density of oligodendrocytes in the medial area of the corpus callosum and in the 
anterior commissure during development starting from P7 and evident until 12 weeks 
of age. The biological relevance of this finding is that, as a consequence of the 
absence of TTR, an alteration in the status of the NSC and oligodendrocyte biology 
occurred. The first in vitro sign of that alteration was the significant increase in the 
proliferation rate of NSC neurosphere colonies isolated from the SVZ of P21 TTR 
null mice. In agreement with our finding, a recent study showed that adding 
exogenous TTR to a NSC neurosphere culture resulted in a decrease in the NSC 
proliferation rate (Lee et al., 2012). This indicates that the presence of TTR may act as 
a negative regulator for NSC proliferation. Thus, in our case, the absence of TTR 
from OPCs from TTR null mice signified the absence of the negative regulator of 
proliferation.  
We found that the absence of TTR promotes differentiation of NSCs into the 
glial lineage at the expense of the neuronal lineage. The decrease in differentiation of 
TTR null NSCs into the neuronal lineage may be reflected in the behaviour of the 
animal. NSCs in the SVZ of mammalian brains differentiate into neuroblasts then 
migrate along the rostral migratory stream into their target, the olfactory bulb (Lois 
and Alvarez buylla, 1993). There, the neuroblasts start to differentiate into neurons 
(Lois and Alvarez buylla, 1993). On the other hand, the NSCs in the SGZ (Doetsch et 
al., 1999, Johansson et al., 1999, Kornack and Rakic, 1999) migrate for a short 
distance into the dentate granule cell layer, and also start to differentiate into neurons 
(Eriksson et al., 1998, Johansson et al., 1999, Kornack and Rakic, 1999), which have 
an essential role in memory and learning (Deng et al., 2010). Therefore, any reduction 
in olfactory bulb neurons might affect the sense smell of the mice. Likewise, 
reduction in dentate granule neurons will affect the memory and behaviour of the 
TTR null mice. Evaluating the sense of smell, which is the main function of olfactory 
bulb neurons, and evaluating the memory and learning ability, which is the main 
function of the dentate granule neurons, will give an indication of the neurogenic 
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process in these two areas. Until now, no study has focussed on evaluating the sense 
of smell in TTR null mice. However, learning and memory ability in these mice was 
evaluated via a Morris water maze (MWM) test. The MWM test was applied to 5-
month-old wild type and TTR null mice. The data revealed that the TTR null mice 
had a limited capacity to acquire learnt behaviours at a young age compared to the 
age-matched wild type mice (Sousa et al., 2007). During aging, the performances of 
(18-month-old) wild type mice on the MWM test began to decrease, and also showed 
a substantial reduction of about 30% in their TTR CSF levels (Sousa et al., 2007). 
However, there were no differences between the performances of 18-month-old TTR 
null mice and younger ones. Moreover, there was no difference between the 
performance of wild type and TTR null mice at 18 months of age (Sousa et al., 2007). 
From the above, it was concluded that TTR may have a functional role in memory, 
and a lack of TTR may accelerate the poorer cognition that is normally associated 
with elderly people (Sousa et al., 2007). Our explanation for this finding is that the 
absence of TTR in the mouse brain caused a reduction in the number of NSCs 
differentiating into neurons. This reduction was reflected in the number of dentate 
granule neurons and resulted in a decrease in the memory and learning abilities.  
Another proposed role for TTR absence, suggested by our data is an 
enhancement of proliferation and migration and a decrease in the apoptosis of OPCs. 
Such alterations in OPC maturation caused a significant increase in the number 
oligodendrocytes, resulting in a hypermyelination phenotype, in the brains of TTR 
null mice. Various growth factors, hormones and signal molecules play different roles 
in controlling OPC proliferation and survival. TTR could be a factor with a direct or 
indirect role in mediating the cell cycle and limiting OPC proliferation and survival. 
The first possible mechanism for TTR’s influence on the cell cycle is via TH, which 
controls the OPC cell cycle (Lemkine et al., 2005). Compared to other TH distributor 
proteins (albumin and thyroxine-binding globulin), TTR has an intermediate affinity 
for T3 and T4 (Robbins, 1996). Therefore, it is possible that endogenous TTR, which 
has been shown to be synthesised by OPCs, holds T4 in the cytosol of the cells; this 
controls the level of T4 available for deiodinated to T3, the functional form of THs. 
This hypothesis has been suggested by recent a study (Lee et al., 2012). They 
observed a decrease in the NSC proliferation rate after treating an NSC neurosphere 
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culture with exogenous TTR. Thus, they suggested that the absence of TTR in TTR 
null mice could result in an increase in the level of tissue T4, and consequently, the 
level of deiodinated T3. Thus, in turn, could affect the rate of OPC proliferation, 
apoptosis and cell survival.  
Another hypothesised mechanism for TTR in OPC proliferation and apoptosis 
is via neuropeptide Y (NPY). TTR null mice were found to have increased levels of 
amidated NPY (Nunes et al., 2006) and were proposed as a model for NPY 
overexpression. A few studies have illustrated the role of NPY in SVZ precursor cells. 
An in vivo study of mice showed that injection of NPY into the 
intracerebroventricular area significantly increased the proliferation of neural 
precursor cells in the SVZ zone (Decressac et al., 2009). When using NPY knockout 
mice, a significant decrease in the proliferation of the olfactory bulb was recorded 
(Decressac et al., 2009). Additionally, an in vitro study using brain slices from the 
NPY receptor of knockout mice showed a significant reduction in cells in the dentate 
gyrus (Howell et al., 2005). These studies concluded that NPY promotes significant 
cellular proliferation in the SVZ of mice and that the function of NPY in the SVZ is 
mediated by the Y1 receptor. Thus, overexpression of NPY in the TTR null mice 
could be contributing cause for alteration of the NSC and OPC maturation. 
Taking these findings together, we conclude there is a hypermyelination 
phenotype in the TTR null mice brain. That hypermyelination phenotype is regulated 
by altered oligodendrocyte maturation; which is a consequence of absence of TTR 
synthesis by OPCs. Further studies should be performed to identify the mechanisms 
of TTR action in OPC biology.  
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6.2 Future directions 
The data from this thesis could pave the way for a possible new target in the 
therapeutics of inherited diseases of developmental myelination or acquired 
demyelinating disease such as multiple sclerosis.  
The following is a short list of the major experiments that need to be 
performed with a view to generating a clear understanding of the role of TTR in OPC 
biology: 
1. Measure the proportion and the number of myelinated axons and their density; 
2. Using various markers for oligodendrocyte, which expressed during each 
maturation stage such as (PDGF, NG2, O4, APC) will be included. That will 
help to quantify the number and level of maturation of the oligodendrocytes 
during TTR null brain development. 
3. Establishment of an in vitro myelination assay by co-culturing cortical neurons 
(isolated from the cortex) with OPCs from TTR null mice. The amount of 
myelination will be measured over a 6-week co-culture period. The control 
will comprise cortical neurons from TTR null mice co-cultured with OPCs 
from wild type mice;  
4. Study the effects of exogenous TTR or overexpression of TTR on NSC 
proliferation/development/differentiation; 
5. Development of TTR null mice with a demyelination disease. Following this, 
the recovery of these mice and the myelination process will be observed 
compared to wild type mice; and 
6. Performance of electrophysiological analyses to investigate any functional 
changes in CNS performance between TTR null and wild type mice. 
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